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Abstract 
Introduction: Over recent decades, there has been an increase in the availability and use of 
Novel Psychoactive Substances (NPS) all over the world. They include several classes of 
chemicals that mimic the effects of illicit drugs and have been purposefully introduced into the 
market to circumvent or undermine the purpose of legal regulation. Currently, there is 
information lacking on the pharmacology of these substances; however, the increasing number 
of cases and outbreaks of intoxications/deaths is becoming a cause for deepening concern. 
Multi-disciplinary research in the fields of biology, chemistry, clinical medicine and web 
analysis is needed to develop responses against this tidal wave. 
Aim: The overall aim of this project is to gain insights into pharmacological, neurochemical 
and molecular properties of selected NPS to provide a reliable background needed for 
detection, assessment, and management of NPS-related harms. A range of approaches and 
methodologies was employed and a spectrum of different fields of knowledge has been 
engaged to gain some understanding into the complex multi-faceted phenomenon of NPS. 
Methods: Different substances have been selected as targets for the present project according 
to the clinical pattern of toxicity raised by their worldwide use and the lack of scientific 
knowledge available about them. The methods employed were: in vitro quantitative 
autoradiography (to evaluate the  binding properties of the novel SCs BB-22, 5F-PB-22, 5F-
AKB-48 and STS-135 at the cannabinoid receptor type 1 and N-methyl-D-aspartate receptor; 
and the binding properties of the synthetic stimulants 5-IT and 2-DPMP at the dopamine 
transporter in rat brain slices); in vitro Fast Scan Cyclic Voltammetry (to assess the effects of 
BB-22 on evoked dopamine efflux and dopamine re-uptake half-life in nucleus accumbens 
brain slices); in vivo microdialysis (to monitor dopamine release in terminal areas of the reward 
system after acute administration of the synthetic cannabinoids BB-22, 5F-PB-22, 5F-AKB-48 
and STS-135; the dieting aid compound 2,4-DNP; the synthetic stimulants 2-DPMP and D2PM 
in freely moving animals); in silico molecular docking (to investigate the intermolecular 
interactions of the SCs BB-22, 5F-PB-22, 5F-AKB-48 and STS-135, and other referent 
compounds, with a homology model of the rodent cannabinoid receptor type 1 (CB1R) and the 
crystal structure of the human CB1R); and a web-based analysis approach (to analyse the 
information provided by a range of fora communities on 4,4’-DMAR use, additionally critical 
reviewing the available evidence-based literature on this topic). 
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Results: Our in vitro quantitative autoradiography studies, confirmed that the index 
compounds BB-22, 5F-PB-22, 5F-AKB-48 and STS-135, behave as highly potent CB1R 
ligands able to compete with the radioligand [3H]CP-55,940 in cortical and striatal brain slices. 
On the other hand, all synthetic cannabinoids tested were unable to compete with the 
radioligand [3H]MK-801 in the same cerebral areas, rejecting the hypothesis of their potential 
binding to the N-methyl-D-aspartate receptor (NMDAR) at all concentrations investigated. 
Consistent with previous in vitro studies, 5-IT and 2-DPMP behaved as highly potent dopamine 
transporter (DAT) ligands able to compete with the radioligand [125 I]RTI-121 in a 
concentration-dependent way in the Caudate Putamen (CPu) and Nucleus Accumbens (NAc) 
brain slices. Notably, 2-DPMP was able to displace the radioligand in both cerebral regions, 
starting from lower concentrations compared to 5-IT. 
In vitro Fast Scan Cyclic Voltammetry findings demonstrated that local application of the 
synthetic cannabinoid BB-22 in brain slices, was unable to change evoked dopamine efflux 
and dopamine reuptake time-constant in the NAc shell at any doses tested. The results obtained 
would suggest the relative contributions of complex neuronal circuits, either within or outside 
the NAc, whose modulation would interfere with the interactions between BB-22 and 
dopaminergic neurons and represent critical pathways accounting for some of the rewarding 
properties of BB-22 exposure. 
In vivo microdialysis outcomes suggested that all SCs tested could increase dopamine release 
in the NAc shell at specific doses, while no changes in dopamine output were observed in other 
areas of the reward system, namely NAc core and medial prefrontal cortex (mPFCx) after BB-
22 administration. These outcomes provided a circumstantial pre-clinical evidence for a greater 
putative abuse liability of SCs compared to the natural compound found in cannabis (Δ9‐THC). 
Furthermore, the acute treatment with 2,4-DNP did not cause any change in dopamine release 
in the NAc shell and CPu rejecting the hypothesis of psychoactivity of this substance at the 
dose tested. On the other hand, the synthetic stimulant 2-DPMP elicited a comparable increase 
of dopamine (DA) release in the NAc shell and CPu at the higher doses tested, while D2PM 
caused a selective increase of DA release in the NAc shell, providing a circumstantial 
preclinical evidence for a putative abuse liability of this compound at the highest dose assessed.  
The in silico molecular docking studies demonstrated that the SCs BB-22, 5F-PB-22, 5F-AKB-
48 and STS-135 interact with CB1 receptor residues that, according to previous mutation and 
computational studies, are considered crucial for synthetic cannabinoid binding recognition. 
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Additionally, they share some interacting residues with other aminoalkylindole derivatives 
(e.g. WIN-55,212-2).  
The web-based analysis focused on 4,4’-DMAR, suggested that fora members co-operate in 
exchanging an extensive body of knowledge about this drug, and the recurring topics of 
discussion include: routes of administration and dosages; desired and undesired effects; 
comparison and association with other drugs and medications; overall impression; provision of 
harm reduction advice. This approach has been useful to better understand some of the clinical 
and psychopharmacological issues pertaining to 4,4’-DMAR. 
Conclusions: Overall, these studies provided new pharmacological, neurochemical and 
molecular knowledge on a range of Novel Psychoactive Substances essential for identifying 
potential therapeutical approaches against their use/abuse. The novelty of this project lies in 
the adoption of a multi-disciplinary approach involving a range of methodologies from 
different areas of expertise (neurobiology, pharmacology, chemistry, netnography) all 
integrated to clarify some aspects of the index NPS, which were not yet available in the current 
literature. Additional studies are needed to better explain short and long-term effects of the 
index NPS, their abuse potential, and their interactions with other drugs of abuse. 
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Aims, objectives and hypotheses of the overall PhD project 
Over the past decades, the unprecedented use/abuse of NPS has led to many toxicity events, 
hospital emergency admissions, and fatalities over the world. Although some progress has been 
made by the international community to address the NPS phenomenon, the exponential 
increase of the NPS market still represents a policy challenge and further efforts are necessary 
to tackle the wide escalation of NPS use. For these reasons, accurate evaluation of the 
pharmacological effects of these drugs, along with careful analysis of the biological 
mechanisms underlying their clinical effects, may contribute to improve the quality of public 
health on a global level.  
In view of the above, the present PhD project adopted a multi-disciplinary approach that best 
addresses the complexities of NPS use/abuse, aiming to understand how compounds belonging 
to different chemical groups, interact with biological systems. Different areas of expertise, 
including biology, in silico molecular modelling, and netnography have been involved. 
Biological studies have been carried out by performing in vitro (using animal tissues) and in 
vivo (using live animals) research to predict what effect(s) the drugs under study might have in 
specific cerebral areas. In silico molecular modelling studies were performed to investigate the 
complex intermolecular interactions between a range of NPS and their targets; while the 
netnography approach was engaged to assess some of the psychopharmacological issues 
inherent to NPS use.  
The index substances in the present PhD project included the synthetic cannabinoids BB-22, 
5F-PB-22, 5F-AKB-48 and STS-135; the synthetic stimulants 2-DPMP, D2PM, 5-IT, 4,4’-
DMAR; and the dieting aid compound 2,4-DNP. These chemicals were all selected for a range 
of reasons, including: evidence of health and social harms associated to their use (e.g. great 
number of Emergency Department admissions, toxicity events and fatalities); continued illegal 
use despite their prohibition; lack of pharmacological and neurochemical data currently 
available; limited prevention strategies and therapeutic approaches presently planned against 
their use/abuse; limited awareness of their associated health risks; misperception of their safety, 
lacking information available on their potential interactions with other drugs in the context of 
polydrug intake; urge to better draft a risk profile for these drugs; necessity to disseminate the 
most current NPS-related information to health professionals and the general public.  
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Although the second largest group monitored by the EMCDDA at the time of our study was 
the synthetic cathinone class, our analysis focused on synthetic stimulants belonging to other 
different pharmacological classes (e.g. pipradrol derivatives, tryptamines).  
The rationale behind this choice was related to the wider neuropharmacological gap of 
knowledge found for these compounds in the preclinical and clinical literature available, 
compared to synthetic cathinones. The effects of several cathinones was already reported in in 
vitro brain slice studies (Opacka-Juffry et al., 2014) as well as in vivo (Pehek et al 1991; 
Suyama et al., 2016), providing important preclinical knowledge on the neurobiological effects 
of these compounds. However, no neurochemical studies were conducted before ours in freely 
moving animals and in brain slices using the index compounds in our study, highlighting the 
necessity to further investigate their activity in the brain. 
Along the same lines, 2,4-DNP was chosen to be evaluated for the potential activity on the 
central nervous system the first time in our studies, in order to find a neuropharmacological 
explanation behind the current alarming use/abuse responsible for several cases of multiple 
body system failures all over the world. 
Multiple hypotheses were generated based on the type of analysis performed. In detail: 
• a potential binding of BB-22, 5F-PB-22, 5F-AKB-48 and STS-135 to the cannabinoid 
receptor, type 1 (CB1R) and N-methyl-D-aspartate receptor (NMDAR) and a likely 
binding of 5-IT and 2-DPMP to the dopamine transporter (DAT) were hypothesised 
and assessed using the in vitro autoradiography studies;  
• a local change in evoked dopamine (DA) release in the nucleus accumbens (NAc) shell 
after BB-22 application was hypothesised and assessed with in vitro Fast Scan Cyclic 
Voltammetry (FSCV) studies; 
• a psychoactive effect mediated by DA release increase in specific cerebral areas of the 
reward system for BB-22, 5F-PB-22, 5F-AKB-48 and STS-135, 2-DPMP and D2PM 
and 2,4-DNP, was hypothesised and assessed using in vivo microdialysis; 
• specific ligand interactions between BB-22, 5F-PB-22, 5F-AKB-48 and STS-135 and 
the CB1 receptor homology model and crystal structure consistent with those observed 
for other aminoalkylindole (AAI) derivates, were hypothesised and investigated, using 
the molecular docking approach;  
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• some of the clinical and psychopharmacological information pertaining to 4,4’-DMAR 
and retrieved from specific online fora, were hypothesised to be consistent with those 
available in the current literature, and were investigated using a critical approach. 
All the data obtained using different approaches, were critically discussed in the light of the 
available published literature. To identify peer-reviewed papers and online reports commenting 
on selected compounds, a comprehensive search on the Embase, Scopus; Google Scholar and 
Pubmed/Medline databases, was undertaken. Among the chemicals under study, particular 
attention was given to SCs primarily responsible for drug-related emergencies involving NPS 
(UNODC, 2016). 
Overall, the present project aimed to gain new knowledge on selected compounds that could 
be used as valuable background to develop valid management strategies and clinical treatment 
approaches against their use/abuse. 
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Chapter 1: Novel Psychoactive Substances (NPS) 
1.1) NPS - general overview 
Over the past years, significant advances in the modern society contributed to widely change 
the international drug market in terms of substance supply; availability; use and prevalence; 
promoting the incessant emergence and diffusion of NPS, and giving rise to a worldwide public 
health threat that is difficult to contain (Reuter et al., 2017).  
The speed and complexity of the NPS phenomenon has led to a wide range of challenges in 
prevention management, policy responses and clinical intervention, highlighting the necessity 
for continuous reviewing and further development of alternative options to cope with this 
highly dynamic threat (Baumann et al., 2016). 
According to the alarming pace of the NPS phenomenon diffusion, different regional patterns 
on NPS emergence have been reported across the world and mostly in Europe, Asia, Africa, 
Americas and Oceania (UNODC, 2016). The European scene has been characterised by a 
growing number of NPS released into the market. By the end of 2016, the EMCDDA had been 
notified more than 620 NPS, with 423 substances being notified in the last five years and 66 
compounds being detected for the first time in Europe. Synthetic cannabinoids (SCs) continue 
to be the largest group of novel substances monitored by the EMCDDA, followed by synthetic 
cathinones. According to the EMCDDA report, the number of NPS that emerged for the first 
time in 2016 (66), was lower compared to that recorded in 2015 (75). The cause of this decrease 
was likely related to the adoption of stricter control measures and law enforcement operations 
especially targeted to the Chinese laboratories and web-marketing platforms responsible for 
spreading a large number of NPS over different countries (EMCDDA, 2017). 
NPS synthesis is based on the production of molecules being chemically/pharmacologically 
similar to existing illicit drugs and sometimes more harmful than their parental compounds in 
terms of toxicity, adverse reactions, dependence, long-term effects, fatalities and psychiatric 
consequences (Schifano et al., 2016). The increasing availability of NPS led to broader public 
health and social harms and often ended up with outbreaks of mass poisonings recorded by 
Emergency Departments (ED) and fatalities across the world (EMCDDA, 2016). 
The wide diffusion of NPS is mostly related to the global nature of the Web that is frequently 
used as a platform for the open sale of NPS (Soussan et al., 2016) and represents the most 
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popular source of information about NPS use (Nelson et al., 2014) with web social 
communities being extensively used as discussion areas on this topic (Orsolini et al., 2015).  
The open sale of NPS products is characterised by deceptive advertising that promotes these 
preparations with attractive and curious names and depicts them as “legal”, “natural” and 
“safe”, but “not intended for human consumption” or “not tested for hazards or toxicity”, as a 
stratagem to avoid legal restrictions (Musselman et al., 2014).  
Furthermore, the lack of safety data information reported on the packaging; the extremely 
changeable and unpredictable composition characterising these products; the abuse/misuse of 
unsafe preparations and their consumption along with other drugs, may all account for 
significantly growing emergency admissions all over the world (Miliano et al., 2016).  
The principal reasons that drive NPS use include curiosity; novelty attraction; accessible price 
and availability; undetectability through standard screening tests; legality; perceived high 
quality and safety. Other incentives overlap with those for using traditional drugs like 
stimulants (e.g. sought-after self-confidence, cognitive enhancement, disinhibition) or 
hallucinogens (e.g. spiritual and intellectual self-exploration, pursued detachment from reality 
and altered perceptions) (Soussan et al., 2016; EMCDDA, 2015).  
1.2) Epidemiology of NPS drugs 
Epidemiological studies on NPS are limited and mostly reflect published epidemiological data 
on different populations and/or substances. Evidences from surveys showed that NPS use is 
mainly confined to generally young male users with previous drug history and sometimes 
knowledgeable about drugs in general. The wide range of chemicals commonly marketed 
entails several motivations for using them. External reasons include price, easy availability, 
and legal status; while more personal reasons include curiosity, pro-social sought-after effects, 
self-exploration and pleasure (Soussan et al., 2016). 
Recently, an online survey focused on drug use history and reasons for use, was performed on 
a large sample of 619 drug users with experiences with both traditional drugs and NPS (Soussan 
et al., 2016). According to this survey, most of the participants (85%) had used several NPS on 
the last five years, and some users (30%) tried nine or more different NPS mainly belonging to 
different drug groups, highlighting the novel sensation seeking attitude that characterised these 
users. Globally, 177 different NPS belonging to different pharmacological classes (e.g. 
22 
 
hallucinogens, stimulants, dissociatives, synthetic cannabinoids) had been used and most 
participants were young males. Some 40% of the NPS described in this study were obtained 
through friends or dealers rather than online, and this occurred especially for banned drugs. 
The most common motivations for using NPS in general were pleasure and enjoyment, with 
most of the participants planning on using NPS again. The reasons and attitudes clearly 
changed and sometimes overlapped based on each drug group. Specifically, use of SCs was 
mainly motivated by affordable price, availability, non-detectability in screening tests; use of 
hallucinogens and dissociatives was related to inner exploration and spiritual attainment; use 
of opioids was primarily connected with addiction; while the reasons for using stimulants were 
mainly linked to mental/physical enhancement and pro-social sought-after effects (Soussan et 
al., 2016). 
In 2015, the European School Survey Project on Alcohol and Other Drugs (ESPAD) performed 
an international survey to monitor substance use among 15-16-year-old students from 35 
European countries, including 23 EU Member States and Norway. According to this survey, 
lifetime use of NPS was reported by 4 % of students, with a higher prevalence among boys and 
highest rates in Estonia and Poland. These substances seemed to be more commonly used than 
other traditional drugs (e.g. amphetamine, ecstasy, cocaine or LSD) (ESPAD, 2015).  
More recently, a comprehensive EU-wide survey on NPS use was conducted among young 
people aged 15 to 24 years randomly selected across the 27 EU Member States (the Flash 
Eurobarometer). According to this survey, lifetime use of NPS was reported by 8% of 
participants, mainly males, with higher prevalence rates in France and Ireland (Flash 
Eurobarometer, 2016).  
Another international online survey was conducted to investigate the reasons for using NPS 
and the level of awareness about potential health risks associated with their use. People from 
17 countries, mainly from Europe, participated to the survey, and most responses came from 
university students. According to this survey, 65% of the respondents were knowledgeable 
about NPS, and among them, the majority was male, employed, with a bisexual or homosexual 
orientation. Additionally, awareness of NPS was greater in those in employment but it was 
unaffected by level of education. Overall, some 14% of participants were NPS users, with 
nearly half of them having limited perception of the potential health risks associated with NPS 
use (Deligianni et al., 2017). 
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Another survey-based study was performed to provide some data about NPS misuse. A 
questionnaire was administered to both, a sample of healthy subjects and a sample of 
psychiatric patients. Socio-economic characteristics and substance use with a special focus on 
the use of some NPS (e.g. spice, bath salts, methamphetamine, phenethylamines, 
methoxetamine, etc.) were investigated. The samples of healthy participants and psychiatric 
patients were mainly composed of females with an average age of about 22 years and high 
school education. Most of them were living with their parents and some of them were students. 
This survey showed a higher prevalence of NPS consumption in the psychiatric group 
compared to the healthy one, with a relevant use of SCs and cathinone derivatives (Martinotti 
et al., 2014). 
An additional survey on the extent of NPS use was conducted in a high-risk population 
composed by attendees of electronic dance music (EDM) parties at nightclubs and festivals in 
New York City in 2015. The prevalence of self-reported use of NPS was assessed on a sample 
of 682 adults (age 18–25). According to this survey, some 35% of participants reported lifetime 
use of NPS with a greater prevalence of use of synthetic cannabinoids, followed by 
phenethylamines, other psychedelics, tryptamines, and dissociatives. Overall, risk factors for 
NPS use included higher frequency of nightclub/festival attendance; use of Ecstasy, LSD, and 
ketamine; and bisexual orientation (Palamar et al., 2016).  
Another online survey was conducted in France in 2014, in the context of the I-TREND3 
project, aiming to gain insights into the profiles, reasons and practices of NPS users. The 
respondents were mainly previous conventional drug users (cannabis, stimulants, 
hallucinogens). The mean age of participants was 28, with women in a minority and some users 
aged over 30 and over 50, suggesting that NPS phenomenon is not just confined to younger 
generations. NPS users were predominantly urban, with fairly high level of education. Their 
professional situation was highly dependent on their age, with those aged under 25 years being 
mainly college or university students, and those over 25 years being primarily employed and 
mostly having their own accommodation. For the majority of respondents, last use of NPS 
occurred in the company of friends and it took place at the user's or friends' home. NPS were 
mainly used to modify perception, to get stoned; to bond with others, to socialise; to give more 
energy; to reduce anxiety levels; for simply curiosity; to stimulate intellectual activity. Most 
widely consumed NPS classes at last use included: phenethylamines, cathinones, 
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arylcyclohexylamines, cannabinoids, tryptamines. Direct online purchases of NPS appeared to 
be more frequent among older users compared to younger respondents (OFDT, 2014). 
Further epidemiological studies are needed to better outline a socio-demographic profile of the 
NPS users and to develop prevention and harm reduction strategies geared toward a specific 
target population. 
1.3) NPS classification 
Considering the wide number of NPS, classifying them represents the starting point from which 
all the other insights may be developed. The parameters used for NPS classification may be 
chemical, or alternatively, pharmacological/clinical. Chemical classification includes: 
synthetic cathinones, phenethylamines, tryptamines, piperazines, pipradrol derivatives, 
arylcyclohexylamines, aminoindanes, aminoalkylindoles; while the pharmacological/clinical 
classification comprises cannabis-like compounds, hallucinogens, stimulants, entactogens 
(Schifano et al., 2015; Miliano et al., 2016). 
Synthetic cathinones  
The chemical structure of synthetic cathinones is related to the natural stimulant compound 
cathinone found in the leaves of the ‘khat plant’ (Catha edulis) (Kalix et al., 1990). Differences 
from amphetamines are due to the additional presence of a ketone oxygen group at the ß-
position which confers higher polarity with consequent decrease in the central nervous system 
penetration (Simmler et al., 2013; Nelson et al., 2014). This property may drive users to 
increase drug dosages with consequent more profound adverse peripheral effects. Commonly 
marketed over the internet as ‘bath salts’, ‘plant food’, ‘insecticides’, their popularity was likely 
driven by a scarce availability of good quality amphetamine, cocaine or MDMA, combined 
with more restrictive legal regulations. Snorting, ingestion, injection are the most typical routes 
of administration (ROAs) used, while tablets, capsules and liquids are the most common 
available formulations. Synthetic cathinones are the second widest group of NPS monitored by 
the EMCDDA. Globally, 118 compounds were detected, with 14 of them being notified for the 
first time in 2016 (EMCDDA, 2017). The potency levels at the serotonin, dopamine and 
noradrenaline transporters (SER, DAT, NET, respectively) can change considerably among 
different compounds but all typically exhibit sympathomimetic effects. Specifically, some 
cathinones are aspecific monoamine transporter inhibitors with some of them being also 
serotonin releasers acting at the SERT (e.g. butylone, ethylone, mephedrone, methylone) 
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and/or dopamine releaser acting at the DAT (methcathinone and flephedrone), while some 
others being highly potent and selective DAT and NET inhibitors without releasing properties 
(e.g. pyrovalerone and MDPV). Additionally, some of them (e.g. mephedrone) exhibit 
interactions with serotoninergic receptors 5HT2A and/or α-2 adrenergic receptors, leading to an 
increased risk of experiencing a serotonergic syndrome or a catecholaminergic toxicity (López-
Arnau et al., 2012). Cathinone-related effects include increased alertness, agitation, aggression, 
euphoria, excited delirium, hallucinations, tachycardia, hypertension, hyperthermia and mood 
disturbances. Many fatalities (hundreds in the UK alone) have been linked to some cathinones 
such as mephedrone, methylone and butylone. Tolerance, dependence and withdrawal 
symptoms related to synthetic cathinones were reported as well (EMCDDA, 2015). 
Phenethylamine/MDMA-like drugs  
This class includes molecules like 2C- and 3C-series drugs (2C-B, 2C-I, 2C-E, 3C-bromo-
Dragonfly), 4-MTA, MPA, 6-APB, and NBOMe series drugs. These chemicals typically show 
high affinity for the serotonin receptors 5-HT2A/C sometimes coupled with monoamine 
reuptake inhibition. They are usually marketed and consumed as MDMA substitutes, and may 
elicit a range of entactogenic, stimulant and hallucinogenic effects (increased empathy and 
confidence, openness, feeling of friendliness, emotional closeness to others, euphoria, energy, 
alertness, disinhibition, perceptual alterations, hallucinations). The consumption of these drugs 
has become a cause for concern as a result of a range of serotonergic and sympathomimetic 
toxicity effects developed after their use (e.g. tachycardia, hypertension, hyperthermia, 
vomiting, diarrhoea, convulsions, sweatiness, acute renal failure). Among these drugs, 3C-
bromo-Dragonfly (“B-Fly”) has been considered an extremely potent stimulant with long-
lasting hallucinogenic effects (up to 3 days of psychoactive effects) associated with confusion 
and anxiety (Schifano et al., 2015). NBOMe drugs show LSD-like effects, and include the 25X-
NBOMe series of hallucinogens. They interact with several receptors and exhibit a significant 
higher affinity for 5-HT2A receptors. The most commonly reported psychedelic effects include: 
mood lift, greatly heightened awareness, changes in visual, auditory, tactile, olfactory, 
gustatory, and kinaesthetic perceptions. Symptoms of acute toxicity include tachycardia, 
hypertension, agitation, aggression, seizures, liver and kidney failure. 25C-NBOMe (“N-
bomb”, “Pandora”) is one of the most harmful among the NBOMe compounds. It is a partial 
agonist of 5-HT2A receptors and it is typically consumed orally or sublingually. It produces 
stimulation, hallucinations, and unpredictable violent episodes (Schifano et al., 2015). Overall, 
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several cases of toxicity events and fatalities have been linked to Phenethylamines/MDMA like 
drugs (Miliano et al., 2016; Schifano et al., 2015 and 2016). 
Tryptamines 
Tryptamine derivatives include several compounds chemically related to the endogenous 
compounds serotonin (5-HT) and melatonin (N-acetyl-5-methoxytryptamine) naturally 
produced by the human/animal body. Many tryptamines are naturally found in certain fungi 
(psilocin and psilocybin), plants (DMT and 5-MeO-DMT) and as constituents of venoms from 
some amphibians (bufotenin, 5-hydroxy-indolethylamines) (Schultes et al., 1979; Cimino et 
al., 1978). Additionally, other tryptamines have been synthesised and researched as 
medications for migraine (Brandes et al., 2007; Schifano et al., 2016). Synthetic tryptamines 
appeared in the drug scenario in the 1990s and dominated the market until they were listed as 
narcotics in 2007 (Schifano et al., 2016). Nevertheless, several novel tryptamines continue to 
be sold as designer drugs over the Internet, including: 5-MeO-DALT, AMT, 5-MeO-AMT and 
5-IT (EMCDDA, 2015). While natural tryptamines are sold as products containing dried 
mushrooms (‘magic mushrooms’), synthetic tryptamines are typically found as components of 
capsules, powders, tablets, or liquids. Sniffing, swallowing, smoking or injections are the most 
typical ROAs used, while brand names for tryptamines include ‘Foxy-Methoxy’, ‘alpha-O’, 
‘alpha’, ‘changa’ (www.bluelight.com).  
The primary clinical symptoms produced by tryptamines are visual hallucinations and 
psychedelic effects resulting from agonistic activity at the level of 5HT1A, 5HT2A, and 5HT2C 
receptors with lower affinity for 5HT2A receptors compared to phenethylamines. Other targets 
involved in tryptamine activity are serotonin transporters, vesicular monoamine transporters 
type 2 (VMAT2) and trace amine-associated receptors (TAAR) (Fantegrossi et al., 2008; Su et 
al., 2009; Ray, 2010). Other clinical symptoms are euphoria, pro-social effects, alterations in 
sensory perceptions and depersonalization; while side-effects include common 
sympathomimetic effects (e.g. agitation, aggression, anxiety, tachycardia, hypertension) and 
serotoninergic toxicity (high body temperature, tremor, sweating, dilated pupils, diarrhoea, 
seizures) (Dargan and Wood, 2013; Schifano et al., 2016). Additionally, hallucinogen 
persisting perception disorder (HPPD) with recurrent presence of sensory disturbances, may 
be sometimes observed, causing a serious concern related to the emergence of psychiatric 
symptoms/syndromes following tryptamine exposure (Orsolini et al., 2017). Among 
tryptamines, AMT caused the highest number of fatalities in the UK with an overall amount of 
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7 fatalities between 2012 and 2013 (Schifano et al., 2016). 5-IT, a positional AMT isomer, 
appeared in the illicit market since 2012 and it exhibits both hallucinogenic and stimulant 
effects (Sanders et al., 2008). Recently, the tryptamine class has spread to another subclass of 
tryptamines called ‘ergolines’ which are derivatives of LSD (Tittarelli et al., 2015; ACMD 
2014a). They produce effects similar to LSD as a result of their activity at the level of 5HT2A 
receptors with subtle different potencies on cortical neurons. Some novel LSD derivatives 
include: LSZ (lysergic acid 2,4-dimethylazetidide), ETH-LAD (6-ethyl-6-nor-lysergic) and 
AL-LAD (6-allyl-6-nor-lysergic acid diethylamide). Clinical effects are similar to those 
produced by LSD and include: headache, nausea, hyperthermia, perceptual disturbances, 
distortions of body image, synaesthesia. Although the psychedelics’ pharmacological 
mechanism of action has been widely debated over the years, the most commonly accepted 
theory involves the stimulation of serotonin 5HT2A receptors on cortical neurons. The 
hyperactivation of these receptors, following psychedelic exposure, may affect cognitive and 
sensory information by disrupting the functioning of the cortico-striato-thalamo-cortical 
pathways, causing occurrence of aberrant feelings and altered perceptions (Rolland et al., 
2014). 
Piperazines 
Piperazines belong to a wide class of chemical compounds that contain a core piperazine 
functional group. They are synthetic substances without natural counterparts, initially intended 
to be used as antihelminthic drugs but later researched as antidepressants (Nelson et al., 2014). 
Benzylpiperazines and phenylpiperazines are the main subclasses of piperazines used with 
recreational purposes. Among them the most common piperazines encountered are 1-
benzylpiperazine (BZP), 1-methyl-4-benzylpiperazine,1-(3-trifluoromethylphenyl)piperazine 
(TFMPP), 1-(2-methoxy-phenyl)piperazine, 1-(3-chlorophenyl)piperazine (Iversen et al., 
2014; Nelson et al., 2014). They have become popular on the online market to mimic Ecstasy 
effects as MDMA became forbidden. They may be found as constituents of capsules, pills, 
tablets, powders or liquids, under different brand names like: ‘Rapture,’ ‘Herbal ecstasy’, 
‘Legal X’ (Iversen et al., 2014).  They may also be present in preparations containing mixtures 
of piperazines (BZP/TFMPP) along with other drugs and especially stimulants (Nelson et al., 
2014). Benzylpiperazines are monoamine releasing agents acting at the level of DAT, SERT, 
NET. In contrast, phenylpiperazines (e.g. TFMPP) act as serotonin releasers at the SERT and 
interact with serotonin receptors (likely responsible for their hallucinogenic effects), but have 
little effects on dopamine or norepinephrine pathways (Nelson et al., 2014). Among 
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piperazines, the onset, peak time, and duration of symptoms change considerably (Iversen et 
al., 2014).  Overall, the most common reported side-effects are: anxiety, agitation, aggression, 
tremors, confusion, insomnia, appetite loss, nausea, psychosis, hallucinations, serotoninergic 
syndrome; while desired effects include MDMA-like effects (e.g. euphoria, disinhibition, pro-
social effects, enhanced empathy and sociability) (Arbo et al., 2012; Schifano et al., 2015). 
Several BZP-related fatalities have been described with piperazines being found in post-
mortem samples as causative agents or contributory factors (Nelson et al., 2014).  
Pipradrol-derivatives   
Pipradrol derivatives are synthetic stimulants that are typically sold as replacements for 
MDMA. Recreational use of pipradrol-derivatives was first detected in 2007 with a quick 
increase in popularity the year after. They are usually sold in powder form highly soluble in 
liquids and act as norepinephrine-dopamine reuptake inhibitors (NDRI), with some of them 
showing an additional releasing activity at these transporters (Simmler et al., 2014). Typical 
desired effects include: euphoria, sociability, increased energy, alertness and awareness; while 
untoward effects are: hypertension, tachycardia, sweating, tremors, insomnia, aggression, 
psychosis (Corkery et al., 2012).  
Arylcyclohexylamines 
The arylcyclohexylamine chemical class includes phencyclidine analogues (e.g. 
methoxetamine, ketamine, 3-MeO-PCP, 3-MeO-PCE and 3-MeO-PCPr) that have emerged as 
legal alternatives to phencyclidine (PCP). Common routes of administration include: oral, 
sublingual or nasal administration and when administered, produce hallucinogenic and highly 
dose-sensitive dissociative effects. These chemicals, similarly to PCP, act as NMDA receptor 
antagonists and SERT inhibitors.  Positive effects include: perceptions enhancement, 
stimulation and dissociative effects; while side-effects consist of mania, delusions, psychosis 
and sensory suppressions (Roth et al., 2013).  
Aminoindanes  
The class of aminoindanes is represented by molecules that are based on the 2-aminoindane 
nucleus. According to the UNODC, the most commonly aminoindanes reported were 5-iodo-
2-aminoindane (5-IAI), 5,6-methylenedioxy-2-aminoindane (MDAI) and 2-aminoindane (2-
AI). Commonly sold over the Internet with brand names such as ‘Blurberrys’, ‘Champagne’ 
‘gold’, ‘Groove-e’, ‘Pink’, are typically found as powder, capsules, tablets and may be ingested 
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or snorted (Schifano et al., 2016). Since 2010, aminoindanes became increasingly popular over 
the Internet as legal alternatives to MDMA and sought for their hallucinogenic, entactogenic 
and stimulant properties (Sainsbury et al., 2011; Coppola et al., 2013). Common sought-after 
effects are: hallucinations, euphoria, increased energy, increased libido and empathy; while 
untoward effects include nausea, vomiting, hypertension, hyperthermia, sweatiness, tremors, 
psychosis (Schifano et al., 2016). Some cases of fatalities consistent with a serotonin syndrome 
have occurred over the years with aminoindanes being identified at post-mortem. Specifically, 
in the UK, 3 fatalities related to MDAI alone or in combination with other drugs of abuse were 
reported (Corkery et al., 2013; Schifano et al., 2016). Recently, the pharmacological activity 
of 5-IAI and MDAI was studied using in vitro release assays in human embryonic kidney 293 
cells (HEK 293) that highly express DAT, NET and SERT. According to this study, 5-IAI and 
MDAI, similarly to MDMA, were more potent SERT and NET inhibitors vs DAT inhibitors 
and both showed monoaminergic releasing activity at SERT. On the other hand, MDAI showed 
additional norepinephrine releasing properties while 5-IAI mediated additional dopamine 
releasing properties (Simmler et al., 2014). In vitro release assays in brain synaptosomes 
showed slightly different results with both MDAI and 5-IAI being more potent SERT and DAT 
vs. NET inhibitors (Johnson et al., 1991; Simmler et al., 2014). Differently from MDAI and 
MDMA, 5-IAI interacts with 5-HT2A receptors, leading to hallucinogenic effects (Nichols et 
al., 2004). Drug discrimination studies in rats demonstrated that both 5-IAI and MDAI 
substituted for MDMA although they seem less neurotoxic (Nichols et al., 1991; Simmler et 
al., 2014). The comparable subjective effects of MDAI and MDMA are furthermore supported 
by users’ reports (Corkery et al., 2013). Among aminoindanes, 2-AI exhibits a profile like BZP 
as it is a selective NET inhibitor with additional norepinephrine- and dopamine-releasing 
properties. Based on this profile it is a mild psychostimulant compared to MDMA.  
Aminoalkylindoles 
The fast-changing class of aminoalkylindoles (AAIs) comprises hundreds of CB1/CB2 agonists, 
often referred to as synthetic cannabinoids as they mimic the pharmacological actions of Δ9‐
tetrahydrocannabinol (Δ9‐THC), the key psychoactive ingredient found in cannabis. The lead 
compound of this AAI class is the synthetic cannabinoid JWH-018 originally synthesized in 
1995 in the laboratory of Clemson University (USA) for research purposes and subsequently 
marketed all over the world along with other synthetic cannabinoids (e.g. dybenzopirans, 
cycloesyphenols) as a psychoactive component of recreational smoking herbal products 
commonly known as ‘Spice’, ‘Fire, ‘Smoke’, ‘Yucatan’, ‘Skunk’. When compared to the 
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partial CB1 agonist Δ9‐THC, JWH-018 shows a full CB1 agonistic activity with fourfold 
affinity (3.4 ± 0.6 nM) (De Luca et al., 2015). Euphoria, well-being, increased creativity, sense 
of relaxation, emotional alterations, sedation are the most common positive effects reported, 
while hallucinations, psychomotor agitation, aggressiveness, intense paranoia and psychotic 
episodes, are the typical side-effects linked to the aminoalkylindoles (Fattore and Fratta, 2011). 
Chapter 2: Index compounds in the present PhD project 
2.1) Synthetic cannabinoids  
The history of synthetic cannabinoids (SCs) started in the 1960s when Raphael Mechoulam 
and his colleague Yehiel Gaoni, firstly identified and synthesized delta-9-tetrahydrocannabinol 
(Δ9‐THC), the principal psychoactive compound in cannabis. Their discovery opened the door 
to the synthesis of a range of novel SCs chemically/pharmacologically related to Δ9‐THC and 
potentially useful to provide new insights into the activities of the endogenous cannabinoid 
system. HU-210, widely known as the lead compound of the dibenzopyran group, was the first 
SC designed in Mechoulam’s lab with the purpose of probing the endogenous cannabinoid 
system. Along this path, between 1970 and 1980 the cyclohexylphenol CP-55,940 was 
synthesized in Pfizer’s laboratory and designed to target cannabinoid receptors. In the 1990s, 
the new chemical group of aminoalkylindoles was designed in John W. Huffman’s laboratory, 
with WIN-55,212-2 and JWH-018 investigated as potential pharmacotherapies (Castaneto et 
al., 2014). Aware of the powerful psychoactive activities produced by these designer drugs, 
clandestine laboratories started synthesising a range of SCs illegally, kicking off the illicit 
trading of these drugs over the internet, smart shops, head shops, gas/petrol stations. In a few 
years, they became quickly popular as powerful/abusable psychoactive components of Spice 
drugs and for their undetectability in standard cannabinoid screening tests (EMCDDA, 2014). 
2.1.1) Classification of synthetic cannabinoids 
Starting in 2009, legal restrictions aimed at some SCs, promoted the synthesis of three 
subsequent generations of analogue replacements, purposefully added to herbal mixtures to 
emphasize the sought-after desired effects of Spice preparations (ACMD, 2009, 2012, 2014b; 
Pintori et al., 2017).  
The first generation of SCs comprises compounds considered harmful according to the first 
round of control (enacted in 2009) under the Misuse of Drugs Act 1971 and includes: alkyl, 
alkenyl, cycloalkylmethyl, cycloalkylethyl derivatives of naphthoylindoles (e.g. JWH-018, 
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JWH-073, WIN-55,212-2); naphthylmethylindoles (e.g. JWH-075, JWH-084); 
naphthoylpyrroles (e.g. JWH-145, 146); naphthylmethylindenes (e.g. JWH-176); 
phenylacetylindoles  (e.g. JWH-167, 203); cyclohexylphenols (CP-47,497); and dibenzopyrans 
(HU-210) (ACMD, 2009). 
Over a couple of years, the second generation of synthetic cannabinoids appeared on the market 
and  embraced all chemicals outside the scope of the 2009 control (ACMD, 2012), including 
compounds with haloalkyl side chains (e.g. AM-694, MAM-2201); with (N-methylpiperidin-
2-yl)methyl side chains (e.g. cannabipiperidiethanone, AM-2233, AM-1220); Benzoylindoles 
(e.g. AM-679, 1-pentyl-3-(4-methoxybenzoyl)indole, pentyl-3-(2-methoxybenzoyl)indole); 
Adamantoylindoles (e.g. AM-1248, AB-001); 3-(2,2,3,3-
Tetramethylcyclopropylcarbonyl)indoles (e.g. UR-144). 
Since the SC market continued growing exponentially, in 2014 the ACMD proposed a revised 
generic control covering a wide number of third generation SC compounds chemically related 
to JWH-018, and showing specific modifications on its substructures (indole ring, pentyl 
substituent, methanone and naphthyl ring). Some controlled modifications include: substitution 
of the indole ring with indazole, imidazole, benzimidazole; replacement of the pentyl 
substituent with alkyl, benzyl, cycloalkylethyl; replacement of the methanone group with a 
carboxylate, ethanone, methylene bridge, carboxamide; replacement of the 1-naphthyl ring 
with adamantyl, benzoyl, cycloalkyl, quinolinyl, piperazinyl (ACMD, 2014b).  
2.1.2) Third generation synthetic cannabinoids  
BB-22 
 
 
Figure 1: Chemical structures of JWH-018 and BB-22 
BB-22 or 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester) (see Figure 1) 
is a synthetic cannabinoid marketed online as a recreational drug whose popularity quickly 
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increased due to its powerful psychoactive effects that have been described as stronger 
compared to the parental compound JWH-018. The recreational use of BB-22 was first reported 
in Japan in 2013 (Uchiyama et al., 2013) and in a couple of years began spreading in the 
worldwide NPS market. Analytical investigations identified BB-22 in recreational herbal 
preparations commonly smoked by users seeking cannabis-like effects. Typical street names 
are “QUCHIC” or “VERTEX” and a range of emergency admissions in the UK has been 
recently reported (Abouchedid et al., 2017; De Luca et al., 2016). 
Compared to JWH-018, BB-22 preserves the indole structure, shows replacement of the pentyl 
substituent with a cyclohexylmethyl group, substitution of the 1-naphthyl ring with a quinolinyl 
group and replacement of the methanone group with a carboxylate. 
The extremely high CB1 affinity, potency, dose-response efficacy of BB-22 may potentially 
concur for more severe psychoses (paranoia, hallucinations) and side-effects (agitation, 
tachycardia, anxiety, hypertension) compared to JWH-018, giving rise to even more worrying 
clinical concerns. Since 14th December 2016, BB-22 is a Class B drug under the Misuse of 
Drugs Act 1971. This makes it an offence to import, export, supply, possess, produce this drug 
without Home Office authorization (ACMD, 2016). 
5F-PB-22 
 
Figure 2: Chemical structures of JWH-018 and 5F-PB-22 
5F-PB-22 or Quinolin-8-yl 1-pentyfluoro-1H-indole-3-8-carboxylate (see Figure 2) is a 
synthetic cannabimimetic showing slight chemical differences compared to BB-22. It is 
marketed as an herbal incense product and it is typically found as a component of herbal 
preparations alone or along with other analogues. Psychoactive effects (mood lift, increased 
energy and sociability) have been described as powerful and comparable to those produced by 
BB-22 (De Luca et al., 2016); while several toxicity events (Fujita et al., 2016) and deaths 
(Behonick et al., 2014) have been reported after its consumption alone or in combination with 
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other substances. Typical street names are ‘QUPIC’, ‘atomic bomb’, ‘black mamba’ (Pintori 
et al., 2017). Compared to JWH-018, 5F-PB-22 preserves the indole group, shows a 
fluorination on the pentyl tail, substitution of the 1-naphthyl ring with a quinolinyl secondary 
structure (similarly to BB-22), and replacement of the methanone group with a carboxylate 
(ester bond).  
The ester bond featured by 5F-PB-22 (and BB-22 as well) may undergo in vivo hydrolysis 
reaction mediated by carboxylesterase enzymes, causing an accumulation of toxic metabolites 
that is not observed with compounds featuring a ketone group instead of the ester bond, like 
JWH-018 (Behonick et al., 2014). The accumulation of toxic metabolites may be one of the 
mechanisms underlying the extreme harmfulness that characterises quinolinyl carboxylate 
synthetic cannabinoids.  
Since 14th December 2016, 5F-PB-22 is a Class B drug under the Misuse of Drugs Act 1971 
(ACMD, 2016). 
5F-AKB-48 
 
Figure 3: Chemical structures of JWH-018 and 5F-AKB-48 
5F-AKB-48 or N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (see 
Figure 3) is an indazole-based synthetic cannabinoid commonly contained in herbs often mixed 
with tobacco and smoked using bongs, joints and pipes. Common street names are: ‘5F-
APINACA’, ‘Sweet Leaf C-Liquid’, ‘Aladin Legend 3rd Edition’, ‘Super snake green’, 
‘Voodoo’, ‘Voodoo Gold’. The main routes of administration reported are smoking, oral, 
followed by inhalation and sniffing (World Health Organization, 2016). 
Compared to JWH-018, 5F-AKB-48 shows a fluorination on the pentyl tail, substitution of the 
indole core with an indazole group, replacement of the 1-naphthyl ring with an adamantyl 
structure and substitution of the methanone group with a carboxamide.  
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Structurally, it is identical to AKB-48 except for a fluorination on the terminal carbon of the 
pentyl side chain. The presence of the indazole structure may promote 5-HT2A receptor 
dysfunction and cause hallucinations, psychosis and serotonin syndrome. Furthermore, the 
fluorination of the pentyl side chain may facilitate diffusion through the blood-brain barrier 
enabling rapid absorption of the compound (Schifano et al., 2015), and increase CB1 receptor 
activity in the range of 2 to 5-fold higher compared to corresponding defluorinated analogues 
(Banister et al., 2015).  
Overall, users describe 5F-AKB-48 as a very short-acting cannabinoid with a quick high, and 
rapid developing dependence. A range of side-effects has been reported such as tachycardia, 
agitation, panic attacks, nausea, vomiting, hallucinations, hypertension, psychosis, seizures; 
while withdrawal symptoms include chest pains, tachycardia, insomnia, paranoia.  Since 14th 
December 2016, 5F-AKB-48 is a Class B drug under the Misuse of Drugs Act 1971 (ACMD, 
2016). 
STS-135 
 
  
 
 
Figure 4: Chemical structures of JWH-018 and STS-135 
STS-135 or (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (see Figure 4) 
is a psychoactive substance that originated in Thailand, typically found in herbal incense 
products and dried herbal preparations suitable for smoking. Liquid injectable formulations are 
also available along with dry powder formulations suitable for oral administration. Its common 
street name is ‘5F-APICA’.  
Compared to JWH-018, STS-135 shows a fluorination on the pentyl tail, replacement of the 1-
naphthyl ring with an adamantyl structure and substitution of the methanone group with a 
carboxamide. Structurally, it is identical to 5F-AKB-48 except for the presence of the indole 
group instead of the indazole ring.  
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The adamantyl-cannabinoids like STS-135, along with 5F-AKB-48, have been the most 
popular SCs marketed in the UK. However, they are still undetectable through conventional 
toxicology screening tests (Mcllroy et al., 2016).  
STS-135 is rapidly metabolized with only 25% initial compound remaining after three hours 
of incubation with human hepatocytes. By high resolution mass spectrometry, about thirty-nine 
potentially active or toxic metabolites of STS-135 resulting from processes of 
monohydroxylation, dihydroxylation, trihydroxylation, with or without glucuronidation were 
isolated (Gandhi et al., 2015). 
Compared to cannabis, the abuse of STS-135 has been associated with more serious side-
effects and toxicity events in general. Reported cognitive effects include anxiety, paranoia, 
emotionality enhancement, psychosis, dream suppression; while physical effects comprise 
cardiovascular disturbances (myocardial infarction) typically observed with compounds with 
adamantyl moieties (Mcllroy et al., 2016).  
According to its recognised potential to cause life-threatening conditions, since 14th December 
2016, STS-135 has been classified as a Class B drug under the Misuse of Drugs Act 1971 
(ACMD, 2016).  
2.1.3) ‘Spice’ drugs 
‘Spice’ drugs are herbal preparations that contain synthetically-derived compounds (synthetic 
cannabinoids) targeting CB1 receptors. They were initially traded as legal alternatives to 
marijuana in Europe in the early 2000s, and they became quickly very popular. The term 
‘Spice’, originally used as a brand name, is nowadays used as a generic term for SC 
preparations (Castaneto et al., 2014).  
These products are suitable for smoking through traditional cigarette papers, cannabis pipes or 
electronic cigarettes; alternatively, they can be inhaled or consumed as infusions (Pintori et al., 
2017).  Brand names are quite curious and attractive (e.g. ‘K2’, ‘Black mamba’, ‘Black magic 
smoke’, ‘Herbal Incense’, ‘Blue Berry Yum-Yum’, ‘Ace of Spades’, ‘Atomic bomb’) aiming 
to capture the imagination and attention of millions of people of every age, race and gender 
(Corazza et al., 2014; Support Spice Addiction, 2017).  
Their widespread distribution can be attributed to ingenious marketing strategies which 
typically adopt multi-coloured packaging and misleading labels intended to depict Spice drugs 
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as ‘safe’ herbal mixtures which are ‘not intended for human consumption’. Despite law 
enforcement and other regulatory efforts to curb their accessibility, commercial Spice products 
remain available on the web, fuelling illegal business activities and giving users the deceive 
idea that these drugs are ‘harmless’ and ‘natural’. Overall, the main reasons that drive SC use 
are their intense psychoactive effects; novelty attraction; accessible price and availability; lack 
of detectability in drug screening tests; legality and misperceived safety (Pintori et al., 2017). 
Analysing the pharmacological analogies between SCs and Δ9-tetrahydrocannabinol (Δ9-
THC), has been a subject of huge relevance in the scientific field. In this regard, in a variety of 
in vitro and in vivo assays, SCs have been described as showing higher binding affinity, potency 
and efficacy at CB1 receptors compared to the partial agonist Δ9-THC (De Luca et al., 2016). 
Furthermore, metabolites of SCs may preserve higher CB1 affinity compared to Δ9-THC 
explaining the increased mortality and toxicity events linked to SC use/abuse, compared to 
marijuana (Tai et al., 2014).  
2.1.4) Epidemiology of synthetic cannabinoids 
Over the past years, several epidemiological studies have been conducted on SC use, and 
especially three worldwide surveys have turned out to be of key importance to picture the SC 
user profile (Vandrey et al., 2012; Winstock and Barratt, 2013; Winstock et al., 2015; Castaneto 
et al., 2014).  
The first one was carried out between 2011-2012 and included members from 13 different 
countries and 42 US states, mainly engaged from online web fora focusing on SCs. Only first-
hand SC users from 18 years onwards, and English-speaking, were considered (168 out 391 
individuals in total). Most of them turned out to be White men, with at least a high school 
education. The average age of first SC use was 26 years. The concomitant intake of alcohol or 
cannabis along with SCs, was frequently reported. Smoking followed by oral, rectal and 
vaporizing were the most typical routes of administration described, while the main reasons 
driving SC use were curiosity, sought-after desired effects, and positive drug test avoidance. 
About 15% of them experienced dependence and withdrawal effects (e.g. anxiety, irritability, 
depression) as a result of SC abuse (Vandrey et al., 2012; Castaneto et al., 2014). 
The second worldwide survey was the ‘Global Drug Survey’ (GDS, 2012) that was conducted 
between November and December 2011 and it was widely advertised over the Internet and 
especially through social networking media (e.g. Facebook and Twitter). Overall, this survey 
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collected data from different countries including US, UK, Australia, Canada, Finland, Hungary, 
Ireland, Mexico, New Zealand, Japan, Poland and South Africa. Most respondents were White, 
males, with an average age of 26 years old.  
Overall 14,966 participants responded, and 6.5% of them described themselves as recent SC 
users (last 12-month use). Among recent users, most of them were White, males, heterosexual, 
with an average age of 25 years, currently employed and typically living with their parents. 
The main countries of origin were US followed by UK. Among those who reported a recent 
use of SCs, the majority described a weekly frequency of use. Almost all recent SC users were 
previous natural cannabis users with the majority of them reporting to prefer cannabis over SCs 
because of the latter’s untoward effects. On the other hand, the remaining ones, preferred using 
SCs for other reasons, such as cheapness, easy availability, recreational effects, undetectability 
in standard toxicological screening tests (Winstock and Barratt, 2013).  
At the time of this survey just a very small number of participants was reported asking for 
emergency medical treatment following the use of SCs; however, two years after Winstock et 
co-authors found that, according to the data obtained from another online worldwide survey 
(with 22,289 respondents), the risk of asking for emergency medical treatment was 30 times 
lower for natural cannabis users compared to SC users (Winstock et al., 2015).  
Additionally, more recent figures from the latest Global Drug Survey (GDS, 2017) 
demonstrated that the risk of seeking emergency medical treatment was higher in men 
compared to women with men over the age of 25 years old being most at risk. Notably, episodes 
of three or more withdrawal symptoms were recorded in people who have used SCs on at least 
50 days in the last year. A total of 1240 last year SC users participated in this survey, and most 
of them obtained SCs from friends rather than online (GDS, 2017).  
2.1.5) Social issues represented by synthetic cannabinoids and their effects 
To date, several different SCs have been found widely differing in chemical structure, potency, 
and pharmacodynamics. The SC-based preparations themselves are herbal blends onto which 
potent SCs are sprayed (Fattore and Fratta, 2011). The acute adverse symptoms reported after 
use of SC products are tachycardia, agitation, anxiety, psychosis, vomiting and seizures 
(Castellanos and Thornton, 2012; Hoyte et al., 2012).  
Recent studies demonstrated the higher health risks caused by SCs compared to cannabis 
according to their distinct pharmacodynamics which may contribute to the observed toxicity. 
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Additionally, the interactive effects resulting from multi-compound formulations and their 
active metabolites, highpoint the intrinsic threat related to the use of these substances (Schifano 
et al., 2015). Ready-to-use drug formulations generally contain a couple of grams of herbal 
material such as ‘Leonotis leonurus’, commonly known as ‘wild dagga’, and ‘Pedicularis 
densiflora’ typically advertised as ‘Indian warrior’ (Zuba et al., 2011). The herbal-based 
substrate gives the users the false feeling they are consuming a ‘safe’ and ‘natural’ product, 
without realising the powerful and dangerous effects of SCs laced with the plant material (Seely 
et al., 2012). To synthetise these preparations, SCs are first dissolved in ethanol or acetone and 
then mixed with plant material. Once the solvent evaporates, variable concentrations of these 
toxic drugs result laced with herbal material suitable for smoking (Fattore and Fratta, 2011). 
Compared to marijuana, SCs are extremely cheap, widely available, and particularly attractive 
for young users who want to experience cannabis-like effects, but are concerned of legal/social 
repercussions (Vandrey et al., 2012). Overall, Spice use is a serious public health threat, 
especially since several clinical reports demonstrated it can cause acute cardiovascular and 
central nervous system toxicity (Gunderson et al., 2012). 
The public health concern caused by these drugs gave rise to several regulations in most 
European countries and in the U.S. where the most popular SCs were classified into the 
Schedule 1 drugs under the Controlled Substances Act of the Drug Enforcement 
Administration (Fantegrossi et al., 2014). Although the research around SCs is quite 
challenging, it is also continuously evolving, and several testing laboratories started relying on 
analytical applications to assess SCs in human samples (Lovett et al., 2013). Considering the 
wide popularity of SC abuse around the world, a preclinical characterisation of these 
compounds is needed; additionally, a full understanding of their pharmacological, 
pharmacodynamical and toxicological properties is necessary. Particularly, these findings will 
support public health and administrative activities willing to draft a health impact profile for 
these drugs (Seely et al., 2012).  
2.1.6) Pharmacology of synthetic cannabinoids, focus on their effects on the reward 
circuit 
Most SCs identified in herbal blends have higher binding affinity at the CB1 receptor compared 
to Δ9-tetrahydrocannabinol (Δ9‐THC), and greater affinity at the CB1 compared to the CB2 
receptor. The CB1 receptor is the major subtype found in the brain, but it also occurs in the 
peripheral nervous system, and in organs such as the heart, lung, liver, in the vascular 
endothelium and reproductive system (Castaneto et al., 2014; Howlett et al., 2002). On the 
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other hand, CB2 receptors are mainly expressed in the immune system, while their expression 
in the central nervous system is minimal and significantly lower than CB1 receptors (Onaivi et 
al., 2008; Castaneto et al., 2014).  
The CB1 receptors may be activated by endogenous (anandamide and 2-arachidonoylglycerol) 
and exogenous cannabinoids (e.g. Δ9‐THC, and SCs). Physiologically, the endocannabinoids 
play important roles in the regulation of synaptic brain functions as they may act as ‘retrograde 
messengers’ in various brains regions (e.g. NAc and ventral tegmental area) by activating CB1 
receptors located in the presynaptic terminals and promoting a cascade of events such as: 
changes in calcium influx and potassium efflux, presynaptic hyperpolarisation, and reduction 
in neurotransmitter release (Alger, 2002; Wilson, 2002; Howlett et al., 2010) (see Figure 5, 
panel A). On the other hand, exogenous SCs directly interact with CB1 receptors enabling 
similar mechanisms (see Figure 5, panel A) (Ameri, 1999).  
It is likely that positive effects promoted by SCs (e.g. pleasure, euphoria, increased energy and 
sociability, relaxation, talkativeness) are mediated by activation of CB1 receptors located in the 
brain reward circuit (Gardner, 2002). 
This central neuronal circuit originates from a structure of the mesencephalon (ventral 
tegmental area) containing dopaminergic neurons, whose terminals interact with GABAergic 
medium spiny neurons located in the ventral striatum or NAc (area of the limbic forebrain) and 
glutamatergic neurons located in the frontal cortex. The ventral tegmental area (VTA) also 
contains GABAergic neurons which project to the NAc and the prefrontal cortex or locally 
target DA neurons through axon collaterals. Furthermore, the VTA receives glutamatergic 
projections from the amygdala, medial prefrontal cortex, pedunculopontine nucleus, and the 
subthalamic nucleus, while NAc sends axonal projections to the ventral globus pallidum (VP). 
Overall, the VTA, NAc, and VP are interconnected through reciprocal axonal projections 
whose functional integrity is crucial to observe drug-related reward behaviour in self-
administration studies (Lupica et al., 2004). 
It is possible that SCs, similarly to Δ9‐THC, act upon the central drug reward circuit increasing 
DA release in the target regions of the VTA DA neurons (Di Chiara and Imperato, 1988). To 
study the activity of SCs on the reward system, researchers usually refer to Δ9‐THC as an 
element of comparison. 
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Previous preclinical microdialysis studies in freely moving rats demonstrated the ability of Δ9‐
THC to increase DA release in the NAc after intravenous administration. This increase was 
reversed through three different methods: eliminating the calcium from the dialysate; blocking 
sodium channels with administration of tetrodotoxin; antagonising opioid receptors with 
systemic administration of naloxone (Chen et al., 1990). A subsequent study demonstrated that 
the synthetic cannabinoid WIN-55,212-2, similarly to Δ9‐THC, enhances DA function in the 
NAc and this effect was reversed antagonising either CB1 receptors with systemic 
administration in the VTA of SR141716A, or opioid receptors with the infusion in the VTA of 
the antagonist naloxone. Overall, these data demonstrated that, similarly to other abused drugs, 
SCs can increase DA release in the NAc through mechanisms critically dependent on action 
potentials and calcium activity, but also demonstrated that opioid and cannabinoid systems 
interact somehow in the reward circuit (Lupica et al., 2004). In particular, it is likely that 
cannabinoids may promote the opioidergic inhibition of GABA release onto DA neurons, 
suggesting a CB1-mediated disinhibitory mechanism (see Figure 5, panel B) (Lupica et al., 
2004).  
Additional electrophysiological studies (single unit recordings) in rodents (Gessa et al., 1998) 
and in brain slices containing VTA (Cheer et al., 2000), demonstrated that Δ9‐THC and 
synthetic cannabinoids such as WIN-55,212-2, HU-210, and CP-55,940 may cause an increase 
of the DA neuron-firing rate and DA neuron burst activity in the VTA with consequent 
enhancement of terminal release of DA in the NAc (see Figure 5, panel B). These effects were 
reversed either with the CB1 receptor antagonist SR141716A (confirming an involvement of 
CB1 receptors) or with the GABAA receptor antagonist bicuculline, suggesting a disinhibitory 
mechanism mediated by CB1 receptors similar to that observed for opioid receptors (Gessa et 
al., 1998, Cheer et al., 2000). 
This hypothesis was furthermore supported by the ability of WIN-55,212-2 to decrease 
electrically evoked inhibitory postsynaptic currents (IPSCs GABAA -mediated) in brain slices 
containing the VTA, suggesting an activation of CB1 receptors present on GABAergic neuron 
terminals of the VTA, which was antagonised by the CB1 antagonist SR141716A (Szabo et al., 
2002; Lupica et al., 2004).  
Overall, SCs are thought to modulate the activity of GABAergic projections originating in the 
NAc and targeting GABAB receptors located on VTA DA neurons, and the activity of 
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GABAergic neurons within the VTA that target GABAA receptors on VTA DA neurons (see 
Figure 5, panels B and C) (Lupica et al., 2004).  
Both the observed presynaptic inhibition of neurotransmitter release (Hoffman and Lupica, 
2000) and the high concentration of CB1 receptors in GABAergic terminals of the central 
nervous system helped to characterise the effects of synthetic cannabinoids at the level of the 
reward circuit (Freund et al., 2003).  
Furthermore, part of the rewarding actions of the SCs are mediated by actions occurring within 
the NAc, where these drugs are thought to reduce GABA release from intrinsic interneurons 
onto medium spiny neurons, producing a disinhibition of this GABAergic output to the VTA 
and other brain structures. Additionally, SCs can inhibit excitatory input from the prefrontal 
cortex onto GABA neurons by activation of CB1 receptors in the glutamatergic terminals 
thereby decreasing the inhibition of DA neurons in the VTA (see Figure 5, panel B) (Robbe et 
al., 2001). 
Overall, these observations highlighted the relative contributions of complex neuronal circuits, 
either within or outside the VTA (e.g. intrinsic and extrinsic GABAergic, glutamatergic, 
opioidergic pathways), whose modulation interferes with the interactions between 
cannabinoids and DA neurons and represent critical pathways accounting for some of the 
rewarding properties of cannabinoid exposure (Lupica et al., 2004). 
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Figure 5: Cannabinoid signal in the brain. Panel A: The mechanism of action of cannabinoids and the multi-step 
retrograde signalling pathway. 1) neurotransmitter is released from vescicles within the presynaptic neuron; 2) the 
postsynaptic CB1R is activated and endocannabinoids are synthesised and released; 3) the endogenous CB1R 
ligand diffuses back and activates the presynaptic CB1R; 4) activation of the presynaptic CB1R results in inhibition 
of neurotransmitter release; 5 and 6) SCs directly activate CB1 receptors and enhance the function of the 
cannabinoid system (this picture was adapted from Ware et al., 2008). Panel B: Simplified schematic 
demonstrating cannabinoid actions in the VTA. Panel C: Simplified schematic demonstrating cannabinoid actions 
in the NAc (These pictures were adapted from Lupica et al., 2004).   
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2.1.7) Synthetic cannabinoids and pharmacodynamics 
According to recent pharmacodynamical studies, the majority of SCs detected in herbal 
products possess higher affinity, efficacy and lower Ki values compared to the natural partial 
CB1 agonist Δ9-THC (Castaneto et al., 2014; De Luca et al., 2015). 
The pharmacodynamic properties of some Spice components have been recently fully 
investigated in rat cortical membranes using the radio-labelled competition binding assay (De 
Luca et al., 2016). The cortical brain area has been selected as target cerebral region as it 
exhibits a high expression of CB1 receptors and a negligible presence of CB2 receptors 
(Pertwee, 2005).  
According to these studies, JWH-018 fully inhibited the specific binding of [3H]CP-55,940 
with a Ki of 3.4 ± 0.6 nM. On the other hand, the Ki values of BB-22 (0.11 ± 0.03 nM), 5F-PB-
22 (0.13 ± 0.01 nM), 5F-AKB-48 (0.87 ± 0.14 nM) and STS-135 (1.93 ± 0.18 nM) were 
significantly lower compared to the first-generation SC JWH-018. According to these results, 
the rank order of CB1 receptor affinity was as follows: JWH-018< STS-135<5F-AKB-48< BB-
22=5F-PB-22 (De Luca et al., 2016). 
Additionally, all molecules showed high potency at the level of CB1 receptors, with BB-22 and 
5F-PB-22 showing EC50 values (2.9 ± 0.6 and 3.7 ± 0.6 nM) significantly lower than JWH-018 
(20.2 ± 1.3 nM), while no differences were observed compared to STS-135 (32.3 ± 2.9 nM) 
and 5F-AKB-48 (31.0 ± 7.5 nM). As regards to the efficacy (Emax), BB-22, 5F-PB-22 and 5F-
AKB-48 exhibited higher efficacy (217 ± 4; 203 ± 2; 190 ± 11% over basal) compared to JWH-
018 (163 ± 3% over basal) and STS-135 (168 ± 9% over basal) (De Luca et al., 2016). Overall, 
all SCs tested stimulated in a concentration-dependent and saturable way [35S]GTPγS binding, 
with BB-22 and 5F-PB-22 producing a greater stimulation compared to WIN-55,212-2 (De 
Luca et al., 2016). This effect was reversed by the CB1 receptor antagonist/inverse agonist AM-
251, suggesting the involvement of the activation of G-proteins paired with CB1 receptors. 
In another study [35S]GTPγS binding assay was repeated in CB1 knockout mice, using the same 
SCs and no activation of G protein was observed. These findings confirmed the involvement 
of the CB1 receptor in G protein stimulation (De Luca et al., 2016). 
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2.2 Pipradrol-derivatives   
Desoxypipradol (2-DPMP)   
 
Figure 6: Chemical structure of 2-DPMP 
Desoxypipradrol, also known as 2-diphenylmethylpiperidine (2-DPMP) (see Figure 6), is 
chemically related to methylphenidate and pipradrol and shares with them a similar 
pharmacology. It is a highly lipophilic molecule with longer duration of action when compared 
to most psychostimulants of the same class. The absence of polar functional groups, usually 
targeted by metabolic enzymes, accounts for its long elimination half-life and persistent activity 
after use. Initially developed by the pharmaceutical company CIBA for research in the 
application of narcolepsy and ADHD (Attention deficit hyperactivity disorder) (Tripod et al., 
1954), it was quickly replaced with the short acting compound methylphenidate and researched 
for alternative applications, such as promotion of recovery from anaesthesia, but without 
success (Bellucci, 1955). 
Starting from 2008, the popularity of 2-DPMP and its availability for purchase dramatically 
increased in the UK. Originally marketed under the brand name of ‘Ivory Wave’, ‘Whack’, 
‘Lunar Wave’ as a white crystal powder with a purity of up to 99.9%, quickly spread over the 
internet, head shops, smart shops, causing several accidents and emergency admissions. The 
most typical used routes of administration were: oral, insufflation, injection, rectal with dosages 
ranging from 1-10 mg depending on the route used (Corkery et al., 2012). Toxic 
symptomatology was characterised by long-lasting agitation (lasting up to five days) 
sometimes requiring physical restraint, hallucination, paranoia, psychosis, muscle spasms. 
Numerous emergency room toxicology reports led to the decision to classify Desoxypipradrol 
as a Class B drug in the UK under the Misuse of Drugs Act, 1971 on 13 June 2012 (Home 
Office, 2012). 
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Diphenylprolinol (D2PM) 
 
Figure 7: Chemical structure of D2PM 
Diphenylprolinol also known as D2PM or diphenyl-2-pyrrolidin-2-yl-methanol (see Figure 7), 
is a pyrrolidine analogue of pipradrol, sold primarily over the Internet and found in Ecstasy 
tablets as replacement for MDMA. Recreational use of D2PM started in March 2007, but only 
developed slowly, achieving a peak in spring 2011 with several Emergency Department 
admissions recorded. It was typically marketed as ‘head candy’ and described as an odourless 
crystalline powder easily soluble in liquids and with high purity levels (e.g. ≥98%). The most 
typical used route of administration was rectal followed by snorting and oral (Corkery et al., 
2012). Following several reports of acute toxicity and fatalities related to its use, 
Diphenylprolinol was classified as a Class B drug in the UK under the Misuse of Drugs Act, 
1971 on 13 June 2012 (Home Office, 2012). 
2.2.1) Pharmacological studies on 2-DPMP and D2PM  
From a pharmacological point of view, 2-DPMP and D2PM may act as potent DAT and NET 
inhibitors with a weak activity at the level of SERT. The activity at the NET, DAT, SERT   was 
evaluated in human embryonic kidney 293 cells (HEK 293) that highly and stably express these 
transporters. Initially the cells were incubated with increasing concentrations of either 2-DPMP 
or D2PM (10-10-10-3M) for 10 minutes, then DA, NE, 5-HT tritiated were added to the buffer 
in order to promote uptake transport of labelled monoamines for another ten minutes. The 
uptake was then blocked by separating the cells from the buffer through rapid centrifugation. 
Afterwards, the tubes were frozen, the cell pellet was isolated from the essay buffer layers, and 
scintillation fluid was added in order to count the radioactivity in a beta-counter. Specific 
uptake was assessed by subtracting the non-specific uptake (determined in the presence of 
nisoxetine for NET cells, mazindol for DAT cells, fluoxetine for SERT cells) from the total 
counts. The IC50 values were then calculated and the DAT/SERT ratios were established to 
predict the psychoactive properties of these substances. Higher activity at the DAT may 
indicate a higher abuse potential, while greater potency at SERT may predict MDMA-like 
effects with lower abuse potential. Overall, according to this study, the pipradrol derivatives 2-
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DPMP and D2PM, were more potent DAT and NET vs. SERT inhibitors. IC50 values for 2-
DPMP were as follows: 0.04 µM for DAT, 0.14 µM for NET and >10 for SERT, while IC50 
values for D2PM were 0.86 µM for DAT, 0.41 µM for NET and 38 µM for SERT (Simmler et 
al., 2014). 
In another study, the effects of 2-DPMP and D2PM (100 mM) on transporter-mediated NE, 5-
HT, and DA release were assessed in HEK 293 cells. Briefly the cells were preloaded with NE, 
DA, 5-HT tritiated and release was evaluated by adding release buffer containing either 2-
DPMP or D2PM (100 mM). After 15 minutes for serotonin and dopamine cells, and 45 minutes 
for norepinephrine cells, an adequate amount of radioactivity was released and a comparison 
with controls was made. The negative control conditions were assessed using nisoxetine (NET 
cells), mazindol (DAT cells) and citalopram (SERT cells). The release was stopped by 
removing the buffer and washing the cells twice with fresh buffer. The radioactivity was then 
quantified and the compounds showing greater monoamine release compared to the respective 
transporter inhibitors, were considered monoamine releasers. Overall, according to this study, 
the pipradrol derivatives 2-DPMP and D2PM were not substrate releasers at the level of 
monoaminergic transporters (Simmler et al., 2014). 
Furthermore, another in vitro study demonstrated the ability of 2-DPMP to stimulate evoked 
dopamine efflux in NAc brain slices to a greater extent compared to cocaine. Briefly, rat brain 
slices from the NAc core were exposed to cocaine or 2-DPMP for 60 minutes, and then DA 
release was evoked and recorded using Fast Scan Cyclic voltammetry (FSCV). According to 
this study 2-DPMP (1, 3 or 10 µM) increased evoked DA efflux and slowed DA reuptake to a 
greater extent compared to cocaine at the same doses. Specifically, the increase of evoked DA 
efflux was two-fold higher, while the inhibition of DA reuptake was 3-fold higher compared 
to cocaine.   
These data suggested that 2-DPMP stimulated evoked DA efflux without releasing activities 
in a more potent way than cocaine, and this mechanism accounts for its psychotogenic effects 
(Davidson and Ramsey, 2012).  
2.2.2) Social issues represented by 2-DPMP and D2PM and their effects 
According to some user fora reports, the effects of 2-DPMP start within one hour and may last 
up to 48 hours (ACMD, 2010), while desired psychoactive effects of D2PM begin after 15 
minutes and may last up to 10 hours. The sought-after effects of the pipradrol-derivatives are 
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similar to those of other stimulants and include euphoria, stimulation, increased energy, 
alertness, arousal, disinhibition; while untoward effects are anxiety, agitation, aggression, 
paranoia, psychosis, delusions, tachycardia, sweating, hypertension, hyperthermia, headache, 
chest pain, tremors (Corkery et al., 2012). In 2010, the biological samples of 19 patients who 
presented to an Edinburgh ED with untoward psychiatric effects after using ‘Ivory Wave’, 
tested positive for 2-DPMP (James et al., 2011; Corkery et al., 2012). Recently Wood et al. 
(2012) reported a case series of five individuals, aged between 21 and 33 years old, showing 
long-lasting psychiatric symptoms, agitation, anxiety, aggression and insomnia lasting up to 
24-96 h after ingestion. All urine samples were tested positive for D2PM (Wood et al., 2012; 
Corkery et al., 2012). Another study reported a case of a male patient, with no risk factors for 
ischemic heart disease, complaining of chest pain following the ingestion of two units of ‘Head 
Candy’. Blood and urine analyses detected the presence of D2PM and glaucine (Lidder et al., 
2008; Wood et al., 2008). Additionally, in August 2010, three cases of fatalities were linked in 
the UK to 2-DPMP use (Corkery et al., 2012).  
 
2.3) 5-(2-Aminopropyl)indole (5-IT) 
 
 
 
Figure 8: Chemical structure of 5-IT 
2.3.1) Social issues represented by 5-IT and its effects 
5-(2-Aminopropyl)indole (5-API or 5-IT) (see Figure 8) is a tryptamine derivative considered 
particularly harmful because of its side-effects. It is a positional isomer of alpha-
methyltryptamine (AMT) and a substituted phenethylamine with stimulant and hallucinogenic 
properties.  
In 2012, an overall number of 21 fatalities (15 in Sweden, 2 in Hungary and 4 in the UK) 
occurred with 5-IT being found in biological samples alone or in combination with other drugs 
of abuse (e.g. 5-APB, MDMA) or medications (Seetohul and Pounder, 2013; EMCDDA, 
2014). Additionally, numerous toxicity events consistent with sympathomimetic toxidromes 
have been linked to 5-IT (EMCDDA, 2014). Originally developed for research purposes, it has 
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been recently diverted to the illicit market as a ‘MDMA’ replacement and improperly 
advertised as ‘benzofury’ or ‘ecstasy’ (Seetohul and Pounder, 2013). Overall, 5-IT detection 
was reported in several countries including United Kingdom, Denmark, Finland, Germany, 
Hungary, the Netherlands, Sweden and Norway (EMCDDA, 2014). Powders, tablets and 
capsules were the most described physical forms for 5-IT; while ingestion, insufflation were 
the most typical ROAs used, although injection occurred as well. Side-effects linked to 5-IT 
include tachycardia, hyperthermia, hypertension, agitation, anxiety, disorientation (Herraiz and 
Brandt, 2014).  
2.3.2) Pharmacological studies on 5-IT 
A recent study confirmed that the clinical effects of 5-IT partly result from selective and 
reversible inhibition of monoamine oxidase, type A (MAOA), enzymes which ultimately may 
contribute to increase the levels of monoamine in the synaptic cleft and account for 
serotoninergic/catecholaminergic effects. The effect of 5-IT on human MAOA and MAOB 
isozymes was assessed by monitoring the conversion of the kynuramine substrate in 4-
hydroxyquinoline using high-performance liquid chromatography (HPLC). According to this 
study, 5-IT was able to fully inhibit MAOA with high potency (IC50=1.6 μM and Ki=0.25μM) 
while MAOB inhibition was not detected (Herraiz and Brandt, 2014). A more recent study 
demonstrated the additional role played by 5-IT in potentiating serotonergic/monoaminergic 
effects, by coupling MAOA inhibition with monoamine releasing activity. The monoamine 
releasing properties of 5-IT were monitored using in vitro release assays in brain synaptosomes 
prepared from rat striatum for DAT, and obtained from the entire rat brain except striatum and 
cerebellum, for SERT and NET (Marusich et al., 2016). For release assay procedures 
synaptosomes were pre-loaded with the labelled DAT/NET substrate ([3H]MPP+), and with 
[3H]serotonin for SERT.  Reserpine was added in the buffer to block vesicular uptake of 
labelled substrates and unlabelled inhibitors were added to block uptake by competing 
transporters. Release assays were promoted incubating pre-loaded synaptosomes with the test 
drug for 30 minutes for DAT and NET studies or for 5 minutes for SERT studies. Then release 
was stopped using vacuum filtration and radioactivity was measured by liquid scintillation 
counting (Marusich et al., 2016). According to this study 5-IT mediated full efficacy releasing 
activity with 8-fold selectivity for DAT (EC50 12.9 ± 1.5 nM) and NET (EC50 13.3 ± 1.8) 
compared to its activity at SERT (EC50 104.8 ± 18.2 nM) and higher selectivity for DAT (13-
fold) and NET (7-fold) compared to MDMA. Overall, this compound seems to act similar to 
MDMA, mephedrone, methylone and BZP, while behaving differently to other cathinones like 
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MDPV and pyrovalerone, which are pure monoaminergic transporter inhibitors without 
releasing properties. As previously observed with other drugs of abuse, the high selectivity for 
DAT/NET versus SERT accounts for the high abuse potential of 5-IT in humans and animals 
(Banks et al., 2014; Negus and Miller, 2014).  
 
2.4) Aminorex derivatives: focus on 4,4’-DMAR  
 
 
 
Figure 9: Chemical structure of 4,4’-DMAR 
This class includes a range of molecules chemically related to the parent compound aminorex 
that retain the primary amine function and show some modifications of the phenyl ring. 4-
methylaminorex (2-Amino-4-methyl-5-phenyl-2-oxazoline) and aminorex (2-amino-5-phenyl-
oxazoline) were both first synthesized by McNeil Laboratories in the 1960s and introduced as 
prescription drugs for weight loss in Europe in 1965 (Poos et al, 1963; Carson et al., 1965). 
Because of serious adverse effects and fatal complications reported (Follath et al., 1971; 
Gurtner et al., 1985), aminorex and 4-MAR were classified under schedule 1 of the Misuse of 
Drugs Act 1971. From a pharmacological point of view, aminorex derivatives are monoamine-
releasing agents that display high potency at all three monoamine transporters (DAT, SERT, 
NET), producing typical stimulant effects (e.g. increased energy, euphoria, sociability) and 
monoaminergic toxicity (hypertension, hyperthermia, tremors, sweatiness, cardiovascular 
disturbances). Recently the novel aminorex derivative 4,4’-DMAR (4-methyl-5-(4-
methylphenyl)-4,5-dihydrooxazol-2-amine) (see Figure 9) has emerged in the illicit drug 
market as a popular drug of abuse, gaining the attention of people looking for some MDMA 
legal alternatives. 4,4’-DMAR is an oxazoline derivative which can be found as (±)-cis or (±) 
trans isomer, with the former one being involved in many deaths (Brandt et al., 2014). 
Since 2012, the popularity of this drug quickly spread from the Netherlands to other countries 
including United Kingdom, Denmark, Finland, Romania, Poland, Sweden with a preferential 
availability in the Hungarian drug market (EMCDDA and Europol, 2014). Powders with 
curious and attractive multi-coloured packaging, or tablets in all sorts of shapes, sizes and 
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colours were the most typical formulations found for 4,4’-DMAR. Sometimes, mislabelling 
such as ‘ecstasy’ or ‘amphetamine’ was adopted in the packaging to highlight the similarity of 
4,4’-DMAR preparations to traditional drug products in terms of psychoactive effects. Typical 
alternative brand names used for these preparations were ‘Speckled Cherry’ or ‘Speckled 
Cross’, and the presence of 4,4’-DMAR alone or mixed with other stimulants (e.g. synthetic 
cathinones, benzofurans) was analytically confirmed (EMCDDA and Europol, 2014). 
According to some fora reports, the most widely used routes of administration were nasal 
insufflation and ingestion, followed by inhalation and injection, while commonly reported 
desired effects included: euphoria, disinhibition increased energy and confidence (ACMD, 
2014c; EMCDDA and Europol, 2014; Loi et al., 2017). 
As a result of serious adverse effects and fatalities reported, this drug was classified under 
schedule 1 of the Misuse of Drugs Act 1971 (ACMD, 2014c) and then it was internationally 
controlled under schedule 2 of the Convention on Psychotropic Substances of 1971 (UNODC, 
2016).  
2.4.1) Pharmacological studies on 4,4’-DMAR 
Recently, the pharmacological activity of 4,4’-DMAR was studied using in vitro release assays 
in brain synaptosomes. For release assay procedures synaptosomes were pre-loaded with the 
labelled DAT/NET substrate ([3H]MPP+), and with [3H]serotonin for SERT in Krebs-
phosphate buffer for one hour (steady state). Reserpine was added into the buffer to block 
vesicular uptake of labelled substrates and unlabelled inhibitors were added to inhibit uptake 
by competing transporters. Release assays were promoted incubating pre-loaded synaptosomes 
with the test drug. Then release was stopped using vacuum filtration and radioactivity was 
measured by liquid scintillation counting. According to this study, (±)cis-4,4′-DMAR acted as 
a monoamine-releasing agent at the level of DAT, SERT, NET and showed greater potency at 
the SERT and similar potency at the DAT and NET compared to aminorex and d-amphetamine 
(Brandt et al., 2014). In another recent study the monoamine-releasing activity of both isomers 
(±)cis-4,4’-DMAR and (±)trans-4,4’-DMAR was compared to that of MDMA in rat brain 
synaptosomes using the same procedure. According to this study, both racemates exhibited a 
greater potency at the DAT and NET compared to MDMA, while (±)cis-4,4’-DMAR acted as 
a fully effective releasing agent at the SERT and (±)trans-4,4’-DMAR acted as a pure serotonin 
transporter inhibitor without releasing properties (McLaughlin et al., 2015).  
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2.4.2) Social issues represented by 4,4’-DMAR and its effects 
Since October 2013, several fatalities have occurred with 4,4’-DMAR being found alone or 
along with other recreational drugs (e.g. cocaine, amphetamines, cannabis) and/or prescribed 
medications (benzodiazepines, antidepressants, second-generation antipsychotics, opioids) at 
post-mortem (ACMD, 2014c). Specifically, 47 deaths have been recorded up to date, with 38 
of them being reported in the UK, 1 in Poland and 8 in Hungary (ACMD, 2014c; EMCDDA 
and Europol, 2014). Notably, the decrease in fatalities observed in 2015 likely occurred 
because of its legal restriction and as a result of a decreasing number of people using it because 
of its adverse effects (Corkery, 2016; Loi et al., 2017).  
Non-fatal toxicity events were characterised by agitation, confusion hyperthermia, muscular 
spasm, seizures, cardiac and respiratory arrest, convulsions, unconsciousness, aggression and 
paranoia.  The 4,4′-DMAR activity on catecholamine transporters may account for these side-
effects that may be exacerbated if the molecule is concomitantly used with compounds acting 
on similar targets, increasing the risks of serotoninergic syndrome or catecholaminergic 
toxidrome (McLaughlin et al., 2015; Loi et al., 2017).  
2.5) Dieting aid compound 2,4-DNP 
 
 
 
 
Figure 10: Chemical structure of 2,4-DNP 
2,4-DNP (see Figure 10) is an organic compound extensively used as a dieting aid from 1933 
to 1938 according to its ability to increase basal metabolic rate; accelerate gluconeogenesis and 
glycolysis and promote fat mobilization (Tainter et al., 1933 and 1934). During the 1930s, it 
was advertised as a safe medication and it was commercialised without prescription (Tainter et 
al.,1933 and 1934); as a result, between 1933 and 1935 about 100,000 patients (mostly women) 
took 2,4-DNP. Capsules containing about 100 mg of 2,4-DNP were generally ingested 1-3 
times per day, depending on the desired total dose (Tainter et al., 1933 and 1934). This 
compound was particularly attractive because, apparently, it was able to promote fat and 
carbohydrates breakdown, without causing proteolysis (Cutting et al., 1933). The diffusion 
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occurred despite the concerns raised by the Council on Pharmacy and Chemistry related to the 
potential toxicity of this compound (Council on Pharmacy and Chemistry, 1935). Because of 
several episodes of toxicity and fatalities, this drug was banned in 1938 by the Food and Drug 
Administration (FDA) in the U.S. (Parascandola et al., 1974; Kurt et al., 1986). Additionally, 
in 2003 the UK Food Standard Agency declared DNP as ‘not for human consumption’ (Food 
Standard Agency, 2003); and in 2015 INTERPOL issued a global alert for potential lethal illicit 
diet drugs, including 2,4-DNP (INTERPOL, 2015).  
Despite legal restrictions, 2,4-DNP continues to be illegally marketed through the internet as a 
supplement for weight reduction, gaining popularity among bodybuilders, athletes and young 
males and females (Lee et al., 2014). Usually sold in the form of a yellow and crystalline 
powder, tablets or pills, is typically ingested by users (Cutting et. al, 1933). 
2,4-DNP is highly toxic because it is rapidly absorbed by all routes of administration: 
swallowing, inhalation, skin and eye contact. Dermal exposure has been described as the most 
common route of unintentional exposure (Grundlingh et al., 2011) resulting from 2,4-DNP use 
in the manufacturing of dyes, fungicides, photographic developers and insecticides 
(Parascandola et al., 1974). By contrast, the oral route is currently the most common route of 
conscious exposure. According to previous studies, 2,4-DNP’s half-life ranges from 3 hours 
(Korde et al., 2005) to 5–14 days (Hsiao et al., 2005). 
The toxicity of 2,4-DNP is related to its ability to affect cellular energy production by 
increasing the proton conductance of the mitochondria with conversion of the energy released 
as heat and resulting thermogenesis (Harper et al., 2001; Ray et al., 2008). Increase of metabolic 
rate; glycolysis; lipolysis; fat store reduction; extensive production of pyruvic acid and lactic 
acid, are also observed after 2,4-DNP exposure (Agency for Toxic Substances and Disease 
Registry, 1995; Grundlingh et al., 2011). Additionally, the risk of toxicity increases after 
concomitant use of 2,4-DNP with other anorectic compounds (amphetamines) able to uncouple 
oxidative phosphorylation similarly to 2,4-DNP.  
Classic symptoms associated with brief or long-term use of 2,4-DNP include anorexia, nausea, 
vomiting, headache, dizziness, respiratory distress, muscle rigidity, hyperpyrexia, yellow skin, 
agranulosis, as well as generalized weakness and weight loss (Tewari et al., 2009). 
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2.5.1) Social issues represented by 2,4-DNP and its effects 
2,4-DNP and emergency admissions  
Over the last years, the National Poison Information Service (NPIS) commissioned by Public 
Health England, has been expressing its concern about the sharply increase in frequency of 
enquiries related to 2,4-DNP toxicity despite a warning from the Food Standards Agency (FSA) 
issued in November 2012 (Kamour et al. 2015; Food Standards Agency, 2012). The clinical 
features reported were severe and the majority of them concerned subacute exposure of 2,4-
DNP with a prevalent involvement of male body builders or body sculptors. Toxicity symptoms 
reported by enquirers to the NPIS were consistent with those reported previously (Agency for 
Toxic Substances and Disease Registry, 1995; Grundlingh et al., 2011). Clinical reported 
features included: yellow skin, agitation, confusion, alteration of the conscious level, seizures, 
metabolic acidosis, liver and renal functions impairment, muscle rigidity and the severity of 
toxicity was dose-dependent (Colman et al., 2007; Barlett et al., 2010).  In another study, two 
cases of 2,4-DNP misuse in Hong Kong Chinese patients were reported (Lee et al., 2014). 
Clinical presentations were recognised as consequences of adverse reactions of 2,4-DNP use. 
The observed symptoms were: skin rash associated to the immunogenic reactions toward the 
compound, hyperthermia and muscle injury related to 2,4-DNP thermogenic properties.  
According to the latest NPIS report, during 2016/17, both the numbers of patients who called 
asking about systemic 2,4-DNP exposure, and the number of accesses to the TOXBASE entry 
on 2,4-DNP, sharply decreased compared to 2015/2016 (NPIS, 2017). 
2,4-DNP-related fatalities  
Fatalities related to 2,4-DNP intake have been reported since the turn of the twentieth century. 
Perkins et al. (1919) published the largest publication of deaths due to occupational exposure 
to 2,4-DNP in munition factories in Paris (Perkins et al., 1919). As reported by Grundlingh et 
al. (2011), during the 1930s, 2,4-DNP-related fatalities were all individuals who had taken it 
for weight loss. After the 1930s, there was a decline in fatalities which reflected 2,4-DNP 
prohibition released by the US Food and Drug Administration in 1938. Over the last years, 
several deaths have been occurred related to 2,4-DNP exposure. Specifically, Grundlingh et al. 
(2011) claimed that from 2001 to 2010, there have been 12 deaths related to 2,4-DNP 
use/exposure. These fatalities have been linked to deliberate overdose, accidental toxicity and 
accidental occupational exposure. Recent studies reported several Emergency Department 
admissions in the UK and fatalities occurred after 2,4-DNP use. These data included 
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respectively outcomes of patients reported to the National Poisons Information Service (NPIS) 
and to the National Programme on Substance Abuse Deaths (NPSAD) (Kamour et al. 2015; 
Corkery et al., 2014). In detail, during 2016/17, two fatalities related to 2,4-DNP have been 
recorded by the NPIS service, leading to an increase of the total number of DNP-related deaths 
reported to the service to 13 since 2008 (NPIS, 2017). 
2.5.2) Pharmacological studies on 2,4-DNP: focus on preclinical studies 
Preclinical studies on 2,4-DNP toxicity were performed mostly in the 1930s -1940s, when this 
drug firstly became popular as a dieting aid.  
In line with clinical observations, oral administration by gavage (forced administration of a 
drug typically by means of a tube leading down the throat to the stomach) in rats caused dose-
dependent mortality with 100% of fatalities recorded at 100 mg/kg and no cases of fatal 
intoxication occurred in the dose range of l0-27 mg/kg. The cause of death in these acute studies 
was generally related to the pyretic effect mediated by 2,4-DNP resulting from an increase in 
metabolic rate (Spencer et al., 1948). 
On the other hand, intraperitoneal administration of 2,4-DNP (16, 20, 25, 31, 39 mg/kg) in rats, 
promoted a malignant hyperpyrexia as a result of oxidative phosphorylation disruption, with 
higher doses (e.g. 39 mg/kg, i.p.) causing a significant increase of body temperature (e.g. 
ΔT=6.7 ± 0.4) and 100% mortality rate. Conversely, lower doses (e.g. 20 mg/kg, i.p.) lead to a 
moderate increase of temperature (e.g. ΔT=2.3 ± 0.2) and respiration rate without fatal 
complications (Gatz and Jones, 1970).  
Additionally, rats exhibit a strong taste aversion to this drug and when exposed to a dietary 
concentration of 2,4-DNP (≈420 mg/kg/day), they consumed about 50% less food than the 
control group, and all died within 94 days. Starvation probably contributed to mortality among 
rats exposed to high levels of dietary 2,4-DNP. A significant reduction of body weight was 
observed as well (Tainter, 1938). 
Chapter 3: In vitro quantitative autoradiography studies 
3.1) In vitro quantitative autoradiography overview 
Over the years, the growing availability of radioactively labelled compounds that bind with 
high affinity and selectivity to neurotransmitter receptors and transporters, has allowed 
researchers to label and quantitatively assay the proteins that mediate some effects of many 
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psychotropic drugs in the brain, including NPS. Such studies have indeed resulted in a 
significant increase in our understanding of the underlying mechanisms of psychoactive drugs 
through the discovery of their high-affinity binding sites. The amount of information in this 
rapid-growing field of research continues to increase especially in view of novel ligand/drugs 
being introduced in the market (Reuter et al., 2017). 
After initial studies performed on tissue homogenates, some additional refined methods were 
developed to establish the anatomical distribution of drug-target interactions in the central 
nervous system.  In this regard, in vitro autoradiographic binding-site assay is a radiological 
technique which may be used in neuroscience as a tool to identify the targets (receptors, 
transporters) of novel drugs on which little is known in terms of pharmacology and 
pharmacodynamics in the brain (Davenport, 2005).  
Specifically, in vitro autoradiography in brain slices, enables the interpretation of the regional 
distribution of binding sites by employing pharmacological techniques originally developed 
for binding studies on homogenates (e.g. competition analysis) and providing a high anatomical 
resolution. Autoradiography has indeed the advantage of preserving tissue architecture, 
producing a detailed and reliable regional distribution of binding sites (Davenport and Russell, 
1996). 
An extensive range of radionuclides can be employed in autoradiography, including: 3H, 35S, 
125I. The radioligand selected depends on the aim of the study, and should meet the following 
criteria: high purity; high stability; high specific activity; biological activity; high degree of 
affinity and selectivity for the target protein (Boulton et al., 1998). 
The in vitro quantitative autoradiography presents several advantages: small amounts of 
ligands are required, more than one target protein can be assessed in serial brain slices from 
the same animal, different protocols can be employed (competition or full saturation studies). 
On the other hand, the main disadvantage of this technique is that the incubation with the ligand 
occurs in artificial solution which may not exactly reproduce the in vivo physiological 
conditions (Boulton et al., 1998).  
3.2) Competition binding assay 
Neuroprotein–ligand interactions play a crucial role in modern pharmacology development and 
numerous assays (such as competition experiments) can be employed to screen novel 
chemicals.  
56 
 
The basic assumption in autoradiography is that in the presence of low concentrations of the 
radioligand most of the binding occurs to specific saturable binding sites (recognition), and 
only small concentrations bind with low affinity to non-saturable and non-specific binding 
sites. Specifically, the competition binding assays rely on the availability of increasing 
concentrations of a non-labelled molecule which compete with a fixed concentration of a radio-
labelled ligand (Knoche, 1991) which binds to a specific active site on the target protein. 
Increasing concentrations of the unlabelled ligand (e.g. drug) cause a proportional decrease of 
the amount of radioactive ligand bound to the target of interest (specific binding) until the 
achievement of mass equilibrium. 
The specific binding of a radioligand can be quantified by subtraction of the total binding 
(which includes both specific and non-specific binding) from the non-specific binding (not 
displaceable binding to lipids, membrane, other proteins). The affinity of the unlabelled ligand 
for the target protein can be established by calculating the quantity of the unlabelled ligand 
(drug) required to inhibit 50% of the radioactive ligand binding (IC50). 
Differently from competition binding studies, in saturation experiments, the slices are exposed 
to increasing concentrations of the radioligand in the presence (non-specific binding) or 
absence (total binding) of an excess of displacer. This study provides a measure of the 
equilibrium dissociation constant (Kd) and the maximum number of binding sites (Bmax) 
(Davenport and Russel, 1996).  
 
3.3) Autoradiography procedure 
Dissections and brain preparation 
Brain slices for autoradiography studies are obtained from whole brains extracted from rats 
sacrificed through dislocation. In detail, the brain is extracted as follows: the head is removed, 
a midline incision is made from the nose to the neck to expose the skull; the neck muscles are 
trimmed off to expose the base of the neck, the sharp end of a pair of scissors is positioned into 
the foramen magnum and moved into the inner surface of the skull. A cut is made on both sides 
extending to the distal edge of the posterior skull surface. The brain is gently lifted using a 
spatula, the olfactory bulbs and nervous connections are cut, the meninges still connecting the 
brain to the skull are trimmed away and the whole brain is extracted. Afterwards, brains are 
rapidly frozen (2 minutes) at −40 °C in a beaker containing dry ice and isopentane and stored 
at −80 °C. 
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Brain sectioning 
Authenticity of information in autoradiography depends on proper tissue preparation and 
preservation. Frozen sectioning is performed with a cryostat that allows motorized or manual 
cutting of thin frozen sections (20 nM) at low temperature (-30 °C). The cryostat is usually an 
upright freezer powered by electricity, with a wheel mounted outside the chamber for rotating 
the microtome. Frozen brains are typically mounted on a metal chuck and placed on the 
microtome. During cutting, the wheel is rotated and the brain advances towards the cutting 
blade. Cutting of thin sections requires a sharp and cold knife and the development of specific 
skills. 
The thickness of the slices (20 nM) provides optimal absorption of radioactivity and minimizes 
superimposition of structures. Once the brain is cut to a satisfactory quality, thaw mounting is 
done by lowering the polysine-coated glass slide to the surface of the knife and by performing 
a quick touch of the slice section with the polysine surface of the slide without any pressure. 
Notably, during tissue preparation the temperature of the tissue must not increase in order to 
minimize tissue disruption. After cutting the slides are stored in a deep freezer (-80º C) until 
the day of the experiment.  
Incubation and washing  
On the day of the experiment brain slices are left to thaw out and then are incubated with the 
radioligand at optimal conditions (proper pH and temperature) to allow the highest degree of 
specific binding. Increasing concentrations of the drug are then added to compete with the fixed 
concentration of a radio-labelled ligand. Non-specific binding determination can be measured 
by adding to the incubation buffer a ligand (antagonist or agonist) with high affinity for the 
target protein which acts as a ‘block’. Various buffers (e.g. Tris-HCl, phosphate) are employed 
as media in binding assays with a pH usually maintained at 7.4-7.6. The concentration of the 
radioligand should be kept relatively low to reduce the non-specific component of total binding. 
Measurement of the ligand bound to tissue requires separation of the bound and free ligand. 
This can be achieved by multiple washings with the buffer. At the end of the incubation, slides 
are rinsed in cold distilled water and left to dry overnight. 
Apposition and development  
The autoradiography (ARG) experiment is followed by apposition of the slides to specific films 
in X-ray cassettes wrapped in aluminium foil, folded up in black plastic bags and stored in a 
fridge (4 ºC) to optimize the process of photographic exposure.  
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During the apposition, the energy emitted from the radioisotope contained in the specimen is 
absorbed by the emulsion crystals of the film causing the conversion of silver ions into silver 
atoms. The activation of the film is proportional to the amount of radioactivity contained in the 
slices. The period of apposition changes according to the specific activity of the radioligand 
employed. At the end of the apposition period, the films are removed from the cassettes and 
immersed into a fluid containing reducing agents in alkaline solutions (developing fluid) for 
one minute. The immersion into the developing fluid enables the conversion of the remaining 
silver ions into silver atoms with consequent opacification of the emulsion and formation of a 
negative visual image. Afterwards, the film is immersed in a stopping solution for one minute 
to block the developing process and then immersed in a fixing solution for three minutes to 
remove any remaining silver ions and fix the negative visual image (film fixation). At the end 
of the fixation process the film is washed under running water for 30 minutes and left to dry 
overnight. 
Image capturing and analysis  
During image capturing, autoradiographic films are placed over a Northern Light desktop 
illuminator and scanned electronically by a video camera with constant focal point and lens 
aperture. The images are then saved and analysed using the image analysis software (MCIDTM). 
The localization of binding sites in autoradiography, relies on the recognition of the anatomical 
regions and comparison of the labelled regions with anatomical landmarks taken from the 
stereotaxic atlas of Paxinos and Watson (1998), while the quantification of binding sites is 
based on the measure of optical densities of radioactive-sensitive films that have been exposed 
to a radiation source originating from the specimen. The density readings of brain regions on 
the autoradiograms are typically compared with those of commercial calibration scales 
(standards) and then converted into molar concentrations per mg of protein. Notably, density 
readings of non-specific binding must be systematically detracted from the corresponding total 
binding values to obtain precise quantitative readings for specific binding. Multiple readings 
should be taken for each region and high standard deviations could provide information on the 
anatomical heterogeneity within each structure.  
3.4) Synthetic cannabinoids and autoradiography studies 
Aims 
Over the years, the binding properties of several SCs have been assessed in animal tissues using 
different procedures. One common finding this wide family of drugs shares is the binding to 
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the CB1 receptors with affinity, potency, and efficacy properties that vary according to the 
chemical classes. The first aim of the present study was to investigate the potential binding 
properties of four different synthetic cannabinoids (BB-22, 5F-BP-22, 5F-AKB-48 and STS-
135), all belonging to the third-generation class, to the CB1 receptors. 
The rationale behind the choice of these drugs was related to the growing concern about the 
serious health implications raised by using these new generation SCs potentially resulting from 
their peculiar pharmacodynamical profile.  
The binding properties of these drugs, have been recently fully investigated on tissue 
homogenates (rat cortical membranes) using the radio-labelled competition binding assay (De 
Luca et al., 2016). According to these recent studies, these SCs were described as full agonists 
at the CB1 receptors able to inhibit the specific binding of [
3H]CP-55,940 with the following 
Ki values:  BB-22 (0.11 ± 0.03 nM), 5F-PB-22 (0.13 ± 0.01 nM), 5F-AKB-48 (0.87 ± 0.14 nM) 
and STS-135 (1.93 ± 0.18 nM) (De Luca et al., 2016). In view of these initial binding studies 
performed on tissue homogenates, we decided to employ the ARG procedure which is a more 
refined method used to establish the anatomical distribution of drug-target interactions in 
specific areas of coronal brain sections with the advantage of preserving tissue architecture. 
Consistent with the experiments performed on tissue homogenates, we employed the 
competition binding assay, by which increasing concentrations of SCs were tested for their 
ability to compete with a fixed concentration of the radio-labelled ligand [3H]CP-55,940 
characterised by high affinity and selectivity for the CB1 receptor (Dalton et al., 2010). The 
target regions examined were the Cortex and the CPu which exhibit a high expression of CB1 
receptors (Pertwee, 2005). The concentration range used was in accordance with that employed 
on tissue homogenate experiments (0.1 nM-10 µM), although in the present studies, only five 
concentrations were assessed (0.3, 1.0, 3.0, 10, 30 µM). The small number of concentrations 
used represented a limitation of our study, as a wider number of concentrations tested would 
have allowed us to calculate reliable concentration-effect curves and IC50 values. In view of 
the above, we limited the elaborations of our data to the statistical analysis and graphical 
representation of the binding data of [3H]CP-55,940 in the presence of increasing 
concentrations of the SCs in both Cortex and CPu. The methods used were the same described 
by Dalton et al. (2010). 
 
The second aim of the present study was to investigate the potential binding properties of the 
same SCs at the level of glutamate NMDA receptors. The rationale behind this choice was 
related to the necessity to discover the underlying pharmacological mechanism responsible for 
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hallucinogenic events experienced by SC users. Hallucinations may indeed result from 
NMDAR dysfunction, which has been previously described as a potential and specific 
hallucinatory mechanism (Rolland et al., 2014). In this regard, the effects of SCs have been 
sometimes described by users comparable to those experienced with the dissociative 
anaesthetic phencyclidine (PCP) which exhibits antagonistic effects on NMDA receptors and 
causes a combination of hallucinations and dissociative symptoms resulting from disruption of 
the cortico-striato-thalamo-cortical loops, acting directly in the limbic striatum (Richardson et 
al., 2016).  
From a chemical point of view, it was not excluded that SCs could act as NMDA receptor 
ligands, since other SCs of previous generations (e.g. HU-211) have been described as NMDA 
receptor antagonists (Belayev et al., 1995). Additionally, SCs similarly to PCP can induce 
cognitive deficits (likely related to glutamatergic pathway dysfunctions), and psychotic 
symptoms (potentially linked to a NMDAR hypofunction and considered to be a major 
neurobiological hypothesis for psychosis) (Rolland et al., 2014). The concentrations tested (0.3, 
1, 3, 10, 30 µM) in our study and the target areas investigated (Cortex and CPu) were the same 
used in the CB1 autoradiography experiments especially considering the high concentrations of 
NMDA receptors present in both areas. The methods employed were the same as those 
described by Lee et al. (2011).  
 
3.4.1) SCs and CB1 receptor autoradiography studies: materials and methods 
Animals 
Adult male Wistar rats (body weight: 250 grams) used for our experiments were housed in 
groups of four per cage. The animal environment was kept under an inverted 12:12 hour 
light/dark cycle and at a constant temperature of 22 ± 2 °C and humidity of about 60%. Tap 
water and standard food were available ad libitum in the home cage.  
Dissections and brain preparation 
Brain slices for autoradiography studies were obtained from six whole brains extracted from 
rats sacrificed through dislocation. Brains were rapidly frozen (two minutes) at −40 °C in a 
beaker containing dry ice and isopentane, and stored at −80 °C. 
Brain cutting and slides preparation 
Frozen brains from six animals were coronally and serially sliced using a cryostat (Bright 
instruments), into 20 nM sections in a rostro-caudal direction from +3.0 to +1.0 mm versus 
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bregma, to harvest slices containing the Cortex and the CPu. The slices were collected using 
glass polysine-coated slides (4 slices per slide) and then stored in a deep freezer (-80 degree 
Celsius) until the day of the experiment (Dalton et al., 2010). Four different synthetic 
cannabinoids were tested (BB-22, 5F-PB-22, STS-135, 5F-AKB-48) at six different 
concentrations: 0 (or total), 0.3, 1, 3, 10, 30 μM on serial brain sections. Overall 21 slides were 
prepared per drug (84 in total), individually containing 2 pairs of slices (168 pairs in total), 
each one destined at different concentrations of a drug (2 concentrations per slide) except for 
3 slides destined for the binding block.  
Chemicals used for autoradiography experiment 
The radioligand for CB1 receptors, [
3H]CP-55,940 (specific activity 154.2 Ci/mM) was 
purchased from Perkin Elmer (UK) while the synthetic cannabinoids were bought from an 
Internet source (www.researchchemist.co.uk) and chemically identified with nuclear magnetic 
resonance (NMR). The other chemicals were purchased from Sigma-Aldrich (UK). 
Preincubation, incubation, washing  
On the day of the experiment the slides were removed from the deep freezer and allowed to 
thaw for three hours in trays. The sections were then preincubated for one hour at room 
temperature in 50 mM tris buffer (pH 7.4) containing 5% bovine serum albumin (BSA). The 
preincubation ensured the removal of endogenous ligands present in the tissue. Different 
concentrations of the drugs were prepared from initial concentrations (7 mM for BB-22 and 
5F-PB-22 and 10 mM for 5F-AKB-48 and STS-135) through serial dilutions with the working 
ligand (50 mM tris buffer + 1 μM AM360 + 5% Albumin Bovine serum + 5 nM [3H]CP-
55,940) for two hours at room temperature. AM-360 1 μM was added into the working ligand 
buffer to block CB2 receptors while albumin bovine serum was used because of its ability to 
increase signal in assays without affecting biochemical reactions. 
In detail, during incubation, 18 slides for each drug were incubated with 0.5 ml of working 
ligand buffer in the absence of antagonist, while non-specific binding (block) was determined 
by incubating 3 slides per drug with 0.5 mL of buffer in the same way as described above but 
in the presence of the CB1 antagonist rimonabant (10 μM) and in the absence of the tested drug.  
Slides were washed two times for two hours in tris buffer with 1% albumin bovine serum then 
dipped in cold deionised water and left to dry overnight. 
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Apposition and film development  
The day after the slides were apposed to an x-ray film (Kodak biomax MR film) and left in x-
ray cassettes folded up in aluminium foil, wrapped in black plastic bags and stored in a fridge 
(4 ºC) for ten weeks (Dalton et al., 2010). Afterwards, the films were removed from the 
cassettes and immersed in a fluid containing reducing agents in alkaline solutions (developing 
fluid, Kodak). Each film was then immersed for one minute in a stopping solution (diluted 
solution of acetic acid) and afterwards in a fixing solution (Kodak rapid fixer, purchased from 
Sigma Aldrich, UK) for three minutes in order to remove any remaining silver ions and fix the 
negative visual image (film fixation). At the end of the fixation process the film was washed 
under running water for thirty minutes and left to dry overnight. 
Image capturing and analysis 
During image capturing, autoradiographic films were placed over a Northern Light desktop 
illuminator B95 equipped with a Nikon camera (50mm, f2.8 lens), by which the images were 
scanned electronically and saved for analysis. Image analysis was performed using the image 
analysis software MCIDTM (version 7.0, Imaging Research Inc., Interfocus Ltd, UK). Flat field 
correction was applied. Measurement of the optical densities was performed on both 
hemispheres in the frontal Cortex and dorsal striatum (regions of interest or ROIs) of each 
section. A standard brain atlas was used to identify brain regions for quantification (Paxinos 
and Watson, 2008). The means of optical density values from both sides of duplicate sections 
were calculated to assess the specific binding. To ensure consistency during the sampling, the 
size of the ROIs was kept constant. Changes in the optical densities were calculated as the 
average percentage of changes in adjacent brain sections against the control value (100%).  
CB1 receptor and statistical analysis of autoradiography data 
Autoradiography data on radioligand binding were analysed by using one-way and two-way 
ANOVAs followed by post-hoc Tukey's tests. Data were presented as mean percentage ± 
standard error of mean (SEM) against the control value with significance set at p<0.05. Binding 
of [3H]CP-55,940 in presence of increasing concentrations of the drugs in both Cortex and CPu 
was analysed. Statistica (version 10) was used as the statistical software. 
3.4.2) SCs and CB1 receptor autoradiography studies: results 
The displacement of [3H]CP-55,940 was examined in both Cortex and CPu.  Figures 12, 13, 
14, 15 show autoradiograms of relevant brain sections labelled with this radioligand. According 
to our findings, there was a marked effect of SCs on the intensity of tritium signal in brain 
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tissue indicating competition between SCs and [3H]CP-55,940. One-way ANOVA for each 
drug (see Table 1) revealed a significant effect of SC concentrations in both Cortex and CPu 
vs controls where no drugs were present (total binding). Post-hoc Tukey's test showed that all 
drugs at all dosages caused significantly greater displacement of [3H]CP-55,940 compared to 
the controls. Moreover, the analysis of the binding data for all drugs in Cortex and CPu 
separately (two-way ANOVA), showed a significant effect of the drug types; drug 
concentrations; and interaction drug types x concentrations, with BB-22 and 5F-PB-22 
showing a similar trend both in Cortex and CPu compared to 5F-AKB-48 and STS-135 (see 
Figure 11). 
 
 
Table 1: Statistical results of the binding data of [3H]CP-55,940 in presence of increasing concentrations of BB-
22, 5F-PB-22, 5F-AKB-48, STS-135 in both Cortex and CPu. One-way and two-way ANOVA analyses (post-
hoc Tukey’s tests). 
. 
 
 
 
 
 
 
 One-way ANOVA  
Drugs Cortex CPu 
BB-22 F(5,30)=62.21 p<0.0001 F(5,30)=88.91 p<0.0001 
5F-PB-22 F(5,30)=76.03 p<0.0001 F(5,30)=139.9 p<0.0001 
5F-AKB-48 F(5,30)=45.39 p<0.0001 F(5,30)=29.51 p<0.0001 
STS-135 F(5,30)=27.5 p<0.0001 F(5,30)=34.3 p<0.0001 
 Two-way ANOVA   
Drugs Cortex CPu 
BB-22, 5F-PB-22,  
5F-AKB-48,  
STS-135 
Finteraction  (15, 120) =4.25          p<0.0001 
Fdrug  (3, 120) = 32.51          p<0.0001 
Fconc (5, 120) = 186.7          p<0.0001 
Finteraction(15, 120) = 6.26            p<0.0001 
Fdrug (3, 120) = 51.44            p<0.0001 
Fconc (5, 120) = 209               p<0.0001 
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Figure 11: Statistical results (two-way ANOVA) on the left, and graphical representation on the right, of pooled 
data from six animals, showing the binding data of [3H]CP-55,940 in presence of increasing concentrations of 
BB-22, 5F-PB-22, 5F-AKB-48, STS-135 in both CPu and Cortex. Data are expressed as mean percentage ± 
standard error of mean (SEM) against the control value with significance set at p<0.05. Two-way ANOVA 
analysis (****p<0.0001, *** p<0.001, ** p<0.005, *p<0.05, post-hoc Tukey’s tests). 
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Effect of increasing concentrations of BB-22 on [3H]CP-55,940 autoradiographic binding 
           
 
 
 
 
                            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Representative computer-enhanced images of brain slices (on the 
left) and graphical representation of pooled data from six animals (on the right) 
showing the binding of [3H]CP-55,940 to CB1R in presence of increasing 
concentrations of BB-22 in both Cortex and CPu. Data are expressed as mean 
percentage ± standard error of mean (SEM) against the control value with 
significance set at p<0.05. One-way ANOVA analysis (****p<0.0001, post-
hoc Tukey’s test). 
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      Effect of increasing concentrations of 5F-PB-22 on [3H]CP-55,940 autoradiographic binding 
                                      
                             
                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Representative computer-enhanced images of brain slices (on 
the left) and graphical representation of pooled data from 6 animals (on 
the right) showing the binding of [3H]CP-55,940 to CB1R in presence of 
increasing concentrations of 5F-PB-22 in both Cortex and CPu. Data are 
expressed as mean percentage ± standard error of mean (SEM) against the 
control value with significance set at p<0.05. One-way ANOVA analysis 
(****p<0.0001, post-hoc Tukey’s tests). 
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Effect of increasing concentrations of 5F-AKB-48 on [3H]CP-55,940 autoradiographic binding 
                                     
                                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Representative computer-enhanced images of brain slices 
(on the left) and graphical representation of pooled data from six 
animals (on the right) showing the binding of [3H]CP-55,940 to CB1R 
in presence of increasing concentrations of 5F-AKB-48 in both Cortex 
and CPu. Data are expressed as mean percentage ± standard error of 
mean (SEM) against the control value with significance set at p<0.05. 
One-way ANOVA analysis (****p<0.0001, **p<0.01, post-hoc 
Tukey’s tests). 
 
 
68 
 
Effect of increasing concentrations of STS-135 on [3H]CP-55,940 autoradiographic binding 
                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Representative computer-enhanced images of brain slices (on the left) 
and graphical representation of pooled data from six rats (on the right) showing 
the binding of [3H]CP-55,940 to CB1R in presence of increasing concentrations 
of STS-135 in both Cortex and CPu. Data are expressed as mean percentage ± 
standard error of mean (SEM) against the control value with significance set at 
p<0.05. One-way ANOVA analysis (****p<0.0001, ***p<0.001, post-hoc 
Tukey’s tests). 
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3.4.3) SCs and NMDA receptor autoradiography studies: materials and methods  
Brain cutting and slides preparation 
Frozen brains from six adult Wistar rats (body weight: 250 grams) were coronally and serially 
sliced into 20 nM sections in a rostro-caudal direction using a cryostat (Bright instruments). 
The slices containing the Cortex and the CPu were collected using glass polysine-coated slides 
(4 slices per slide) and then stored in a deep freezer (-80 °C) until the day of the experiment. 
Four different synthetic cannabinoids were tested (BB-22, 5F-PB-22, STS-135, 5F-AKB-48) 
at six different concentrations: 0 (or total), 0.3, 1, 3, 10, 30 μM on serial brain sections. Overall 
21 slides were prepared per drug (84 in total), individually containing 2 pairs of slices (168 
pairs in total), each one destined at different concentrations of a drug (2 concentrations per 
slide) except for 3 slides destined for the binding block.  
Chemicals used for NMDA autoradiography experiment 
The radioligand for NMDA receptors, [3H]MK-801 (specific activity 26.4 Ci/mmol) was 
purchased from Perkin Elmer (UK). The synthetic cannabinoids were purchased from an 
Internet source (www.researchchemist.co.uk) and chemically identified with NMR. The other 
chemicals were purchased from Sigma-Aldrich (UK).  
Preincubation and incubation 
On the day of the experiment the slides were removed from the deep freezer and allowed to 
thaw for three hours in trays. The sections were then preincubated for thirty minutes at room 
temperature in 0.5 ml of TrisGG (Tris 50 mM + 30 µM glutamate + 10 µM glycine). Different 
concentrations of the drugs were prepared from initial concentrations (7 mM for BB-22 and 
5F-PB-22 and 10 mM for 5F-AKB-48 and STS-135) through serial dilution with the working 
ligand (50 mM Tris + 5 nM [3H]MK-801 + 30 µM glutamate + 10 µM glycine). In detail, 
during incubation, 18 slides for drug were incubated for two hours in 0.5 ml of working ligand 
buffer, while non-specific binding (block) was determined by incubating 3 slides per drug with 
0.5 mL of buffer in the same way as described above but in the presence of (+) MK-801 (cold) 
(50μM) and in the absence of the tested drug. Following incubation, the slides were washed 
twice for thirty minutes in tris buffer at room temperature, then rinsed for ten seconds in cold 
deionised water. Slides were then air dried overnight (Lee et al., 2011).  
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Apposition and film development  
The day after the slides were apposed to an x-ray film (Kodak biomax MR film), left into x-
ray cassettes and stored in a fridge (4 ºC) for ten weeks (Lee et al., 2011). Afterwards, the films 
were developed, washed under running water for thirty minutes and left to dry overnight. 
Image capturing and analysis 
The images were captured and analysed. The means of optical density values from both sides 
of duplicate sections were calculated to assess the specific binding. Measurement of the optical 
densities was performed on both hemispheres in the frontal Cortex and CPu (regions of interest 
or ROIs) of each section. Changes in the optical densities were calculated as the average 
percentage of changes in adjacent brain sections against the control value (100%). 
NMDA receptor and statistical analysis of autoradiography data 
Autoradiography data on radioligand binding were analysed using one-way ANOVA. Data 
were presented as mean percentage ± standard error of mean (SEM) against the control value 
with significance set at p<0.05. Binding of [3H]MK-801 in presence of increasing 
concentrations of the drugs in both Cortex and CPu was analysed. Statistica (version 10) was 
used as the statistical software. 
3.4.4) SCs and NMDAR autoradiography studies: results 
The displacement of [3H]MK-801 was examined in both Cortex and CPu.  Figures 16, 17, 18, 
19, show autoradiograms of relevant brain sections labelled with this radioligand. According 
to our findings, data analysis revealed no effect of all SCs at all concentrations tested on the 
intensity of tritium signal in brain tissue indicating the absence of competition between SCs 
and [3H]MK-801. 
 
 
 
 
 
 
 
71 
 
Effect of increasing concentrations of BB-22 on [3H]MK-801 autoradiographic binding  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Representative computer-enhanced images of brain slices (on the left) 
and graphical representation of pooled data from 6 rats (on the right) showing the 
binding of [3H]MK-801 to NMDAR in presence of increasing concentrations of 
BB-22 in both Cortex and CPu. Data are expressed as mean percentage ± standard 
error of mean (SEM) against the control value with significance set at p<0.05. 
One-way ANOVA analysis.    
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 Effect of increasing concentrations of 5F-PB-22 on [3H]MK-801 autoradiographic binding  
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Representative computer-enhanced images of brain slices (on the 
left) and graphical representation of pooled data from 6 rats (on the right) 
showing the binding of [3H]MK-801 to NMDAR in presence of increasing 
concentrations of 5F-PB-22 in both Cortex and CPu. Data are expressed as 
mean percentage ± standard error of mean (SEM) against the control value 
with significance set at p<0.05. One-way ANOVA analysis.    
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Effect of increasing concentrations of 5F-AKB-48 on [3H]MK-801 autoradiographic binding 
                                
                                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Representative computer-enhanced images of brain slices (on the 
left) and graphical representation of pooled data from 6 rats (on the right) 
showing the binding of [3H]MK-801 to NMDAR in presence of increasing 
concentrations of 5F-AKB-48 in both Cortex and CPu. Data are expressed as 
mean percentage ± standard error of mean (SEM) against the control value 
with significance set at p<0.05. One-way ANOVA analysis.    
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Effect of increasing concentrations of STS-135 on [3H]MK-801 autoradiographic binding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Representative computer-enhanced images of brain slices 
(on the left) and graphical representation of pooled data from 6 rats (on 
the right) showing the binding of [3H]MK-801 to NMDAR in presence 
of increasing concentrations of STS-135 in both Cortex and CPu. Data 
are expressed as mean percentage ± standard error of mean (SEM) 
against the control value with significance set at p<0.05. One-way 
ANOVA analysis.    
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3.4.5) CB1R and NMDAR autoradiography studies with SCs: discussion 
The first aim of the present study was to investigate the potential binding properties of the SCs 
BB-22, 5F-PB-22, 5F-AKB-48 and STS-135 at the level of CB1 receptors. As expected, our 
results confirmed that the investigated compounds behave as highly potent CB1 receptor 
ligands able to compete with the radioligand [3H]CP-55,940. Consistent with homogenate 
studies (De Luca et al., 2016), BB-22 and 5F-PB-22 showed similar levels of displacement 
compared to the control values at all concentrations tested in both areas, Cortex and CPu. 
Indeed, the post-hoc Tukey’s test did not reveal any significant differences between these two 
drugs on the percentage of the radioligand bound, against the control value, in both areas (two-
way ANOVA) (see Figure 11). Similar effects between these two drugs can be easily observed 
in the graphical representation of the radioligand bound in presence of increasing 
concentrations of the drugs where BB-22 and 5F-PB-22 curves mostly overlap (see Figure 11). 
On the other hand, 5F-AKB-48 and STS-135 showed lower ability to compete with the 
radioligand compared to BB-22 and 5F-PB-22. Specifically, significant differences between 
5F-AKB-48 vs BB-22 and 5F-PB-22 effects were observed at low and high concentrations 
(0.3, 10.0 and 30.0 µM) in the Cortex, and at all concentrations tested except for 3.0 µM (at 
which no differences were observed against both drugs), and 30.0 µM (at which a significant 
difference was observed against 5F-PB-22 only) in the CPu.  On the other hand, significant 
differences between STS-135 vs BB-22 and 5F-PB-22 effects were observed at low 
concentrations in the Cortex (0.3, 1.0, 3.0 µM). As regards to CPu, all concentrations of STS-
135 except for 30.0 µM, were significantly different against 5F-PB-22, and only low 
concentrations (0.3, 1.0, 3.0 µM) showed significance against BB-22 (see Figure 11). To sum 
up, our results were consistent with previous homogenate study findings, by which all index 
SCs in our study were described as high-affinity agonists at CB1 receptors, with BB-22 and 5F-
PB-22 showing higher affinities compared to 5F-AKB-48 and STS-135. 
The second aim of the present study was to investigate the potential binding properties of the 
same SCs at the level of glutamate NMDA receptors in order to discover the underlying 
pharmacological mechanism responsible for several hallucinogenic events experienced by SC 
users. According to our findings, all SCs tested were not able to compete with the NMDAR 
radioligand [3H]MK-801 (see Figures 16, 17, 18, 19), rejecting the hypothesis of potential 
binding of these SCs to the NMDA receptors at all concentrations investigated, and leading us 
to consider alternative mechanisms responsible for hallucinogenic events. In this regard, two 
other main pharmacological models of hallucinations may be alternatively considered such as 
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the dopaminergic model which involves a stimulation of D2 receptors in the limbic striatum 
and the serotoninergic model which involves the stimulation of 5HT2A receptors on cortical 
neurons. Both these mechanisms cause an alteration of the functioning of the cortico-striato-
thalamo-cortical loops, as already observed with the glutamatergic model (Rolland et al., 
2014). In view of the above, further binding studies are needed to exclude the potential binding 
of SCs to serotoninergic and dopaminergic receptors. Anyway, although there has been much 
debate regarding the underlying exact pharmacological mechanism responsible for 
hallucinations and psychosis after SC use, the most commonly accepted mode of activity of 
this class seems to involve a pure CB1 receptor mediated dis-inhibitory or inhibitory 
mechanism of other pathways (GABAergic, glutamatergic, dopaminergic) that ultimately may 
affect the functioning of the cortico-striato-thalamo-cortical loop responsible for altered 
perceptions and psychoses. Additionally, their high affinity and intrinsic activity at CB1 
receptors might partially explain their high potential to trigger psychotic-like symptoms 
(including hallucinations) (Fattore et al., 2016).  
These outcomes confirmed that these SCs are able to enhance the function of the endogenous 
cannabinoid system, fully activating CB1 receptors which are mainly sited in the central 
nervous system. Since the cannabinoid system is implicated in several physiological functions 
(e.g. pain, mood, appetite, memory, stress response, social behaviour, anxiety), the super-
agonism of SCs at the CB1 receptor highlights the potential side effects that can arise from their 
use (alteration of mood, agitation, vomiting, hallucinations, psychoses, seizures, convulsions, 
and panic attacks).  
These more serious adverse effects in contrast to use of cannabis are potentially related to the 
full agonism showed by SCs at the CB1 receptor compared to Δ9‐THC which is only a partial 
agonist of this receptor and thus not able to activate and saturate all of the receptor population. 
Our outcomes, along with cases of serious toxic effects, highlight the emergent clinical issues 
caused by the use of these drugs.  
According to their high potential for abuse and their unpredictable serious side effects, novel 
SCs have no medical benefit and authorities have made it illegal to sell, buy, or possess some 
these chemicals (ACMD, 2016). Indeed, although some SCs have been shown to stimulate 
appetite, suppress nausea, and to have some benefits in the treatment of PTSD (Post-Traumatic 
Stress Disorder) (Fraser et al., 2009), they may also cause profound psychological and physical 
effects, highlighting their narrow therapeutic index (Seely et al., 2012). 
77 
 
Overall, the alarming popularity of SCs highlights the urgent need to plan effective tailored 
treatment strategies against the risks related to both acute intoxication and chronic use of SCs. 
Additional pharmacological and toxicological studies are needed to assess the long-term effects 
of these drugs (Cooper et al., 2016).  
3.5 Synthetic stimulants and DAT autoradiography studies  
Aims 
5-(2-Aminopropyl)indole (5-API or 5-IT) and 2-DPMP are two synthetic stimulants belonging 
to the NPS class considered particularly harmful as a result of numerous toxicity events 
consistent with sympathomimetic toxidromes associated with their use. In detail, 5-IT is a 
tryptamine derivative and a substituted phenethylamine with stimulant and hallucinogenic 
properties, while desoxypipradrol also known as 2-diphenylmethylpiperidine (2-DPMP), is 
chemically related to methylphenidate and pipradrol and shares with them a similar 
pharmacology. Both entered the illicit market as MDMA replacements and have become 
quickly popular for their strong psychoactive effects. From a pharmacological point of view, a 
recent study confirmed that the clinical effects of 5-IT partly result from selective and 
reversible inhibition of MAOA enzymes (Herraiz and Brandt, 2014) and from its full efficacy 
releasing activity at the level of DAT and NET. Additionally, a higher selectivity for DAT and 
NET compared to MDMA has been demonstrated (Marusich et al., 2016). As previously 
observed with other drugs of abuse, the high selectivity for DAT/NET versus SERT may 
account for the high abuse potential of 5-IT in humans and animals (Banks et al., 2014; Negus 
and Miller, 2014).  
On the other hand, 2-DPMP is a synthetic stimulant with high abuse potential that may act as 
a potent DAT and NET inhibitor without releasing properties (Simmler et al., 2014) able to 
stimulate evoked dopamine efflux in NAc brain slices to a greater extent compared to cocaine 
(Davidson and Ramsey, 2012). Notably, the monoamine uptake transport inhibition and 
releasing properties of 5-IT were monitored using in vitro release assays in brain synaptosomes 
(Marusich et al., 2016) while 2-DPMP studies have been conducted in embryonic kidney 293 
cells (HEK 293) (Simmler et al., 2014). In view of the above we decided to investigate the 
potential binding properties of these two stimulants to the dopamine transporter in rat brain 
slices using the autoradiography procedure.  
The rationale behind the choice of these drugs was related to the numerous clinical 
implications, toxicity events and fatalities related to their use and potentially resulting from 
their peculiar pharmacodynamical profile.  
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The autoradiography procedure was performed in specific areas of coronal brain sections and 
we employed the competition binding essay by which increasing concentrations of 5-IT and 2-
DPMP were tested for their ability to compete with a fixed concentration of the radio-labelled 
ligand [125I]RTI-121 characterised by high affinity and selectivity for the target protein DAT 
(Strazielle et al., 1998). The target brain regions examined were the CPu and NAc shell which 
exhibit a high expression of dopamine transporters.  
The concentration range used was in accordance with that employed in previous in vitro studies 
(10-10- 10-4 M), although in our studies, only five concentrations were assessed (0.3, 1.0, 3.0, 
10, 30 µM). The small number of concentrations assessed represented a limitation of our study, 
as a wider number of concentrations would have allowed us to calculate reliable concentration-
effect curves and IC50 values. In view of the above, we limited the elaborations of our data to 
the statistical analysis and graphical representation of the binding data of [125I]RTI-121 in 
presence of increasing concentrations of the synthetic stimulants in both CPu and NAc shell. 
The methods used were the same as those described by Strazielle et al. (1998).  
 
3.5.1) Synthetic stimulants and DAT autoradiography studies: materials and methods  
Brain cutting and slides preparation 
Frozen brains from six adult Wistar rats (body weight: 250 grams) were coronally and serially 
sliced, using a cryostat (Bright instruments), into 20 nM sections in a rostro-caudal direction 
from +2.2 to +1.0 mm versus bregma, to harvest the NAc and the CPu. Afterwards, the slices 
were collected using glass polysine-coated slides (4 slices per slide) and then stored in deep 
freezer at −80 °C, until the day of the experiment. Two synthetic stimulants were tested (5-IT 
and 2-DPMP) at six different concentrations: 0 (or total), 0.3, 1, 3, 10, 30 μM on serial brain 
sections. Overall, 21 slides were prepared per drug (42 in total), individually containing 2 pairs 
of slices (84 pairs in total), each one destined at different concentrations of a drug (2 
concentrations per slide) except for 3 slides destined for the binding block.  
Chemicals used for DAT autoradiography experiment 
The radioligand for dopamine transporters, [125I]RTI 121 (specific activity 2200 Ci/mM) was 
purchased from Perkin Elmer (UK). All the other chemicals, including the synthetic stimulants 
(Desoxypipradrol hydrochloride solution: D-082, and 5-IT solution: A-107) were purchased 
from Sigma-Aldrich (UK).  
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Preincubation and incubation 
On the day of the experiment the slides were removed from the deep freezer and allowed to 
thaw for three hours in trays. The sections were then preincubated for thirty minutes at room 
temperature in 0.5 ml of phosphate saline buffer (PBS) at pH 7.4 (137 mM NaCl, 2.7 mM KCl, 
10.14 mM Na2HPO4, 1.76 mM K2HPO4). Different concentrations of the drugs were prepared 
from initial concentrations (5.7 mM for 5-IT and 3.5 mM for 2-DPMP) through serial dilution 
with the working ligand ([125I]RTI-121 (20 pM) + phosphate-saline buffer). In detail, during 
incubation (60 minutes), 18 slides for drug were incubated in 0.5 ml of working ligand buffer 
in the absence of antagonist, while non-specific binding (block) was determined by incubating 
3 slides per drug with 0.5 mL of buffer in the same way as described above but in the presence 
of nomifensine (400 μM) and in the absence of the tested drug. Following incubation, the slides 
were dipped in ice cold buffer two times for twenty minutes and left to dry overnight (Strazielle 
et al., 1998). 
Apposition and film development 
The day after the slides were apposed to an x-ray film (Kodak biomax MR film), left into x-
ray cassettes and stored in a fridge (4 ºC) for three days (Strazielle et al., 1998). Afterwards, 
the films were developed, washed under running water for thirty minutes and left to dry 
overnight. 
Image capturing and analysis 
The images were captured and analysed. The means of optical density values from both sides 
of duplicate sections were calculated to assess the specific binding. Measurement of the optical 
densities was performed on both hemispheres in the CPu and NAc shell (regions of interest or 
ROIs) of each section. Changes in the optical densities were calculated as the average 
percentage of changes in adjacent brain sections against the control value (100%).  
 
Synthetic stimulants and DAT autoradiography statistical analysis 
Autoradiography data on radioligand binding were analysed using one- and three-way 
ANOVAs followed by post-hoc Tukey's tests. Data were expressed as mean percentage ± 
standard error of mean (SEM) against the control value with significance set at p<0.05. Binding 
of [125 I]RTI-121 was analysed in presence of increasing concentrations of the drugs in both 
CPu and NAc shell. Statistica (version 10) was used as the statistical software. 
80 
 
3.5.2) Synthetic stimulants and DAT autoradiography studies: results 
The displacement of [125 I]RTI-121 was examined in both CPu and NAc shell. Figures 21 and 
22 show autoradiograms of relevant brain sections labelled with this radioligand. According to 
our findings, both synthetic stimulants mediated a marked concentration-dependent reduction 
in the radioligand signal intensity in brain tissue, indicating competition between the synthetic 
stimulants and the radioligand. One-way ANOVA for each drug revealed (see Figure 20) a 
significant effect of synthetic stimulant concentrations in both CPu and NAc shell vs controls 
where no drugs were present (total binding). Notably, 2-DPMP was highly effective in reducing 
the radioligand signal intensity in both CPu and NAc shell, starting from the lowest 
concentration tested (0.3 µM); while 5-IT showed a significant competition with the 
radioligand starting from 1.0 µM (p<0.05) in the NAc shell and 3.0 µM (p<0.01) in the CPu.   
Moreover, three-way ANOVA of the binding data of both drugs in both areas (CPu and NAc 
shell) revealed a significant effect of the drug type (p<0.0001), drug concentrations (p<0.0001), 
and a significant effect of concentrations x drug (p<0.0001) and drug x per area interactions 
(p<0.05) (see Figure 20). In detail, post-hoc Tukey’s test showed a significant difference 
between 5-IT CPu data vs 2-DPMP CPu data; and 5-IT NAc shell data vs 2-DPMP NAc shell 
data at 0.3, 1.0, 3.0 µM with 2-DPMP being more effective in displacing the radioligand 
compared to 5-IT (see Figure 20).  
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Figure 20:  The tables on the top and on the bottom, show the statistical results of the binding data of [125I]RTI-
121 to DAT in presence of increasing concentrations of 5-IT and 2-DPMP in CPu and NAc shell (One-way and 
tree way-ANOVAs followed by post-hoc Tukey’s tests). On the middle, graphical representation of pooled data 
from 6 rats showing the binding of [125I]RTI-121 in presence of increasing concentrations of 5-IT and 2-DPMP 
in CPu and NAc shell. 
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Effect of increasing concentrations of 5-IT on [125I]RTI-121 autoradiographic binding 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Representative computer-enhanced images of brain slices (on the 
left) and graphical representation of pooled data from 6 rats (on the right) 
showing the binding of [125I]RTI-121 to DAT in presence of increasing 
concentrations of 5-IT in both NAc shell and CPu. Data are expressed as mean 
percentage ± standard error of mean (SEM) against the control value with 
significance set at p<0.05. One-way ANOVA analysis (****p<0.0001, 
**p<0.01, * p<0.05, post-hoc Tukey’s tests). 
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Effect of increasing concentrations of 2-DPMP on [125I]RTI-121 autoradiographic binding 
 
 
 
 
                                  
 
 
 
 
  
 
 
 
 
 
 
                    
                                                     
 
 
Figure 22: Representative computer-enhanced images of brain slices (on the 
left) and graphical representation of pooled data from 6 rats (on the right) 
showing the binding of [125I]RTI-121 to DAT in presence of increasing 
concentrations of 2-DPMP in both NAc shell and CPu. Data are expressed as 
mean percentage ± standard error of mean (SEM) against the control value 
with significance set at p<0.05. One-way ANOVA analysis (****p<0.0001, 
post-hoc Tukey’s tests). 
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3.5.3) Synthetic stimulants and DAT autoradiography studies: discussion 
Consistent with previous in vitro studies, 5-IT and 2-DPMP behave as highly potent DAT 
ligands able to compete with the radioligand [125 I]RTI-121 in a concentration-dependent way 
in CPu and NAc brain slices. Notably, 2-DPMP could displace the radioligand in both cerebral 
regions, starting from lower concentrations (0.3 µM) compared to 5-IT (1.0 µM in the NAc 
shell and 3.0 µM in the CPu). On the other hand, larger concentrations of 5-IT (10 and 30 µM) 
in both areas caused a comparable displacement of the radioligand as 2-DPMP. The effect of 
these two drugs is notable, especially considering that a prototypical stimulant drug like 
cocaine is able to significantly displace [125 I]RTI-121 at higher concentrations (3, 10 and 30 
μM) compared to 2-DPMP and 5-IT in NAc brain slices, under the same methods (Strazielle 
et al., 1998) and conditions (Opacka-Juffry et al., 2014).  
As previously observed with other drugs of abuse, the high affinity for DAT may account for 
the high abuse potential of these drugs in humans and animals (Banks et al., 2014; Negus and 
Miller, 2014). Indeed, stimulants belonging to different classes share the ability to act at the 
level of DAT as pure inhibitors (like 2-DPMP) or releasing agent (such as 5-IT) influencing 
the duration and the extent of the dopaminergic signal in the reward system and producing 
positive effects such as pleasure, euphoria, increased energy and sociability. On the other hand, 
several sympathomimetic toxidromes can occur as a result of their activity at the level of 
monoamine transporters which, in the case of 5-IT, is furthermore coupled with inhibition of 
monoamine oxidase (MAO) activity.  
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Chapter 4: In vitro fast scan cyclic voltammetry studies 
4.1) In vitro fast scan cyclic voltammetry overview 
Fast-scan cyclic voltammetry (FSCV) is a powerful electrochemical analytical technique that 
has been used extensively to investigate drug mechanisms associated with neurotransmitter 
transmission in order to develop new strategies for therapeutic intervention in drug addiction. 
FSCV presents several advantages, including: real-time investigation of neurotransmitter 
concentrations, quantification of changes in neurotransmitter concentrations in the nanomolar 
to micromolar range, minimal tissue damage and high spatial resolution according to the 
micrometer size of the probe used (Boulton et al., 1995). 
In detail, in vitro FSCV enables the monitoring of neurochemical release of electroactive 
neurotransmitters (e.g. monoamines) with a temporal resolution that allows pharmacological 
manipulation of neurotransmitter release in specific regions of brain slices enabling the 
discrimination between neurotransmitter release and uptake events (Garris and Wightman, 
1995).  
Studies using brain slices have been recognised as particularly advantageous in defining the 
mechanisms underlying neurotransmitter dynamics in different brain regions, and how these 
processes can be affected by pharmacological manipulation (Stamford et al., 1995; John, & 
Jones, 2007). 
In detail, using brain slices provides several advantages:  
✓ numerous slices can be made from each target brain region; 
✓ one single animal can be used to obtain slices from different brain regions; 
✓ electrode placement can be easily and carefully performed in specific anatomical areas, 
including very small regions; 
✓ physiological parameters (pH, temperature, degree of oxygenation) can be constantly 
regulated and monitored;  
✓ pharmacological activity of the drugs can be evaluated avoiding hepatic metabolism; 
✓ unwanted drug interactions can be avoided (e.g. interactions with chemicals typically 
used to anesthetize animals);  
✓ Drugs characterised by high toxicity or poor penetration through the blood-brain barrier 
can be tested (Stamford et al., 1995; John, & Jones, 2007). 
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However, using brain slices has some drawbacks: 
✓ the usual input and output pathways present in the intact brain and the connections with 
the periphery are compromised; 
✓ the tissue degrades at a faster rate than in the live animal; 
✓ the in vivo activity patterns and dynamics are not totally reproduced (loss of hormonal 
regulations and blood circulation through the vascular system; loss of the peripheral 
degradation of the molecules); 
✓ the tissue properties may be altered around the cutting surface, affecting the metabolic 
state of neurons; 
✓ the effects of decapitation ischaemia on the health condition of the slice have not been 
well established (Schurr, 1986). 
 
Electrodes used in Fast Scan Cyclic Voltammetry in rat brain slices 
FSCV recordings are performed using an electrochemical system composed of four different 
electrodes: reference, auxiliary, stimulating and recording electrodes.  
The reference electrode is a silver/silver chloride electrode made from a silver wire coated with 
a layer of silver chloride. The function of this electrode is to provide a stable voltage to which 
the working electrode potential is referenced. 
The auxiliary electrode is an inert conductor and specifically a stainless-steel wire which 
records changes in the working electrode potential. Any electrochemical event in the working 
electrode is associated with an opposite electrochemical reaction in the auxiliary electrode. 
The stimulating electrode is a bipolar steel electrode (A-M Systems, WA, USA) used to apply 
electric current to the tissue. It is made of two epoxy-insulated tungsten microelectrodes whose 
tips are properly tapered and sanded using abrasive paper in order to cause the minimal trauma 
to the tissue whilst allowing the passage of the required amount of the current.  
The recording microelectrode is the electrode on which the reaction of interest takes place. The 
most common form of working electrode used in FSCV is a carbon fibre microelectrode which 
allows scans of wide potential windows (Boulton et al., 1995; Stamford et al., 1995). 
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Carbon fibre microelectrode preparation 
Carbon fibre microelectrodes are made by aspirating a single carbon fibre (8 µm diameter) into 
a borosilicate glass capillary (10 cm length; 2.0 mm outer diameter, 1.16 mm inner diameter; 
Harvard Apparatus Ltd, Kent, UK) through vacuum suction. Each capillary is pulled into two 
electrodes using a microelectrode puller (P-30, Sutter Instruments Co., USA). The electrode is 
then thoroughly examined using a high-power microscope (100-200x magnification) in order 
to check if there is a good glass-carbon junction that indicates a good stability of the electrode. 
The exposed length of the carbon fibre is then trimmed to a length of approximately 75 μm 
using a scalpel under the guidance of a high-power microscope (100-200x magnification). 
Before use, microelectrodes are backfilled with artificial Cerebro-Spinal Fluid (aCSF) using a 
needle (25 gauge, 3.5 in., Becton–Dickinson and Co., Franklin Lakes, NJ) and a single thread 
of copper (Squires Electronics, Inc., Cornelius, OR) is then inserted and pushed into the 
electrode tip and used for connection to the headstage amplifier. An auxiliary electrode and a 
reference electrode are also connected to the headstage amplifier and located in the recording 
chamber in contact with the aCSF solution (John, & Jones, 2007; Brierley & Davidson, 2013). 
The tip of the carbon microelectrode is then left in the aCSF for a period during which scans 
are applied for 15 minutes before use and the noise level and the shape of the current signal is 
closely checked to predict the accuracy and sensitivity of the electrode. After this period, the 
microelectrode is left to equilibrate in aCSF for other 20 minutes before use (‘frying process’). 
Good microelectrodes can be used for a few days and some precautions include: leaving the 
microelectrode in distilled water between experiments, manipulate them with care or sonicate 
them (application of sound energy to speed the removal of the brain tissue that occludes the 
electrodes’ tips by breaking intermolecular interactions) (Boulton et al., 1995; Stamford et al., 
1995). 
4.2) Fast scan cyclic voltammetry principles 
Typically, during the experiment, the carbon fibre microelectrode is inserted into specific brain 
regions of living brain slices and a voltage in a triangular wave fashion is applied allowing the 
oxidation and reduction of the neurotransmitter. For neurotransmitters like DA a -1.0 to +1.4 
V (vs Ag/AgCl) waveform is typically used with a voltage scan rate of 480 V/s and multiple 
waveform repetitions that enable the monitoring of kinetic events (uptake and release) with 
high temporal resolution are applied (Hafizi et al., 1990). The waveforms are originated from 
a generator and applied to the potentiostat. The current output of the working electrode is 
amplified and displayed on a computer used to control an X-Y chart recorder and stored on a 
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disk for data analysis on a computer. In detail, pulses may be programmed using the CED 1401 
AD converter and the peaks may be graphed using the Spike software (Stamford et al., 1995). 
Low voltages applied to the carbon fibre microelectrode enable the electrolysis of the 
neurotransmitter and the electrons resulting from this process represent the current output of 
the working electrode.  Digital subtraction of the background current signals generated at the 
microelectrode before and after stimulation is usually made in order to isolate the Faradaic 
(redox) current originated by the electrolysis of the neurotransmitter. The two signals are 
indeed superimposable except at the redox positions. The extraction of Faradaic signals 
requires high-resolution digital methods that rely on computer-based systems and are used in 
some laboratories to enhance the resolution of data acquisition. The current measured gives an 
indication of the number of molecules oxidized/reduced and thus detection of the 
neurotransmitter levels before and after pharmacological manipulation (Stamford et al., 1995; 
John, & Jones, 2007). 
To provide information on transmitter kinetics, a sample and hold circuit is set to monitor the 
current at the oxidation potential of the transmitter and the signal is displayed on a y-t chart 
recorder in the computer. In detail, while the X-Y recorder displays the cyclic voltammogram, 
the y-t recorder shows changes in oxidation currents and thus in concentrations. For 
quantification of changes in neurotransmitter concentration over time, the current is measured 
real-time and provides an indication of the ability of the pharmacological agents in changing 
neurotransmitter uptake and release events (see Figure 23) (Stamford et al., 1995). 
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Figure 23: Fast Scan Cyclic Voltammetry set up (generator, waveform gate, potentiostat, amplifier, computer, 
sample and hold circuit, X-Y recorder, Y-t recorder). The picture was adapted from Stamford et al., 1995.  
 
4.3) BB-22 and FSCV studies: aims 
According to previous studies, the rewarding properties of synthetic cannabinoids involve the 
relative contributions of complex neuronal circuits (Lupica et al., 2004).  
It is likely that the interaction of SCs with CB1 receptors may promote the inhibition of GABA 
release onto DA neurons projecting from the VTA to the NAc (CB1-mediated disinhibitory 
mechanism) and an increase of DA neuron-firing rate and DA neuron burst activity in the VTA 
with consequent enhance of terminal release of DA in the NAc. Furthermore, part of the 
rewarding actions of SCs seem to be mediated by actions occurring within the NAc, where SCs 
are thought to produce a disinhibition of the GABAergic output to the VTA and other brain 
structures (Lupica et al., 2004). 
However, it has been discovered that many drugs of abuse have a direct effect on synaptic 
processes in the NAc and are self-administered by animals directly into the NAc (McBride et 
al., 1999). Based on these observations, we hypothesized that part of the rewarding actions of 
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these drugs could be mediated via direct interactions of SCs on synaptic processes within the 
NAc not necessarily mediated by CB1 receptors.  To this end, we studied the effects of BB-22 
on evoked DA efflux and DA re-uptake half-life in brain slices containing the NAc, using the 
in vitro FSCV procedure. The rationale behind the choice of this drug was related to its highest 
affinity, potency and efficacy at the level of CB1 receptors compared to the other synthetic 
cannabinoids tested (De Luca et al., 2016), and to the numerous health implications raised by 
using this drug over the recent years. In vitro FSCV was employed according to its ability to 
enable real-time investigation of dopamine dynamics before and after pharmacological 
manipulation in a specific region of brain slices (e.g. NAc shell), enabling discrimination 
between release and uptake events (Garris and Wightman, 1995). The NAc shell was selected 
as the target area in accordance with its role played in addiction. Indeed, typical drugs of abuse 
share the ability to activate the reward pathways and increase DA release preferentially in the 
NAc shell (Di Chiara and Imperato, 1988; Lecca et al., 2006). The mechanism responsible for 
this increase may depend on the effect of neuronal circuits inside or outside the NAc shell, 
highlighting the contributions of distinct pathways originating from different areas of the 
reward system. Using brain slices containing the NAc shell, limits the investigation of 
dopamine dynamics in this specific region, avoiding the potential influence of other regions of 
the reward system. Although this procedure does not reproduce the in vivo dynamics, it allows 
us to demonstrate whether BB-22 is able to increase DA release in the NAc shell without the 
contributions of other neuronal circuits (Lupica et al., 2004). Additionally, the pure 
pharmacological activity of BB-22 can be evaluated avoiding the potential influence of the 
periphery. The concentration range used (0, 0.03, 0.1, 0.3; 1.0 µm) and the strain of animals 
(Wistar rats) employed were in accordance with those used in in vitro autoradiography studies.  
To sum up, our study aimed to investigate the effects of BB-22 on: basal dopamine levels; 
electrically-evoked DA peak efflux; and the time-constant of the dopamine decay phase (index 
of dopamine reuptake) in NAc shell brain slices.  
4.4) BB-22 FSCV studies: materials and method 
Preparation of the aCSF 
The artificial cerebrospinal fluid (aCSF) closely matches the electrolyte concentrations of 
endogenous CSF and is prepared from high purity water and analytical grade reagents as 
previously described by Brierley and Davidson (2013). This media was used for storing brain 
slices after dissections, and for perfusing slices during electrophysiological recordings. The 
composition was as follows:  NaCl 126 mM; KCl 4 mM; KH2PO4 1.4 mM; MgSO4 1.3 mM; 
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NaHCO3 26 mM; D-glucose 4 mM; CaCl2 2.4 mM in de-ionised water and oxygenated with 
95% O2/5% CO2 at 32°C for at least 45 minutes before use. In order to prevent the precipitation 
of insoluble calcium salts, the calcium chloride was added after complete dissolution of the 
other salts. 
Brain slices preparation 
Wistar rats of eight weeks (body weight: 250 grams) were housed in the St George’s University 
of London’s animal house in groups of four per cage and kept under an inverted 12:12 hour 
light/dark cycle and at a constant temperature of 22 ± 2°C and humidity of about 60%. Tap 
water and standard food were available ad libitum in the home cage. The animals were 
sacrificed by cervical dislocation and quickly decapitated. Rats were treated in accordance with 
the UK Animals (Scientific Procedures) Act 1986 and UK Home Office regulations. No ethical 
protocol was required as brain slice studies are not covered by Home Office regulations. Their 
brains were rapidly removed and kept in ice cold oxygenated (95% O2/5% CO2) aCSF before 
being cut in 400 μm serial coronal sections in rostro-caudal direction (coordinates:  from +1.0 
to +2.2 mm versus bregma) (Paxinos and Watson, 2008) using the vibratome. The temperature 
of slicing was kept around 0 ± 1°C (with ice floes present in the aCSF solution) to reduce the 
energy demands of the tissue and to promote easy cutting (Stamford et al., 1995). Thereafter, 
the slices were left to equilibrate for one hour at room temperature on a plastic mesh in a slice 
saver filled with aCSF continuously bubbled with 95% O2/5% CO2. After equilibration, each 
slice was then transferred to the inner bath of a brain slice chamber provided with aCSF at a 
flow rate of 1 ml/min and temperature at 32.5 ± 0.5 °C and left to equilibrate in the new 
environment for about 40-45 minutes before applying electrical stimulation (Stamford et al., 
1995). The temperature in the slice chamber was monitored using a CEM DT-613 digital 
thermometer. Low temperatures allow a long survival of the slice in healthier conditions and 
an optimal recording of the neurotransmitter dynamics. The environment of the inner chamber 
is regulated by an outer chamber containing distilled water continuously warmed by a heating 
coil in communication with a thermostatically heated water bath (Grant, Cambridgeshire, UK). 
The outer chamber allows the passage of oxygenated aCSF through a loop of tubing into the 
inner bath assuring that the liquid into the inner part is kept at a constant temperature. Artificial 
cerebrospinal fluid (aCSF) is constantly removed from the fluid surface through a syringe 
needle connected to a tube in communication with a vacuum pump which exercises a negative 
pressure. The auxiliary and reference electrodes are located away from the slice and immersed 
in the aCSF solution attached to a binding post on the top of the slice chamber (Davidson et al., 
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2011). The recording microelectrode is placed in the NAc shell at the beginning of the 
equilibration period to monitor dopamine levels which could be affected by several factors like 
poor condition of the slice and high temperature (Davidson et al., 2011; Brierley and Davidson, 
2013). All the electrodes (auxiliary, reference and recording) were connected to the headstage 
amplifier (NL 106).  
Drugs 
The synthetic cannabinoid BB-22 was purchased from an Internet source 
(www.researchchemist.co.uk) and its identity and purity were evaluated using nuclear 
magnetic resonance spectroscopy (NMR), gas chromatography mass spectrometry with 
electron ionisation (GC-EI-MS) and HPLC. The drug was solubilised in pure DMSO and five 
different concentrations of the drug were assessed: 0, 0.03, 0.1, 0.3; 1.0 μM. Each concentration 
was tested in six different brain slices from different animals except for BB-22 0.1μM which 
was tested in 7 different brain slices.  
Electrical stimulation protocol 
The electrical stimulation protocol was programmed into the Spike 7 data capture and sent to 
digital to analog and input–output interface boards (National Instruments, Austin, TX), which 
sends the stimulus to optical isolators (Neuro Log NL-800, Medical Systems, Greenvale, NY). 
After optical isolation, the stimulus is sent to the bipolar stimulating steel electrode (A-M 
Systems, WA, USA). The stimulating electrode was mounted on a micromanipulator and the 
tips were positioned on the surface of the slice. The carbon-fibre microelectrode (mounted on 
a separate micromanipulator) was positioned at a depth of 75 μm into the slice, and with a 
distance of 200 μm between the tips of the bipolar stimulating electrode in order to create an 
equilateral triangle. Prior electrical stimulation the stability and the health conditions of the 
brain slices were monitored as in the case of poor slice health large amounts of dopamine may 
be released and affect the experiment (Davidson et al., 2011). Electrode placement was 
performed using a stereo-microscope with a maximum magnification of 20x. According to 
previous studies, midbrain dopaminergic neurons in basal conditions fire at low frequencies of 
5–10 Hz, but in the presence of rewarding stimuli they show more prevalent periodic short 
bursts of high-frequency activity (20 Hz) (Hyland et al., 2002). Accordingly, the stimulation 
protocol applied was conceived to mimic the burst firing typical of rodent dopaminergic 
neurons. A sequence of 10 × 1 ms 10 mA pulses was applied at a frequency of 20 Hz, with 
stimulus sequences applied every 5 min (Davidson & Stamford, 1993). Pulses were 
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programmed using the CED 1401 AD converter and the Spike software. The input voltage 
applied to the carbon electrode went from 0 to −1, up to +1.4, back to −1 and back to 0 V at 
480 V/s. The whole voltage scan took 20 ms. Typically, the DA oxidation peak is at 
approximately 500–700 mV vs Ag/AgCl, while the single DA reduction peak is around −200 
mV (John, & Jones, 2007; Brierley and Davidson, 2013).  
Data acquisition and statistical analysis 
Changes in recorded current in correspondence of the DA oxidation peak were graphed by the 
Spike software. Two parameters were calculated for each efflux episode: the peak height and 
the time constant of the half-life of the decay curve (analysed using Spike 7 software). In detail, 
stimulation events were applied every 5 minutes, the drug was added after three stable 
consecutive baseline events and its effect on dopamine dynamics was observed for one hour. 
All data were presented as percentages of the mean baseline data. Statistical analysis was 
conducted using Statistica (version 10) and performing two-way ANOVA. Data were 
expressed as mean ± standard error of mean (SEM), with significance set at p<0.05 (John, & 
Jones, 2007; Brierley and Davidson 2013). 
4.5) BB-22 FSCV studies: results 
According to our findings, BB-22 had no significant effect on evoked peak dopamine efflux at 
any concentrations tested. In this regard, although two-way ANOVA for repeated measures 
revealed a significant effect of the concentration: F(4,26)=4.53 p<0.01; of the time: 
F(12,312)=1.97 p<0.05; and a significant interaction time x concentration: F(48,312)=1.74 
p<0.005; the  post-hoc Tukey’s test did not reveal any significant effect of BB-22 (0.03, 0.1, 
0.3, 1 uM) in altering evoked dopamine efflux in the NAc shell in comparison to the control 
group (DMSO 1 µM) and any differences compared to the basal levels (see Figure 24). 
Additionally, BB-22 did not elicit any significant effect on the dopamine reuptake time-
constant at any concentrations tested (figure not shown). 
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Figure 24: BB-22 FSCV studies. Dopamine Peak height (Ph) data after BB-22 exposure. The drug was added to 
the perfusion solution in contact with the brain slice after three stable consecutive baseline events and its effect 
on dopamine dynamics was observed for one hour. Data are expressed as percentage of basal values which are 
means ± SEM of at least three determinations (Control: n=6; BB-22 0.03µM, n=6; BB-22 0.1µM, n=7; BB-22 
0.3µM, n=6; BB-22 1.0 µM, n=6). Two-way ANOVA, post-hoc Tukey’s test. 
 
 
4.6) BB-22 and FSCV studies: discussion 
According to our findings, local application of the synthetic cannabinoid BB-22 in brain slices 
was unable to change evoked DA efflux and dopamine reuptake time-constant in the NAc shell 
at any doses tested.  
Based on these observations, the results obtained would suggest the relative contributions of 
complex neuronal circuits, either within or outside the NAc, whose modulation would interfere 
with the interactions between BB-22 and dopaminergic neurons and represent critical pathways 
accounting for some of the rewarding properties of BB-22 exposure.  
In this regard, although FSCV studies in brain slices may be advantageous to focus the 
investigation of dopamine dynamics in a specific brain region, they do not allow us to monitor 
and appreciate the potential influence of mechanisms involving other areas of the reward 
system (e.g. VTA) (Lupica et al., 2004). 
It is indeed likely that BB-22, similarly to other SCs may disinhibit DA neurons projecting 
from the VTA to the NAc by promoting the inhibition of GABAergic neurons within the VTA 
(CB1 disinhibitory mechanism) (Lupica et al., 2004). 
Notably, this mechanism relies on the integrity of DAergic projections from the VTA to the 
NAc which is preserved in in vivo studies, and affected in NAc brain slices. As a result, the 
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increase of DA release mediated by BB-22 could not be appreciated in brain slices where all 
neuronal circuits outside the NAc have been lesioned.  
Anyway, the findings obtained with this procedure allowed us to reject the hypothesis that part 
of the rewarding actions of BB-22 could be mediated via direct interactions on synaptic 
processes within the NAc without the contribution of external neuronal circuits.  Additionally, 
the lack of effects on the dopamine reuptake time-constant, allowed us to discard the hypothesis 
of any direct action of BB-22 at the level of dopamine transporter in the NAc shell at the doses 
tested and to support the idea that neuronal circuits outside the NAc are indispensable to 
mediate DA increase in the NAc shell induced by BB-22.  
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Chapter 5: Microdialysis studies 
5.1) Microdialysis overview 
Microdialysis is a procedure widely used in neuropharmacology to allow continuous recovery 
and quantification of endogenous molecules (e.g. neurotransmitters, hormones, neuropeptides) 
from the extracellular fluid in the brain of freely moving animals (Chefer et al., 2009).  
This procedure relies on the dialysis principle by which small-size molecules and water diffuse 
across a semipermeable membrane, driven by a concentration gradient between the 
extracellular fluid and the perfusion medium. The key element in microdialysis is the probe 
used as a tool to recover molecules from the extracellular space (Chefer et al., 2009). All probes 
are composed of a tubular dialysis membrane, continuously perfused with a liquid (artificial 
extracellular fluid) enabling the passage of compounds with suitable molecular masses 
according to the membrane cut-off. The perfusion liquid is infused slowly and continuously 
through the probe using microinfusion syringe pumps set up with perfusion rates ranging from 
0.3 to 3 μl/min and connected to the probe through polyethylene tubes. Typical sample 
collection time ranges from 1 to 20 minutes. The dialysate fluid is analysed at specific time 
intervals using the High-performance Liquid Chromatography (HPLC) system equipped with 
an electrochemical detector (Chefer et al., 2009). 
Microdialysis probe  
Vertical probe (see Figure 25) is prepared according to the method of Tanda et al. (1996). It is 
composed of an inlet silica wire whose tip is shaped according to a 45-degree angle and by an 
outlet silica capillary whose extremity is modelled according to a truncated conical geometry. 
An inlet capillary is inserted into a stainless-steel tubing (22g) characterised by a sharp tip 
containing a small opening at one extremity, and a truncated conical geometry on the opposed 
side. A further hole is made 8 mm away from the sharp tip and serves as insertion point for the 
outlet capillary whose opposed extremity is surrounded from the metal outlet tubing. The 
lengths of silica capillaries protruding from the inlet stainless-steel tubing are adjusted and 
fixed with superglue (Super attack, Loctite) so that the difference between the inlet and outlet 
silica tube lengths corresponds to the desired extent of the active membrane. Inlet and outlet 
silica tips are covered by an artificial kidney membrane made of an acrylate copolymer of 
sodium-meta-allyl sulfonate (HOSPAL, outer diameter 310 μm and internal diameter 220 μm) 
which allows the passage of compounds with suitable molecular masses (400-600 Da) 
according to the membrane cut-off (Øe=310 μm; Øi=220 μm). The perfusion solution enters 
the probe passing through the inlet capillary, crosses the membrane and is then collected as a 
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dialysate from the outlet silica tubing. A circular-shaped polyethylene tube connected to the 
extremity of the stainless-steel outlet tubing, allows collection of the perfusate which is then 
injected in the HPLC system for analysis.  
 
 
 
 
 
 
Figure 25: Picture of the microdialysis probe. The image was retrieved from the following website: 
http://slideplayer.it/slide/4250028/ 
Microdialysis surgery 
Before starting surgery, stereotaxic coordinates for the target brain regions are determined 
using the rat brain Atlas of Paxinos and Watson (1998) which provides coordinates for the 
anterior-posterior (AP), lateral (L), and dorsal-ventral (DV) planes using as a reference point 
the bony landmark (bregma) on the skull’s animal (Zapata et al., 2009). After anaesthesia, the 
animal is mounted onto the stereotaxic apparatus (see Figure 26) by placing and locking each 
ear bar in contact with each tympanic membrane into the auditory canals and securing the 
mouth with an anterior clamp so that the middle of the animal’s scalp is positioned according 
to a 90° angle with respect to the stereotaxic instrument platform (Geiger et al., 2008). Using 
the point of a scalpel blade, a midline incision is made in order to expose the skull surface; the 
skin is retracted with haemostats to keep the incision open and the connective tissue is scraped 
away. Using sterile cotton swabs, the exposed skull surface is dried and the bregma 
(intersection between coronal and sagittal sutures) and lambda (intersection between occipital 
and sagittal sutures) positions are identified. The proper mounting of the animal onto the 
stereotaxic apparatus is confirmed by detection of bregma and lambda positions on the same 
horizontal plane according to which the brain atlas coordinates are based. Consistent with the 
atlas of Paxinos and Watson (1998), the coordinates used are as follows: NAc shell: Antero-
Posteriority=+2.2, Laterality=±1.1 from bregma and Verticality=- 7.8 from dura; NAc Core: 
Antero-Posteriority =+1.6, Laterality =±1.8 from bregma and Verticality=-7.5 from dura; 
mPFCx: Anteriority=+3.7, Laterality=±0.8 from bregma and Verticality=-4.8 from dura; CPu: 
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Anteriority=+1.2, Laterality=±3.0 from bregma and Verticality=-5.5 from dura. Saline is 
applied to clean the skull surface and anterior-posterior and lateral coordinates of the bregma 
are determined after mounting the probe in the holder and positioning it over the bregma. 
Coordinates for probe placement are then determined by adding or subtracting designated 
values from bregma coordinates and a hole is drilled at this location using an up-and-down 
motion until the dura meninx is achieved. The probe is then brought down until flexion of the 
dura meninx at which the ventral coordinates are recorded, and designated values are subtracted 
for specific brain regions. A sterile needle is then used to gently puncture the meninges and 
allow unhampered insertion of the probe which is then lowered according to the designated 
ventral coordinates. Haemorrhage can be reduced by applying a small ice bag around the 
bleeding. The probe is then tightly fixed to the skull using plastic tips as supports around the 
probe and dental cement for adhesion to the bone. Once the cement has completely dried the 
animal is removed from the stereotaxic apparatus and housed in a plexiglass hemispheric bowl. 
The experiment of microdialysis is performed at least 24 hours after surgery to allow the 
complete recovery of the animal and the restoration of neurotransmitters basal levels on the 
brain (Zapata et al., 2009; Geiger et al., 2008). 
 
 
 
 
 
 
 
Figure 26: Picture of the stereotaxic apparatus. The image was retrieved from the following website: 
http://play.psych.mun.ca/~smilway/stereotax.htm 
Microdialysis experiment 
On the day of the experiment, animals are individually housed in plexiglass hemispheric bowls 
and their probes (aimed at specific brain regions) are connected to micro-infusion syringe 
pumps (CMA, Harvard Apparatus) through polyethylene tubes. The perfusion liquid (Ringer’s 
solution) is infused slowly and continuously at constant rate of 1 μl/min and it mimics the 
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activity of the extracellular fluid present in the brain according to its chemical composition 
(147 mM NaCl, 4 mM KCl, 2.2 mM CaCl2). The perfusion solution enters the probe passing 
through the inlet tubing, and endogenous solutes (neurotransmitters) cross the semipermeable 
membrane by passive diffusion from the extracellular fluid into the perfusion medium. The 
diffusion takes place as a result of a concentration gradient between the extracellular fluid of 
the brain and the artificial one (Ringer’s solution) pumped at very low flow rate through the 
probe (Di Chiara, 1990). The dialysate leaving the probe through the outlet tube, is then 
collected through a circular-shaped polyethylene tube and analysed at certain time intervals 
using the HPLC system equipped with an electrochemical detector. 
Sample analysis 
During microdialysis experiments the dialysate samples are analysed for quantification of 
neurotransmitters using the direct injection of samples into a HPLC apparatus equipped with a 
reverse phase column and a coulometric detector (ESA, Coulochem II, Bedford, MA) 
(Imperato and Di Chiara, 1984). This method has been previously shown reliable for in vivo 
analysis of neurotransmitter release and their metabolites (Imperato and Di Chiara, 1984). The 
HPLC is a separation technique that involves the injection of a small volume of a sample (5 to 
20 µL) into a reversed column (LC-18 DB, 15 cm, 5 μm particle size, Supelco) filled with a 
stationary phase (composed by tiny silica particles and long hydrocarbon chains attached to 
their surface) where the single components of the samples are forced through the column with 
a solvent (mobile phase) under high pressures (in the range of 400- to 600-bar) delivered by a 
pump (Cremella, LC, Italy). Normal flow rates in HPLC are in the 1- 2 ml/min range. A polar 
mobile phase is used (50 mM NaH2PO4, 0.1 mM Na2-EDTA, 0.5 mM n-octylsodium sulfate, 
15% (v/v) methanol, pH 5.5) to ensure a strong attraction between the polar solvent and polar 
molecules in the mixture, while non-polar compounds in the perfusate tend to interact with the 
hydrocarbon groups of the stationary phase to form van der Waals interactions.  
Overall, mixture components are separated as a result of various chemical and/or physical 
interactions with the column’s stationary phase and are quantified by an electrochemical 
detector whose output is analysed by a software program to provide the retention time (time of 
elution) of the sample components and their concentration levels (quantitative analysis) 
(Imperato and Di Chiara, 1984) (see Figure 25).  
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Electrochemical detection  
Typically, coulochem detectors (e.g. ESA Coulochem II, Bedford, MA) present a standard cell 
containing two working electrodes (porous carbon electrodes) four auxiliary electrodes and 
four reference electrodes (Flanagan et al., 2005). The coulometric process is based on the 
complete electrolysis (complete oxidation/reduction) of the analyte at the porous electrode 
structure when a specific voltage is applied. The first electrode of the detector is set at + 125 
mV (oxidation) and the second at - 175 mV (reduction). The electrons resulting from the 
oxidation/reduction processes are detected as current flows and the total charge passing through 
the electrochemical cell during electrolysis is proportional to the absolute amount of analyte. 
The coulometric detector can potentially be the most sensitive, accurate among many detectors 
available for quantitative analysis by HPLC. Overall, after separation and elution from the 
column, the analyte (e.g. dopamine) is oxidized at the first electrode of the detector and then 
reduced at the other electrode, with resulting production of a chromatographic peak. The peak 
is then compared to peaks of known sizes generated after injections of specific concentrations 
of dopamine (25, 50, 100 fentomoles) (Flanagan et al., 2005) (see figure 27).  
 
 
 
 
 
 
 
 
Figure 27: Picture of the microdialysis set-up: 1)perfusion pump; 2)Rat implanted with the probe; 3)Injector; 
4)pump, column; 5)Detector; 6)Data analyser. This picture was retrieved from the following website: 
http://slideplayer.it/slide/4250028/ 
 
  
101 
 
5.2) Synthetic cannabinoids and microdialysis studies 
Aims 
Over the years, the pharmacological effects of synthetic cannabinoids have been assessed in 
animals using different procedures focusing on different brain regions of the reward circuit. 
One common finding these studies share is the evidence for an enhancement in mesolimbic 
DA activity after intraperitoneal, intravenous administration or intracranial infusions of SCs. 
In the present study, four different synthetic cannabinoids (BB-22, 5F-PB-22, 5F-AKB-48 and 
STS-135), all belonging to the third-generation class, were selected to monitor DA release in 
specific areas of the reward system after their intravenous administration in freely moving rats.  
The rationale behind the choice of these drugs was related to the growing concern about the 
more serious health implications (e.g. toxicity events, fatalities, psychiatric consequences) 
raised using these new drugs and their higher abuse liability compared to the first-generation 
SC compounds. More serious clinical adverse effects and higher addiction-sustaining 
properties could be the expression of a distinct pharmacodynamical and pharmacological 
profile typical of these drugs. Indeed, as previously said, according to recent in vitro binding 
studies, all index SCs in the present study possess higher CB1 affinity compared to the first-
generation compound JWH-018; while only BB-22 and 5F-PB-22 show higher potency, with 
EC50 values significantly lower than JWH-018. Referring to their intrinsic activity, all of them 
except for STS-135, exhibit higher efficacy (Emax) compared to JWH-018 (De Luca et al., 
2016).  
In the present study, the effect of the compound with the highest CB1 affinity, efficacy and 
potency, namely BB-22, was monitored in three different areas of the reward system (NAc 
shell, NAc core and mPFCx) and a wide pattern of dosages (0; 0.003; 0.01; 0.03; 0.1 mg/kg, 
i.v.) was tested and chosen in accordance with the Ki value found for this compound (De Luca 
et al., 2016). Additionally, the effect of a pre-treatment with the CB1 inverse agonist/antagonist 
AM-251 (1 mg/kg, i.p.) was assessed, in order to establish the involvement of CB1 receptors 
on the effect mediated by BB-22. 
The other compounds were tested at a single dose level calculated considering their Ki values, 
and the ratio between the Ki value and the dose of BB-22 found effective in increasing DA 
release in the NAc shell. In view of the above, 5F-PB-22 was tested at 0.01 mg/kg, 5F-AKB-
48 at 0.1 mg/kg and STS-135 at 0.15 mg/kg and their effects were monitored only in the NAc 
shell. An acute treatment was performed using the intravenous route of administration in the 
right jugular vein. This ROA was chosen among the others, because intravenous injection of 
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cannabinoids potentially leads to plasma profile similar to those observed after smoking (which 
is the most common way humans consume SCs) (Ohlsson et al., 1980). NAc shell, core and 
medial Prefrontal Cortex were selected as target areas in accordance with the role played by 
these regions in addiction. Indeed, typical drugs of abuse share the ability to activate the reward 
pathways and increase DA release preferentially in the NAc shell (Di Chiara and Imperato, 
1988; Lecca et al., 2006). However, based on the type of drugs and dosages, an increase can 
be observed also in other regions of the reward system including mPFCx and NAc core 
(Moghaddam et al., 1989). The microdialysis procedure was employed in our study as a useful 
and reliable procedure for monitoring changes in DA levels in freely moving animals. Previous 
microdialysis studies have been performed to monitor the effect of JWH-018 in the mPFCx, 
NAc shell and NAc core. According to this study, JWH-018 increased DA selectively in the 
NAc shell (De Luca et al., 2015) similarly to Δ9‐THC and WIN-55,212-2 (Tanda et al., 1997; 
Lecca et al., 2006). The maximal increase of dopamine was observed at 0.25 mg/kg, i.p., with 
a magnitude of about 65% over basal value. Notably, lower (0.125 mg/kg, i.p.) and higher 
doses (0.5 mg/kg, i.p.) were ineffective on DA release according to a concentration-dependent 
U-shaped curve as already observed in self-administration studies (De Luca et al., 2015). In 
our microdialysis experiments, we used the same strain of animals (Sprague-Dawley rats) and 
the same experimental design described in studies above mentioned focusing on JWH-018 (De 
Luca et al., 2015), aiming to avoid inter-strains variability. Overall, our study aimed to 
evaluate: 
▪ whether the index SCs in our study share with JWH-018 the ability to stimulate DA 
transmission in the NAc shell; 
▪ whether the synthetic cannabinoid BB-22 mediates DA transmission changes in other 
areas of the reward system, namely NAc core and mPFCx;  
▪ the magnitude of DA change mediated by the index SCs in the present study; 
▪ the involvement of CB1 receptors on the effect mediated by the highest affinity, 
potency, efficacy compound BB-22. 
No power calculations have been employed in this study and the experimental design was set 
up in accordance with previous studies conducted by the same team (De Luca et al., 2015), 
with the inclusion of some variations in terms of routes of administration and dosages which 
better addressed the aims of our analysis. 
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5.2.1) Synthetic cannabinoid microdialysis studies: materials and methods 
Animals  
Adult male Sprague-Dawley rats (body weight: 275-300 g; Harlan Laboratories, Italy) used for 
our experiments, were housed in groups of four per cage. The animal environment was kept 
under an inverted 12:12 hour light/dark cycle and at a constant temperature of 22 ± 2°C and 
humidity of about 60%. Tap water and standard food (Mucedola, Settimo Milanese, Italy) were 
available ad libitum in the home cage. All in vivo microdialysis experiments were conducted 
at the University of Cagliari (Italy) and carried out in accordance with the Guidelines for the 
Care and Use of Mammals in Neuroscience and Behavioural Research according to Italian 
(D.L. 116/92 and 152/06) and European Council directives (609/86 and 63/2010) and in 
compliance with the approved animal policies by the Ethical Committee for Animal 
Experiments (CESA, University of Cagliari) and the Italian Ministry of Health (Aut. N. 
162/2016- PR). We made all efforts to minimize pain and suffering, and to reduce the number 
of animals used. 
On the day before microdialysis experiment, animals underwent intravenous surgery followed 
by intracranial surgery. 
Intravenous surgery 
Before starting surgery, each animal was anesthetised with Equitesin (chloral hydrate 2.1 g, 
sodium pentobarbital 0.46 g, MgSO4 1.06 g, propylene glycol 21.4 ml, ethanol (90%) 5.7 ml, 
H2O 3 ml; 3 ml/kg i.p.), shaved on the throat, and placed in the dorsal position on a surgical 
table. The legs were restrained to each side of the table and using a scalpel, a 2-cm incision 
was made right of the midline of the neck just over the right jugular vein. The connective tissue 
was stretched apart, and the jugular vein was exposed. The salivary and lymphatic tissues were 
separated and a section (5 mm) of the vessel was isolated. Using a silk suture, a loose tie was 
placed on both sides (cranial and caudal) of the vessel and using a small needle, an incision 
was made to pass the catheter in line with the vein. The catheter (Silastic, Dow Corning 
Corporation, Michigan, USA) was then inserted deeper into the vein towards the heart and 
secured tightening the cranial and caudal ligatures around the vessel. The other extremity of 
the catheter was exteriorised and fixed in the mid-scapular region of the back and the ventral 
incision was sutured (De Luca et al., 2016).  
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Intracranial Surgery  
After intravenous surgery rats were surgically implanted with vertical dialysis probes aimed at 
the nucleus NAc shell, core and mPFCx. In detail, the animal was mounted onto the stereotaxic 
apparatus and a midline incision was made in order to expose the skull surface. Saline was 
applied to clean the skull surface and coordinates of probe placement were calculated using the 
bregma as a landmark. A hole was drilled, the meninge (dura mater) was gently punctured and 
the probe was lowered according to the designated ventral coordinates. At the end, the probe 
was tightly fixed to the skull using dental cement for adhesion to the bone. After surgery, 
experimental animals were removed from the stereotaxic apparatus and individually housed in 
plexiglass hemispheric bowls (Zapata et al., 2009; Geiger et al., 2008). According to the atlas 
of Paxinos and Watson (1998), the coordinates used to determine probe placement were the 
following: NAc shell: Antero-Posteriority=+2.2, Laterality=±1.1 from bregma and 
Verticality=-7.8 from dura; NAc Core: Antero-Posteriority =+1.6, Laterality =±1.8 from 
bregma and Verticality=-7.5 from dura; mPFCx: Anteriority=+3.7, Laterality=±0.8 from 
bregma and Verticality=-4.8 from dura (De Luca et al., 2016).  
Microdialysis experiment 
On the day of the experiment, the animals’ probes were connected to micro-infusion syringe 
pumps (CMA, Harvard Apparatus) using polyethylene tubes. The perfusion liquid (Ringer’s 
solution) was infused slowly and continuously at constant rate of 1 μl/min.  Dialysate samples 
were collected every 10 minutes and the resulting specimens were injected into an HPLC 
system equipped with a coulometric detector (ESA; Coulochem II, Bedford, MA). The first 
electrode of the detector was set at +130 mV (oxidation) and the second at -175 mV (reduction). 
The composition of the mobile phase was: 50 mM NaH2PO4, 0.1 mM Na2-EDTA, 0.5 mM n-
octylsodium sulfate, 15% (v/v) methanol, pH 5.5. The sensitivity of the assay for DA was 5 
fmol/sample. Dopamine recordings were performed for a total period of 180 minutes (De Luca 
et al., 2016). 
Dissection and histology 
Immediately after the microdialysis experiment, rats were sacrificed by injecting them with a 
lethal dose of anaesthetic; the probes were gently removed, and the brains were extracted and 
stored in formalin (8%). Later on, the hemisphere in which the probe was implanted was 
dissected and cut into coronal slices (100 µm of thickness) using a vibratome (Campden 
105 
 
Instruments, Biological Instruments, Besozzo, Italy). The slices were later transferred to 
multiwall plates and analysed under a microscope. Probe placement was evaluated according 
to the atlas of Paxinos and Watson (1998) (De Luca et al., 2016).  
Statistical analysis  
Data between different groups of treatment were analysed using Statistica for Windows 
(Version 10) and the differences in the levels of DA were analysed by ANOVA for repeated 
measures. Results obtained using ANOVA were then examined using the post-hoc Tukey’s test 
(De Luca et al., 2016). ANOVA was used among other tests, because it is a reliable test to 
prove an assumed cause-effect relationship between independent variables (e.g. drug doses, 
time intervals) and dependent variables (e.g. dopamine levels) by comparing the mean scores 
within each group and among different groups based on different observations (variables). 
Specifically, the dependent variables represent measurements of the same variable (e.g. DA 
levels) at different times (measurements of DA levels on the same subject over time and under 
different dosages). The null hypothesis predicts that all data (e.g. all dopamine values) of all 
groups (e.g. all groups of animals that receive different drug dosages) have the same casual 
distribution and the difference between groups is casual. The null hypothesis is verified through 
the analysis of the F-value (ratio of two variances that are expected to be roughly equal under 
the null hypothesis). If the ratio of variances between groups and within groups (F value) is 
low, the group means are close together (low variability). By contrast, if the F-value is high, 
the group means are significantly different (high variability).  
The post-hoc Tukey’s test on the other hand, identifies the mean groups that are significantly 
different from each other. In our case, the post-hoc Tukey’s test compares the means of each 
group of treatment to the means of every other group of treatment and it identifies any 
differences between means that are greater than the expected standard error. The formula for 
post-hoc Tukey’s test is qs=YA-YB/SE, where YA=the larger of two means, YB=the smaller 
of two means, SE=standard error of the data in question. The qs value obtained is then 
compared to a q critical value (calculated on a population with normal distribution). Since the 
null hypothesis for Tukey’s test predicts that the means being compared are from the same 
population, they should be normally distributed; thus, if qs value > q critical, the two means 
are critically different. At the end of analysis, both ANOVA for repeated measures and post-
hoc Tukey’s test provide the p-value (measure of evidence against the null hypothesis). When 
the threshold value assigned is p=0.05, p-value less than 0.05, indicates a significant difference 
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between means, by contrast, if the p-value is greater than 0.05, the null hypothesis cannot be 
rejected, and we cannot conclude that a significant difference between means exists.  
Overall three distinct experiments were performed: 
• Experiment 1: Effect of BB-22 administration on DA transmission in the NAc shell, 
core, and in the mPFC.  
Rats implanted in NAc shell, core and mPFCx were divided into different groups, one 
for each dose in each area. The doses of BB-22 tested were: 0 mg/kg; 0.003 mg/kg; 
0.01mg/kg; 0.03mg/kg; 0.1 mg/kg (NAc shell, n= 29; NAc core, n= 27; mPFC, n= 21). 
 
• Experiment 2: Role of CB1 receptors on the NAc shell DA stimulation induced by BB-
22.  
Rats implanted in NAc shell, were pre-treated intraperitoneally with the CB1 
antagonist/inverse agonist AM-251 (1.0 mg/kg) and injected intravenously with BB-22 
(0.01 mg/kg) after thirty minutes (Veh n=6; AM-251 n=3). 
 
• Experiment 3: Effect of 5F-PB-22, 5F-AKB-48, and STS-135 administration on DA 
transmission in the NAc shell.  
Rats implanted in NAc shell were divided into different groups, one for each drug at a 
specific dose: 5F-PB22 (0.01 mg/kg, n=6), 5F-AKB-48 (0.1 mg/kg, n=7) STS-135 
(0.15 mg/kg, n=5). The vehicles were 17 in total.  
 
5.2.2) Results for experiment 1: Effect of BB-22 administration on DA transmission in 
the NAc shell, core and in the mPFCx 
In the first experiment the effect of a dose range of BB-22 (0.00, 0.003, 0.01, 0.03, 0.1, mg/kg 
i.v.) on DA transmission was assessed in the NAc shell and core, and mPFC. As shown in 
Figure 28, BB-22 (0.01 mg/kg, i.v.), caused an increase of DA levels selectively in the NAc 
shell. Notably, lower (0.003 mg/kg, i.v.) and higher doses (0.03, 0.1 mg/kg, i.v.) were 
ineffective on DA release according to a concentration-dependent U-shaped curve as already 
observed in previous microdialysis studies with JWH-018 (De Luca et al., 2015). Specifically, 
repeated measures three-way ANOVA revealed a significant effect of dose [F(3,75)=4.46; 
p<0.01], brain area [F(2,75)=7.72; p<0.001], and a significant dose x brain area interaction 
[F(6,75)=6.46; p<0.0001]. Furthermore, post-hoc Tukey's tests showed a significant increase 
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of DA, 20-40 and 90-120 minutes after BB-22 (0.01 mg/kg i.v.) injection compared to the basal 
value. Additionally, significant differences on DA dialysate were observed between: 
▪ vehicle treated animals and 0.01 mg/kg i.v. treated animals implanted in NAc shell (90 
min sample); 
▪ 0.01 mg/kg i.v. treated animals implanted in NAc shell and 0.01 mg/kg i.v. treated 
implanted in NAc core (90 min sample);  
▪ 0.01 mg/kg i.v. treated animals implanted in NAc shell and 0.01 mg/kg i.v. treated 
animals implanted in mPFC (30, 90 min sample) (see Figure 28). 
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Figure 28: In vivo effect of BB-22 administration on DA transmission in the NAc shell, NAc core, and mPFC.  
Results are expressed as mean ± SEM of change in DA extracellular levels expressed as the percentage of basal 
values. The arrow indicates the moment of BB-22 i.v. injection at the dose of 0.003 mg/kg (magenta triangles), 
0.01 mg/kg (red triangles), 0.03 mg/kg (green squares), 0.1 mg/kg (blue diamonds), or vehicle (black circles) in 
the NAc shell (A), NAc core (B), and mPFC (C). Solid symbol: p < 0.05 with respect to basal values; *p < 0.05 
vs veh NAc shell group; × p < 0.01 vs 0.01 NAc core group; § p < 0.01 vs 0.01 mPFC group; (NAc shell n= 29; 
NAc core n= 27; mPFC n= 21) (Repeated measures three-way ANOVA, post-hoc Tukey’s tests). 
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5.2.3) Results for experiment 2:  Role mediated by CB1 receptors on the increase of DA 
release in the NAc shell DA induced by BB-22 
In the second experiment, we monitored whether the CB1 inverse agonist/antagonist AM-251 
(1 mg/kg, i.p.) was effective in reversing DA increase in the NAc shell mediated by BB-22 
(0.01 mg/kg, i.v.) (see Figure 29). Two-way ANOVA showed a main effect of treatment 
[F(1,11)=12.07; p< 0.005], and treatment x time interaction [F(18,198)=2.2; p < 0.005] in 
animals pre-treated with the antagonist thirty minutes before BB-22 injection. Post-hoc 
Tukey’s test showed the ability of AM-251 to significantly reduce dialysate DA in the NAc 
shell in comparison with rats pre-treated with the vehicle instead of the antagonist (90, 140, 
150, 180 min sample).  
 
Figure 29: Blockade of BB-22 effect on the increase of DA transmission in the NAc shell mediated by AM-
251. Results are expressed as mean ± SEM of change in DA extracellular levels expressed as the percentage of 
basal values. The arrow indicates the moment of BB-22 (0.01 mg/kg i.v.) injection in rats pre-treated with AM 
251 (1.0 mg/kg i.p., 30 min before agonist) (circles) or vehicle (triangles). Solid symbol: p < 0.05 with respect to 
basal values; *p < 0.05 vs veh group. (veh n=6; AM-251 n=3) (Two-way ANOVA, post-hoc Tukey’s test). 
 
5.2.4) Results for experiment 3: Effect of 5F-PB-22, 5F-AKB-48, and STS-135 
administration on DA transmission in the NAc shell  
In this set of experiments, we studied the effect of 5F-PB-22 (0.01 mg/kg, i.v.), 5F-AKB-48 
(0.1 mg/kg, i.v.) and STS-135 (0.15 mg/kg i.v.) on extracellular DA levels in the NAc shell. 
As shown in Figure 30, all the drugs increased DA levels in the NAc shell. Two-way ANOVA 
analysis showed the following significant effects: 5F-PB-22 treatment [F(1,10)=15.97; p< 
0.005]; 5F-AKB-48 treatment [F(1,11)=63.39; p< 0.001], 5F-AKB-48 time x treatment 
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[F(18,144)=2.1; p< 0.005]. Furthermore, post-hoc Tukey's tests revealed significant 
differences on DA dialysate between: 
▪ 5F-PB-22 (0.01 mg/kg, i.v.) treated-animals vs basal value (30, 40 min sample); 
▪ 5F-AKB-48 (0.1 mg/kg, i.v.) treated-animals vs basal value (60, 100, 150 min sample) 
and vs vehicle treated animals (60, 100 min sample);  
▪ STS-135 (0.15 mg/kg i.v.) treated-animals vs basal value and vs vehicle treated animals 
(60 min sample); 
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Figure 30: In vivo effect of 5F-PB-22, 5F-AKB-48, STS-135 administration on DA transmission in the NAc 
shell.  
Results are expressed as mean ± SEM of change in DA extracellular levels expressed as the percentage of basal 
values. The arrow indicates the moment of synthetic cannabinoid i.v. injection: 5F-PB-22 0.01 mg/kg (triangles), 
5F-AKB-48 0.1 mg/kg (diamonds), and STS-135 0.15 mg/kg (squares), or vehicle (circles) in the NAc shell. Solid 
symbol: p < 0.05 with respect to basal values; *p < 0.05 vs Veh group (5F-PB-22, n= 6; 5F-AKB-48, n= 7; STS-
135 n= 5; Veh n=17) (Repeated measures three-way ANOVA, post-hoc Tukey’s test). 
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5.2.5) Synthetic cannabinoids and microdialysis studies: discussion 
According to the present findings, all synthetic cannabinoids tested could increase dopamine 
release in the NAc shell, while no changes were observed in other areas of the reward system, 
namely NAc core and mPFCx after BB-22 intravenous administration. This result is in line 
with previous research outcomes by which almost all drugs of abuse activate DA release 
preferentially in the NAc shell (Pontieri et al., 1995; Tanda et al., 1997; Cadoni and Di Chiara, 
2000).  
Among all index SCs in the present study, the compound with highest affinity, potency, 
efficacy, namely BB-22, was selected for a careful neurochemical evaluation. A wide pattern 
of dosages (0.00, 0.003, 0.01, 0.03, 0.1 mg/kg, i.v.) was tested in accordance with the Ki value 
found for this compound. The maximal increase of dopamine was observed at 0.01 mg/kg in 
the NAc shell, with a magnitude of about 50% over basal value and a loss of the effect at lower 
(0.003 mg/kg, i.v.) and higher doses (0.03, 0.1 mg/kg, i.v.) according to a concentration-
dependent bell-shaped curve, as already observed with JWH-018 (De Luca et al., 2015 and 
2016). The biphasic time-course of DA in the NAc shell is likely related to the degradation of 
the drug and the resulting formation of active metabolites acting as CB1R agonists. However, 
further pharmacokinetic studies are needed to support this hypothesis.  
Interestingly, the stimulation of dialysate DA in the NAc shell was elicited within a very narrow 
dose-range, similarly to Δ9‐THC and differently from most drugs of abuse (Pontieri et al., 
1995, Di Chiara et al., 2004). 
Notably, the dose of BB-22 effective in stimulating DA release was around 10 times lower 
compared to that of JWH-018 able to stimulate DA release to the same extent (about 50% over 
basal). This finding was consistent with the evidence for different affinities exhibited by these 
two compounds at CB1 receptors (BB-22, 0.11 nM; JWH-018, 3.38 nM) (De Luca et al., 2016). 
Interestingly, the involvement of CB1 receptors in the effect of BB-22, has been confirmed by 
inhibition of dopamine stimulation after pre-treatment with the CB1 antagonist/inverse agonist 
AM-251 (1.0 mg/kg, i.p.).   
Differently from the BB-22 study, all the other compounds were tested at a single dose 
(hypothesized to be effective according to their Ki value) and DA release was monitored in the 
same target region (NAc shell) on which DA output increase was observed after BB-22 (0.01 
mg/kg, i.v.) administration. As expected, all the drugs caused an increase of DA levels with a 
magnitude comparable to that of BB-22 consistent with the dosage established in accordance 
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with their Ki values. Notably, the compound 5F-PB-22, elicited a 50% increase of DA release 
over basal levels at the same dosage (0.01, mg/kg, i.v.) observed with BB-22, while a dose of 
5F-AKB-48 (0.1 mg/kg, i.v.) and STS-135 (0.15 mg/kg, i.v.) ten and fifteen times higher 
respectively, was necessary to obtain a 50% increase on DA release in the NAc shell. Notably, 
the same magnitude of increase was previously observed after administration of a dose 100 
times higher of Δ9‐THC (1 mg/kg, i.v.) (Pistis et al., 2002), providing circumstantial pre-
clinical evidence for a greater putative abuse liability of SCs compared to the natural compound 
found in cannabis (Δ9‐THC). However, additional behavioural studies (e.g. i.v. self-
administration) are needed to support this hypothesis.  
5.3) 2,4-Dinitrophenol (2,4-DNP) and microdialysis studies 
Aims 
Despite legal restrictions issued to contrast 2,4-DNP diffusion, this drug is still available over 
the Internet as a dieting aid according to its ability to increase basal metabolic rate, accelerate 
gluconeogenesis, promote fat mobilization and glycolysis. The underlying mechanism causing 
the abuse of this drug has been widely debated over the years with some researchers trying to 
find a rational explanation for its highly popular impact. Oxidative phosphorylation disruption 
is one of the principal mechanisms underlying the dieting aid properties of this compound, and 
it is also one of the principal mechanisms responsible for its highly toxicity potential, according 
to the small differences found between fat-burning and toxic dosages. Despite its ability to 
cross the blood-brain barrier has been widely documented (Perry et al., 2013), no published 
neurochemical studies up to now have described a central mediation of 2,4-DNP effects. 
However, in a study conducted in 1933 in humans, 2,4-DNP administration was demonstrated 
to be useful in the treatment of similar depressed metabolic states, characterised by mild 
depression, lethargy, apathy. In detail, 6 out of 18 patients orally treated for a 3-month period 
with 2,4-DNP (60 mg, 1 grain) every day, with the dose being increased 60 mg every third day, 
showed lightening of mood, increased activity and interest, which disappeared after drug 
discontinuation (Massermann and Goldsmith, 1933). 
Other chemicals, like amphetamines, that share with 2,4-DNP the ability to uncouple oxidative 
phosphorylation, show an additional central mediation of the effects involving the reward 
pathways. In view of some analogies between 2,4-DNP and amphetamine mechanisms, we 
hypothesised that the oxidative phosphorylation was not the only underlying mechanism in 
common between amphetamines and 2,4-DNP and we further theorised that some alterations 
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could occur in the reward system following 2,4-DNP exposure. Since the NAc in particular is 
a terminal area of the mesolimbic dopaminergic system involved in several aspects of 
addiction, we aimed to monitor DA release in the NAc shell after acute intraperitoneal 
administration of 2,4-DNP using the microdialysis procedure in freely moving rats. DA release 
was additionally monitored in the CPu according to its involvement in some aspects of reward. 
In our microdialysis studies we used a single dose of 2,4-DNP (e.g. 20 mg/kg, i.p.) able to 
cause a moderate increase of temperature (e.g. ΔT=2.3 ± 0.2) without fatal complications (Gatz 
and Jones, 1970). Rat body temperature was monitored by means of a rectal digital 
thermometer during the microdialysis experiment. The intraperitoneal ROA was chosen instead 
of the oral one (common way to consume 2,4-DNP) because although the pharmacokinetics of 
substances administered intraperitoneally are similar to those observed after oral administration 
(the drug is primarily absorbed into the mesenteric vessels, and then gathered into the portal 
vein of liver), the bio-availability produced with the parenteral route of administration is higher 
(Turner et al., 2011). Note that, in our microdialysis experiments we used the same strain of 
animals (Sprague-Dawley rats) described in studies above mentioned focusing on the 
hyperthermia induced by 2,4-DNP (Gatz and Jones, 1970), aiming to avoid inter-strains 
variability. Overall, our study aimed to evaluate: 
▪ whether 2.4-DNP (20 mg/kg, i.v.) shares with other drugs of abuse (e.g. amphetamine) 
the ability to stimulate DA transmission in the NAc shell and CPu; 
▪ whether 2.4-DNP (20 mg/kg, i.v.) causes an increase of temperature comparable to that 
observed by Gatz and Jones (1970). 
 
5.3.1) 2,4-DNP microdialysis studies: materials and methods 
Animals 
Twelve adult male Sprague-Dawley rats (body weight: 275-300 g; Harlan Laboratories, Italy) 
were housed in groups of six per cage. The animal environment was kept under an inverted 
12:12 hour light/dark cycle and at a constant temperature of 22 ± 2°C and humidity of about 
60%. Tap water and standard food were available ad libitum in the home cage. The 
microdialysis experiments were conducted in the University of Cagliari (Italy) and carried out 
in accordance with the Guidelines for the Care and Use of Mammals in Neuroscience and 
Behavioural Research according to Italian (D.L. 116/92 and 152/06) and European Council 
directives (609/86 and 63/2010) and in compliance with the approved animal policies by the 
Ethical Committee for Animal Experiments (CESA, University of Cagliari) and the Italian 
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Ministry of Health (Aut. N. 162/2016- PR). We made all efforts to minimize pain and suffering, 
and to reduce the number of animals used. 
Surgery 
Rats were anesthetized with Equitesin (chloral hydrate 2.1 g, sodium pentobarbital 0.46 g, 
MgSO4 1.06 g, propylene glycol 21.4 ml, ethanol (90%) 5.7 ml, H2O 3 ml; 3 ml/kg i.p.), and 
implanted with vertical dialysis probes aimed at the NAc shell and CPu. According to the atlas 
of Paxinos and Watson (1998), the coordinates used were the following: NAc shell: Antero-
Posteriority=+2.2, Laterality=±1.1 from bregma and Verticality=-7.8 from dura; CPu: 
Anteriority=+1.2, Laterality=±3.0 from bregma and Verticality=-5.5 from dura. 
Microdialysis 
On the day after surgery, an infusion pump constantly perfused with the Ringer’s solution (rate: 
1 μl/min) was connected to the probes. Dialysate samples were collected every 20 minutes and 
the resulting specimens were injected into an HPLC system equipped with a coulometric 
detector (ESA; Coulochem II, Bedford, MA). The parameters of the detector were the same 
used in the previous experiment with SCs. Dopamine recordings were performed every 20 
minutes for a total period of 120 minutes. 
Body Temperature measurement 
Rat body temperature was monitored by means of a rectal digital thermometer. Recordings 
were performed during the microdialysis experiment every 15 minutes for a total period of 120 
minutes after treatment. 
Drug preparation  
2,4-Dinitrophenol was intraperitoneally injected using a single dose of 20 mg/kg. The drug was 
dissolved in water. KOH 1N was added to the drug solution in order to neutralize the pH. 
Groups of treatment 
In preparation for the experiment, animals were divided into 4 groups: 
▪ Rats implanted in CPu and treated with vehicle (n=3) 
▪ Rats implanted in NAc and treated with vehicle (n=3) 
▪ Rats implanted in CPu and treated with 2,4-DNP 20 mg/kg, i.p. (n=3) 
▪ Rats implanted in NAc shell, and treated with 2,4-DNP 20 mg/kg, i.p. (n=3) 
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Dissection and histology 
At the end of the experiment animals previously anesthetized, were sacrificed; the probes were 
gently removed, and the brains were cut in coronal slices using a vibratome. Fibre placement 
was determined consistent with the coordinates suggested in the atlas of Paxinos and Watson 
(1998). 
Statistical analysis: All data were expressed as mean ± SEM. Data between different groups of 
treatment were analysed using Statistica for Windows (Version 10). Specifically, the 
differences in DA levels were analysed by ANOVA for repeated measures. Results obtained 
using ANOVA were then examined using the post-hoc Tukey’s test with significance for p < 
0.05. 
5.3.2) 2,4-DNP microdialysis studies: results 
Dopamine data 
According to our findings, no significant effect of 2,4-DNP treatment on the percentage change 
of dialysate DA was found in the NAc shell compared to the vehicle group F(1;4)=1.89, p>0.05, 
along with no significant effect over time: F(6;24)=0.96, p>0.05 and no significant interaction 
time x treatment: F(6;24)=0.95, p>0.05 (two-way ANOVA) (figure not shown). Additionally, 
no significant effect of 2,4-DNP treatment on percentage change of dialysate DA was found in 
the CPu compared to the vehicle group: F(1;4)=3.13, p>0.05; along with no significant effect 
over time: F(6;24)=1.97, p>0.05 and no significant interaction time x treatment: F(6;24)=2.39 
p>0.05 (two-way ANOVA) (figure not shown). Furthermore, no significant effect of 2,4-DNP 
treatment on percentage change of dialysate DA was found in the CPu compared to the shell: 
F(1;4)=0.13, p>0.05, along with no significant effect of the time: F(6;24)=1.49, p>0.05 and no 
significant interaction time x area: F(6;24)=1.26, p>0.05 (two-way ANOVA) (see Figure 31).  
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Figure 31: In vivo effect of 2,4-DNP (20 mg/kg, i.p.) administration on DA transmission in the NAc shell (n=3) 
and CPu (n=3). Results are mean ±SEM of DA extracellular levels expressed as the percentage of basal values.  
 
Rectal temperature data 
According to our findings, a significant effect of 2,4-DNP treatment on rectal temperature was 
observed compared to the vehicle: F(1,10)=11.23, p<0.01, with a significant effect of the time: 
F(8,80)=6.76, p<0.0001; and a significant interaction time x treatment: F(8, 80)=2.85, p<0.01 
(2-way ANOVA; figure not shown). 
Additionally, one-way ANOVA of the 2,4-DNP data over time, revealed a significant effect of 
the time on body temperature after 2,4-DNP treatment: F(8,40)=12.11, p<0.0001. Specifically, 
post-hoc Tukey’s analysis showed a highly significant effect of 2,4-DNP on body temperature 
in the interval between 15 and 105 minutes after treatment (p<0.0005), with maximum 
observed average temperature increase of about 2.0 degrees Celsius 30 and 75 minutes after 
2,4-DNP injection. The significance decreased 120 minutes after treatment (p<0.005) (see 
Figure 32). 
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Figure 32: Effect of 2,4-DNP (20 mg/kg i.p.) administration on body temperature (n=6). Results are mean ±SEM 
of body temperature levels expressed in degrees Celsius. ***: p<0.0005; **: p<0.005 vs the respective basal 
values. 
5.3.3) 2,4-DNP microdialysis studies: discussion 
According to our findings, the acute treatment with 2,4-DNP (20 mg/kg, i.p.) did not cause any 
change in DA release in the NAc shell and CPu, rejecting the hypothesis of psychoactivity of 
this substance at this specific dose. Notably, this study showed some limitations. Firstly, one 
single dose of 2,4-DNP has been tested, and no dopamine output data have been recorded after 
acute administration of higher doses. This decision has been made according to an ethical 
approach by which animal’s pain and suffering were minimized avoiding administration of 
larger doses that would have been extremely toxic for the rats. For the same ethical reason, we 
avoided any chronic treatment with 2,4-DNP, since repeated administrations would have 
potentially produced cardiovascular disturbances, liver and renal functions impairment, 
malignant hyperpyrexia that would have undoubtedly altered our neurochemical outcomes. An 
alternative approach would have engaged the use of lower doses of 2,4-DNP, but no 
pharmacological data up to date, have supported the hypothesis of a concentration-dependent 
U-shaped curve related to this drug. In view of the above, we concluded that there were not 
acceptable circumstantial reasons to proceed with any of these approaches. However, 
consistently with previous findings, our data confirmed that 2,4-DNP (20 mg/kg, i.p.) was able 
to cause hyperpyrexia in rats with a maximum observed average temperature increase of about 
2.0 degrees Celsius, after 2,4-DNP injection. This compound is indeed known to be able to 
affect the energy production derived from the breakdown of fats and sugars by acting at the 
level of the inner mitochondrial membrane and shuttling protons between the inter-membrane 
space and the matrix. This mechanism increases the proton conductance of mitochondria and 
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affects the synthesis of adenosine triphosphate (ATP). As a result, the cellular energy is 
released as heat and produces thermogenesis (Harper et al., 2001; Ray et al., 2008).  
Other anorectic drugs, like amphetamines, share with 2,4-DNP the ability to uncouple oxidative 
phosphorylation and increase body temperature. Therefore, the association of 2,4-DNP with 
these drugs may increase the risk of incurring fatal hyperthermia giving rise to a health 
emergency difficult to contain. Further studies are needed to elucidate 2,4-DNP 
pharmacological effects aiming at minimizing potential health arms related to its use/abuse. 
 
5.4) 2-DPMP and D2PM microdialysis studies 
Aims 
2-DPMP and D2PM are two synthetic stimulants belonging to the pipradrol-derivative class 
that became popular as MDMA, and cocaine replacements. Their popularity in the UK quickly 
increased causing several toxic events and fatalities. Previous in vitro studies focusing on the 
effect of these drugs demonstrated that the pipradrol derivatives 2-DPMP and D2PM, were 
more potent DAT vs SERT inhibitors without releasing properties (Simmler et al., 2014). 
Furthermore, another in vitro fast scan cyclic voltammetry study demonstrated the ability of 2-
DPMP (1, 3 or 10 µM) to increase evoked DA efflux and slowed DA reuptake to a greater 
extent compared to cocaine at the same doses, with a two-fold increase of DA efflux and a 3-
fold reduction of DA reuptake activity with respect to cocaine (Davidson and Ramsey; 2012). 
All these data suggested that 2-DPMP and D2PM are potent DAT inhibitors and this 
mechanism accounts for their highly psychotogenic effects (Davidson and Ramsey, 2012). 
However, no studies have been conducted until now on the effect of these two drugs on DA 
release in target areas of the reward system in freely moving animals. As previously said, all 
drugs of abuse are able to cause an enhancement of mesolimbic DA activity. The magnitude 
of dopamine increase varies along with the dose, way of administration, and duration of 
treatment. In our study, the pipradrol derivatives 2-DPMP and D2PM were selected among 
other stimulants in order to monitor DA release in two different areas of the reward system: 
NAc shell, and CPu after their intravenous administration in rats. The rationale behind the 
choice of these drugs was related to the necessity to acquire some insights into the effect of 
these drugs in the reward pathways of the central nervous system, especially in view of the 
recent health emergencies raised by using these compounds and their highly psychotogenic 
effects.  
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In our microdialysis studies, a wide dose-range of these two stimulants was tested according to 
the ki values found for 2-DPMP (0.007 ± 0.01 µM) and D2PM (0.07 ± 0.03 µM) at the level of 
DAT by Simmler et al. (2014).  Specifically, the doses tested in the present study were as 
follows: 2-DPMP (0, 0.01, 0.1, 0.3, 0.5, 1.0 mg/kg, i.v.) and D2PM (0, 0.01, 0.1, 1.0, 3.0 mg/kg, 
i.v.). An acute treatment was performed using the intravenous route of administration because 
several reports described this ROA as a common practice to administer 2-DPMP and D2PM; 
additionally, intravenous injection is considered the most efficient means of delivering 
substances, as they are directly administered into blood vessels, avoiding the first-pass effect 
of hepatic metabolism (Turner et al., 2011). NAc shell and CPu were selected as target areas 
in accordance with the role played by these regions in addiction. Indeed, typical drugs of abuse 
share the ability to activate the reward pathways and increase DA release preferentially in the 
NAc shell (Di Chiara and Imperato, 1988; Lecca et al., 2006). Based on the type of drugs and 
dosages, an increase can be observed also in other regions of the reward system including CPu. 
Indeed, intravenous injection of stimulants like cocaine and amphetamine increases dopamine 
release in the dorsal striatum as well, however the magnitude of increase is greater in NAc shell 
than in the dorsal striatum (Lecca et al., 2006). The microdialysis procedure was employed 
among the others in our study, as a useful and reliable tool for monitoring changes of DA levels 
in freely moving animals. Note that, in our microdialysis experiments we used the same strain 
of animals (Wistar rats) described in in vitro fast scan cyclic voltammetry studies above 
mentioned, focusing on the effect of 2-DPMP on DA release in rat brain slices (Davidson and 
Ramsey, 2012), aiming to avoid inter-strains variability. Overall, our study aimed to:  
▪ Evaluate whether the index synthetic stimulants in our study (2-DPMP, D2PM) share 
with other stimulants (e.g. cocaine) the ability to stimulate DA transmission in the NAc 
shell; 
▪ Assess whether the synthetic stimulants tested, mediate DA transmission alteration in 
other areas of the reward system, namely dorsal striatum (CPu);  
▪ Quantify the magnitude of DA change mediated by the index synthetic stimulants in 
the present study. 
 
5.4.1) 2-DPMP and D2PM microdialysis studies: materials and methods 
Animals 
Adult male Wistar rats (body weight: 275-300 g; Envigo, Harlan Laboratories, Italy) destined 
for 2-DPMP and D2PM microdialysis experiments were housed in groups of four per cage. 
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The animal environment was kept under an inverted 12:12 hour light/dark cycle and at a 
constant temperature of 22 ± 2°C and humidity of about 60%. Tap water and standard food 
were available ad libitum in the home cage. All in vivo animal experiments were conducted in 
the University of Cagliari (Italy) and carried out in accordance with the Guidelines for the Care 
and Use of Mammals in Neuroscience and Behavioural Research according to Italian (D.L. 
116/92 and 152/06) and European Council directives (609/86 and 63/2010) and in compliance 
with the approved animal policies by the Ethical Committee for Animal Experiments (CESA, 
University of Cagliari) and the Italian Ministry of Health (Aut. N. 162/2016- PR). We made 
all efforts to minimize pain and suffering, and to reduce the number of animals used. 
Surgery  
Rats were anesthetized with Equitesin (chloral hydrate 2.1 g, sodium pentobarbital 0.46 g, 
MgSO4 1.06 g, propylene glycol 21.4 ml, ethanol (90%) 5.7 ml, H2O 3 ml; 3 ml/kg i.p.), and 
implanted with vertical dialysis probes aimed at the NAc shell and CPu. According to the atlas 
of Paxinos and Watson (1998), the coordinates used were the following: NAc shell: Antero-
Posteriority=+2.2, Laterality=±1.1 from bregma and Verticality=-7.8 from dura; CPu: 
Anteriority=+1.2, Laterality=±3.0 from bregma and Verticality=-5.5 from dura. 
Microdialysis experiment  
On the day after surgery, infusion pumps constantly perfused with the Ringer’s solution (rate: 
1 μl/min) were connected to the probes. Dialysate samples were collected every 20 minutes 
and the resulting specimens were injected into an HPLC system equipped with a coulometric 
detector (ESA; Coulochem II, Bedford, MA). The parameters of the detector were the same 
used in the previous experiment with synthetic cannabinoids. Dopamine recordings were 
performed for a total period of 180 minutes in both experiments. 
Drugs 
Desoxypipradrol hydrochloride solution and Diphenyl-2-pyrrolidinemethanol powder were 
purchased from Sigma-Aldrich, Italy. 2-DPMP dilutions were directly prepared from the stock, 
while D2PM dilutions were performed after dissolving D2PM powder in a small amount of 
ethanol, HCl 2.4 mM, and distilled water.  
2-DPMP microdialysis experiment 
Groups of treatment 
 In preparation for the experiment, animals were divided into different groups: 
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▪ rats implanted in the NAc shell and treated with vehicle (n=4); 2-DPMP (0.01 mg/kg, 
i.v., n=3); (0.1 mg/kg, i.v., n=3); (0.3 mg/kg, i.v., n=3); (0.5 mg/kg, i.v., n=4); (1.0 
mg/kg, i.v., n=3); 
▪ rats implanted in CPu and treated with vehicle (n=4); 2-DPMP (0.01 mg/kg, i.v., n=4); 
(0.1 mg/kg, i.v., n=4); (0.3 mg/kg, i.v., n=3); (0.5 mg/kg, i.v., n=4); (1.0 mg/kg, i.v., 
n=3).  
 
D2PM experiment 
Groups of treatment:  
▪ rats implanted in the NAc shell and treated with vehicle (n=4); D2PM (0.01 mg/kg, i.v., 
n=4); (0.1 mg/kg, i.v., n=5); (1.0 mg/kg, i.v., n=6); (3.0 mg/kg, i.v., n=5); 
▪ rats implanted in the CPu and treated with vehicle (n=4); D2PM (0.01 mg/kg, i.v., n=3); 
(0.1 mg/kg, i.v., n=4); (1.0 mg/kg, i.v., n=3); (3.0 mg/kg, i.v., n=3) 
 
Dissection and histology 
At the end of the experiment animals previously anesthetized were sacrificed; the probes were 
gently removed, and the brains cut in coronal slices using a vibratome. Fibre placement was 
determined consistent with the coordinates suggested in the atlas of Paxinos and Watson 
(1998). 
Statistical analysis  
All data were expressed as mean ± SEM. Data between different groups of treatment were 
analysed using Statistica for Windows (Version 10). Specifically, the differences in DA levels 
were analysed by ANOVA for repeated measures. Results obtained using ANOVA were then 
examined using the post-hoc Tukey’s test with significance for p < 0.05. 
5.4.2) 2-DPMP microdialysis experiment: results 
In this experiment the effect of a dose range of 2-DPMP (0.00, 0.01, 0.1, 0.3, 0.5, 1.0, mg/kg, 
i.v.) on DA transmission was assessed in the NAc shell and CPu in freely moving animals. 
Specifically, two-way ANOVA of DA data over time in NAc shell, revealed a significant effect 
of the dose [F(5,14)=11.73; p<0.0005], time [F(9,126)=20.22; p<0.0001], and a significant 
dose x time interaction [F(45,126)=3.92; p<0.0001]. Furthermore, post-hoc Tukey's test 
showed a significant increase of DA levels in the NAc shell 40 minutes after 2-DPMP (0.5 
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mg/kg, i.v.) injection, compared to the vehicle. Additionally, the highest dose (1.0 mg/kg, i.v.) 
caused a significant increase of DA release compared to the vehicle, 20 and 40 minutes after 
administration. 
Significant differences on DA dialysate in the NAc shell were observed between: 2-DPMP (0.5 
mg/kg, i.v.) treated animals vs basal value (40 min sample) and 2-DPMP (1.0 mg/kg, i.v.) 
treated animals vs basal value (20, 40 min sample) (see Figure 33). 
 
Figure 33: In vivo effect of 2-DPMP administration on DA transmission in the NAc shell. Results are expressed 
as mean ± SEM of change in DA extracellular levels expressed as the percentage of basal values. The arrow 
indicates the moment of 2-DPMP i.v. injection: vehicle (dark circles); 2-DPMP 0.01 mg/kg (orange squares); 2-
DPMP 0.1 mg/kg (green triangles); 2-DPMP 0.3 mg/kg (blue diamonds); 2-DPMP 0.5 mg/kg (violet squares); 2-
DPMP 1.0 mg/kg (red circles) in the NAc shell. Solid symbol: p < 0.0001 with respect to basal values;  **p < 
0.001; ***p < 0.0001 vs veh group (veh, n=4; 2-DPMP 0.01 mg/kg, n=3; 2-DPMP, 0.1 mg/kg, n=3; 2-DPMP 0.3 
mg/kg, n=3; 2-DPMP 0.5 mg/kg, n=4; 2-DPMP 1.0 mg/kg, n=3) (Two-way ANOVA, post-hoc Tukey’s test). 
 
As regards to CPu, 2-way ANOVA of DA data over time, revealed a significant effect of the 
doses [F(5,16)= 3.37; p<0.05], a significant effect of the time [F(9,144)= 30.35; p<0.0001], 
and a significant dose x time interaction [F(45,144)=4.58; p<0.0001]. Furthermore, post-hoc 
Tukey's test showed a significant increase of DA levels in the CPu  20 and 40 minutes after 2-
DPMP (0.5 and 1.0 mg/kg, i.v.) administration, compared to the vehicle. Additionally, 
significant differences on DA dialysate in the CPu were observed between: 2-DPMP (0.1 and 
0.3 mg/kg, i.v.) treated animals vs basal value (40 min sample) and 2-DPMP (0.5 and 1.0 
mg/kg, i.v.) treated animals vs basal value (20, 40 min sample) (see Figure 34).  
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Figure 34: In vivo effect of 2-DPMP administration on DA transmission in the CPu. Results are expressed as mean 
± SEM of change in DA extracellular levels expressed as the percentage of basal values. The arrow indicates the 
moment of 2-DPMP i.v. injection: vehicle (dark circles); 2-DPMP 0.01 mg/kg (orange squares); 2-DPMP 0.1 
mg/kg (green triangles); 2-DPMP 0.3 mg/kg (blue diamonds); 2-DPMP 0.5 mg/kg (violet squares); 2-DPMP 1.0 
mg/kg (red circles) in the CPu. Solid symbol: p < 0.0001 (violet squares and red circles), p<0.01 (blue diamonds),  
p<0.05 (green triangles) with respect to basal values;  *p < 0.05;  **p < 0.01, ***p<0.0005 vs  veh group (veh, 
n=4; 2-DPMP 0.01 mg/kg, n=4; 2-DPMP 0.1 mg/kg,  n=4; 2-DPMP 0.3 mg/kg, n=3; 2-DPMP 0.5 mg/kg, n=4; 
D2PM 1.0 mg/kg, n=3) (Two-way ANOVA, post-hoc Tukey’s test). 
 
Considering both areas, repeated measures three-way ANOVA revealed a significant effect of 
doses [F(5,30)=10.82; p<0.0001], brain area [F(1,30)=6.56; p<0.05], time [F(9,270)=48.003; 
p<0.0001] and a significant time x doses interaction [F(45,270)=7.23; p<0.0001]. Furthermore, 
post hoc Tukey's test showed a significant difference (p<0.005) of DA levels between NAc 
shell and CPu, 20 minutes after injection of 2-DPMP (1 mg/kg, i.v.). 
 
5.4.3) D2PM microdialysis experiment: results 
In this experiment the effect of a dose range of D2PM (0.00, 0.01, 0.1, 1.0, 3.0 mg/kg, i.v.) on 
DA transmission was assessed in the NAc shell and CPu in freely moving animals. Specifically, 
2-way ANOVA of DA data over time in NAc shell, revealed a significant effect of the dose 
[F(4,19)=7.84; p<0.0001], and a significant dose x time interaction [F(36,171)=1.51; p<0.05]. 
Furthermore, post-hoc Tukey's test showed a significant increase of DA levels in the NAc shell 
160 minutes after D2PM injection (3.0 mg/kg, i.v.) compared to the vehicle-treated group and 
basal value as well (see Figure 35). 
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Figure 35: In vivo effect of D2PM administration on DA transmission in the NAc shell. Results are expressed as 
mean ± SEM of change in DA extracellular levels expressed as the percentage of basal values. The arrow indicates 
the moment of D2PM i.v. injection: vehicle (dark circles); D2PM 0.01 mg/kg (orange squares); D2PM 0.1 mg/kg 
(green triangles); D2PM 1.0 mg/kg (blue diamonds); D2PM 3.0 mg/kg (violet squares) in the NAc shell. Solid 
symbol: p < 0.0001 with respect to basal values; **p < 0.005 vs veh group (veh, n=4; D2PM 0.01 mg/kg, n=4; 
D2PM 0.1 mg/kg, n=5; D2PM 1.0, mg/kg, n=6; D2PM 3.0 mg/kg, n=5) (Two-way ANOVA, post-hoc Tukey’s 
test). 
 
As regards to CPu, 2-way ANOVA of DA data over time, revealed no significant effect of the 
doses [F(4,12)= 2.80; p>0.05], no effect of the time [F(9,108)= 1.00; p>0.05], and no 
significant dose x time interaction [F(36,108)=1.13; p>0.05] (see Figure 36). 
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Figure 36: In vivo effect of D2PM administration on DA transmission in the CPu. Results are expressed as mean 
± SEM of change in DA extracellular levels expressed as the percentage of basal values. The arrow indicates the 
moment of D2PM i.v. injection: vehicle (dark circles); D2PM 0.01 mg/kg (orange squares); D2PM 0.1 mg/kg 
(green triangles); D2PM 1.0 mg/kg (blue diamonds); D2PM 3.0 mg/kg (violet squares) in the CPu. Veh, n=4; 
D2PM 0.01 mg/kg, n=3; D2PM 0.1 mg/kg, n=4; D2PM 1.0 mg/kg, n=3; D2PM 3.0 mg/kg, n=3) (Two-way 
ANOVA, post-hoc Tukey’s test). 
 
Considering both areas, repeated measures three-way ANOVA revealed a significant effect of 
brain area [F(1,31)=8.88; p<0.01], a significant area x doses interaction [F(4,31)=6.40; 
p<0.001], and a significant time x area x doses interaction [F(36,279)=1.77; p<0.01]. 
Furthermore, post-hoc Tukey's test showed a significant difference (p<0.01) of DA levels 
between the NAc shell and the CPu 160 minutes after injection of D2PM (3 mg/kg, i.v.). 
 
5.4.4) 2-DPMP and D2PM microdialysis experiments: discussion 
In these experiments the effect of a dose range of 2-DPMP (0.00, 0.01, 0.1, 0.3, 0.5, 1.0, mg/kg, 
i.v.) and D2PM (0.00, 0.01, 0.1, 1.0, 3.0 mg/kg, i.v.) on DA transmission was assessed in the 
NAc shell and CPu of freely moving animals. According to our findings the acute treatment 
with 2-DPMP elicited a dose-dependent increase of DA release in the NAc shell with a fast 
onset of action and a short-lasting effect. The maximal peak effect (200% over basal levels) 
was observed between 20-40 minutes after the highest dose injection (1 mg/kg), with dopamine 
levels sharply decreasing at 60 minutes and achieving a plateau around the basal levels over 
the rest of the time. A similar DA time course was observed after injection of 2-DPMP (0.5 
mg/kg), with the maximal increase occurring 40 minutes after injection and being much less 
pronounced (100% over basal levels) compared to that produced by the highest dose. 
Interestingly, lower doses were ineffective on DA release suggesting a dose-dependent related 
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effect of 2-DPMP. Notably, 2-DPMP elicited an increase of DA output in the CPu at the same 
dosages (0.5 mg/kg, i.v. and 1.0 mg/kg, i.v.) and with a percentage of increase comparable to 
that observed for the NAc shell at both doses.  
Referring to D2PM, a dopamine release increase (78% over basal levels) was observed 
selectively in the NAc shell 160 minutes after injection of the highest dose (3.0 mg/kg, i.v.) 
with dopamine levels returning to the basal levels 180 minutes after injection. Interestingly, 
lower doses were ineffective on DA release in the NAc shell suggesting a dose-dependent 
related effect of D2PM. Notably, no doses caused any increase of DA levels in the CPu at any 
time.  
The delayed onset of effect observed after D2PM injection in the NAc shell, could be likely 
related to the presence, in its structure, of the polar functional group -OH, likely responsible 
for its slow passage through the blood-brain-barrier (BBB); while the absence of polar groups 
in 2-DPMP chemical structure, may account for its rapid absorption through the BBB and its 
quick onset of effects.  
Overall, these studies present some limitations. It is likely that larger doses of both drugs would 
have caused a higher dopamine peak effect in the target regions according to a dose-dependent 
effect. In view of this consideration, testing larger doses of both drugs, would have been useful 
to find the highest effective dose and to quantify the maximum DA peak effect. Furthermore, 
behavioural observations (e.g. motility, freezing, piloerection, grooming, sniffing, gnawing, 
rearing, scratching) during microdialysis studies, would have provided some additional 
information on the level of behavioural stimulation caused by these stimulants. In this regard, 
according to some preliminary observations in our laboratory, only high doses of 2-DPMP (0.5 
and 1.0 mg/kg) seemed to produce stimulant behavioural effects; however, detailed preclinical 
studies are needed to better draft a behavioural profile of these drugs. 
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Chapter 6: Molecular modelling studies 
6.1) Molecular modelling overview 
Over the years, drug designers started to synthetise novel compounds intended to mimic the 
effects of controlled drugs, by introducing slight modifications to the chemical structure of 
illicit compounds in order to escape legal regulations (Liechti, 2015).  
In this regard, the chemogenomics principles, which assume that structurally similar ligands 
share similar targets, allowed researchers to predict the possible effects of a drug on a set of 
targets by using the combination of molecular modelling with bioactivity databases available 
(Börjessonet al., 2005).  
Computational chemistry and molecular modelling rely on the use of computers to simulate 
complex chemical systems including drug-target interactions in the central nervous system. 
These interactions can be represented by several variables using the principles of mathematics, 
chemistry, physics and computer science. The simulation studies by computer may be 
conducted in order to help researchers to either rationalize experimental observations and/or 
make predictions about what will happen in a real biological system at multiple levels (from 
atomistic to macroscopic modelling) and allowing scientists to save animals, time, money and 
materials (Young, 2009). 
Against a background of increasing numbers of NPS used and their prevalence on the drug 
market, molecular modelling was utilized to postulate the mechanisms of action of novel 
compounds as the scientific literature was lacking to guide the design of experimental studies 
in humans and animals. The potential use of molecular modelling for the prediction and 
recognition of characteristic features of NPS (pharmacology, pharmacodynamics, toxicity, 
psychoactivity) has represented a step forward in biological science (Dargan and Wood, 2013). 
Molecular modelling has become an integrated part of predicting and rationalising the 
properties of potential drug candidates as well as understanding the side-effects and toxicity of 
small molecules. From a clinical point of view, in silico studies use computer models to identify 
the potential target of novel drugs, and they may also prove useful in helping to predict the 
mechanism of action of a drug, driving the development of intervention strategies aimed to 
protect the public from the consequences of side effects and drug interactions (Dargan and 
Wood, 2013). Overall, these studies have the potential to speed up the rate of drug target 
discovery, reducing the number of failed expensive laboratory and clinical trials. However, in 
silico studies require constant experimental interplay with medicinal chemistry and biology to 
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validate the results predicted and provide structural context for NPS at specific targets relating 
them with their functional properties. Such approaches can be employed to assess addictive 
potential of NPS, and to plan new therapeutic strategies against their use/abuse (Dargan and 
Wood, 2013). 
From a pragmatic point of view, several preliminary molecular modelling studies have been 
performed to get better understanding into binding properties and biological activities of some 
NPS at the level of specific targets (Menghani et al., 2016).  
In this regard, in silico studies were performed to screen the activity of a range of N-benzyl 
phenethylamines (e.g. DOI NBOMe, 25H-NBOMe, 25I-NBOMe, etc) at the level of the 5-
HT2A receptor (Braden et al., 2006) and two highly conserved aromatic amino acids (Phe 339 
and Phe 340) were identified as key residues involved in the recognition of these compounds 
(Roth et al., 1997). These data, along with experimental studies, may imply that these aromatic 
residues play a crucial role in agonist binding and signal transduction, offering molecular 
evidence of the mechanism of action of these drugs along with their potential pharmacological 
and clinical effects.  
Further studies employed molecular modelling to explore the possible differences in the 
binding modes of the novel cathinones 4-MEC and 4-MePPP at DAT and SERT, and 
demonstrated that both compounds show analogous poses in DAT, while SERT is less able to 
accommodate 4-MePPP when compared with 4-MEC because of the steric hindrance caused 
by the bulky pyrrolidine ring structure of 4-MePPP. Overall, these results provide crucial clues 
about the pharmacology of these mephedrone analogues, and give information on the molecular 
requirements that drive drug selectivity at DAT vs SERT, providing new insights into the 
biological and pharmacological properties of these substances (Saha et al., 2015).  
Other previous in silico studies, along with in vitro binding studies assessed the binding 
properties of the novel benzofuran 5-MAPB at DAT and demonstrated a binding mode for 5-
MAPB that overlaps with the binding site of other stimulants such as amphetamine, MDMA, 
5-APB, cocaine. These novel insights, offered by the interplay of computational methods with 
neurochemical procedures, relate these NPS to their functional properties at DAT, explaining 
their similarity in terms of pharmacological/clinical effects with other categories of stimulants 
(e.g. MDMA, cocaine) (Sahai et al., 2017). 
Additional molecular modelling studies have been performed to assess the binding modes of 
the psychoactive compound of the Khat plant cathinone along with its metabolites 
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norephedrine and norpseudoephedrine at DAT (Kolodziejczyket al., 2016). These studies 
revealed all the conformers interact with an active binding pocket highly comparable with that 
of D-amphetamine, and suggested that the metabolites can have a crucial role in producing 
long-lasting effects after cathinone use. 
Overall, these studies helped to elucidate the mechanism of action which may underlie the 
potential clinical and side-effects of a range of NPS, providing new insights into their biological 
activity for more successful abuse management and treatment plans against the use/abuse of 
these drugs. 
Furthermore, molecular modelling studies have been also employed in drug discovery and 
structure-based drug design and have played a crucial role in the assessment of potential novel 
therapeutics in the treatment of a variety of diseases (Sliwoski et al., 2013). 
In this respect, in a previous study, 10 thiourea derivatives were synthesized and assessed for 
the treatment of the Parkinson's disease psychosis and molecular docking studies were 
employed to screen their activity using a homology model of 5-HT2A receptor. Significant 
interactions between both thiourea NH groups and specific residues of the receptor were 
observed and provided new information related to their structural properties responsible for 
affinity towards the 5-HT2A receptor (Bielenica et al., 2016).  
Further studies employed in silico simulations to screen the activity of a set of Risperidone 
derivatives using a homology model of the D2 receptor, in order to discover novel therapeutics 
for the treatment of the schizophrenia (Bhargava et al., 2014). 
In another study, a series of novel quinazoline derivatives were synthesized and evaluated for 
their anti-inflammatory activity. To this aim in silico studies were performed to recognize the 
hypothetical binding mode of these compounds with the cyclooxygenase isoenzymes (COX-1 
and COX-2) and specific substituents were regarded as responsible for affinity toward these 
enzymes (Balakumar et al., 2010).  
Overall, computer-aided drug discovery and structure-based drug design allow researchers to 
save money and time, avoiding a large population of predicted inactive compounds and 
focusing resources on testing compounds likely to have any activity of interest in the treatment 
of a variety of diseases (Sliwoski et al., 2013).  
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Drug targets, focus on CB1 receptors 
The majority of drug targets are proteins (receptors, transporters, enzymes) having active 
binding sites usually with highly conserved amino acids. Natural substrates, as well as drugs 
and drugs candidates can establish a range of different types of interactions within the binding 
site (e.g. hydrogen bonds, π-system staking, ionic bonds, van der Waals interactions, 
electrostatic interactions) (Bull et al., 2015), allowing a protein to exert or modulate its 
function, respectively. In this regard, cannabinoids receptors (subtype 1) regulate a variety of 
physiological processes (appetite, mood, pain), while their pharmacological manipulations can 
lead to a range of clinical consequences.  
The CB1 receptor is a member of the superfamily of G-protein-coupled receptors (GPCRs), 
characterised by an intracellular C-terminal tail, seven transmembrane helices linked by three 
extracellular and three intracellular loops, and an extracellular N-terminal tail (Turu et al., 
2010). It is the major cannabinoid receptor subtype found in the brain, but it also occurs in the 
peripheral nervous system (Castaneto et al., 2014; Howlett et al., 2002). It can interact with 
endogenous (e.g. anandamide, 2-AG) and exogenous cannabinoids which include structurally 
distinct classes of compounds such as: classical cannabinoid agonists (Δ9‐THC), non-classical 
cannabinoid agonists (CP-55,940), aminoalkylindole agonists (AAI), CB1 antagonists 
(rimonabant, AM-6358). CB1 receptors are highly conserved among vertebrates and according 
to a comparative analysis, the human receptor presents 97% of identity at the amino acid level 
compared to the rodent CB1 receptor and presents one less amino acid in the N- terminal (472 
amino acids).  
In response to ligand binding, the CB1 receptor changes its conformation to activate the 
associated G-proteins and to promote a cascade of intracellular events including: decrease of 
cAMP level, inhibition of potassium, sodium, and N- and P/Q-type- calcium channels, 
inhibition of neurotransmitter release (Howlett et al., 2010).  
Evaluation of binding modes of CB1 receptor ligands using molecular modelling and 
mutation studies 
Over the years, single-point mutagenesis and computational modelling studies on CB1 
receptors have provided valuable insights into the characterisation of the key residues involved 
in the recognition of specific ligands. In particular, mutation studies demonstrated that the 
binding pockets for classical (Δ9‐THC), non-classical (CP-55,940) and endogenous 
cannabinoids (2-AG, Anandamide) is topologically different from that observed for 
aminoalkylindoles (JWH-018, WIN-55,212-2) although they spatially overlap (see Table 2).  
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Mutation of specific residues resulted in profound loss of affinity and recognition for these 
specific ligands, suggesting their crucial role in ligand binding (Song and Bonners 1996, Mc 
Allister et al., 2003; Shim and Howlett, 2006; Ahn et al., 2009; Shim, 2010; Shim et al., 2012; 
Hua et al., 2016; Shao et al., 2016).  
More recently, the crystal structure of the human CB1 receptor was synthesized and used in 
conjunction with computational molecular modelling to provide insights into the binding mode 
of the synthetic cannabinoid constituent of ‘Spice’ such as JWH-018 and other CB1 agonists 
(e.g. anandamide, 2-AG, Δ9‐THC, CP-55,940, WIN-55,212-2); and CB1 antagonists (e.g. 
rimonabant, AM-6358, Otenabant, Taranabant) (Hua et al., 2016). 
According to these studies, the CB1 agonists mainly interact with the 3, 6, 7 helices and the N-
terminal loop of the crystal structure of the CB1 receptor; while the CB1 antagonists mostly 
share interactions with the 2, 3, 6, 7 helices and ECL2 (extracellular loop 2). These findings 
were consistent with previous mutation study outcomes (see Table 2) (Mc Allister et al., 2003, 
Ahn et al., 2009).  
 
Table 2: Key interacting residues crucial for CB1 ligand binding recognition according to experimental mutation 
studies. 
6.2) Homology modelling overview 
The primary amino acid sequences for almost all human proteins are largely available. 
However, to assess the potential interactions between drugs and proteins, knowledge of the 
three-dimensional structure of the protein is required and crystallography is the most accurate 
way to predict and determine protein geometry (Engh and R. Huber, 1991).  
Determination of appropriate protein crystallization is generally considered quite challenging 
and sometimes not feasible due to peculiar physicochemical characteristics of certain proteins 
and their high sensitivity to alterations of pH, temperature and ionic strength (Bergfors, 1999). 
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Considering that not all proteins have their crystal structure available, homology models 
represent the next best way of obtaining putative protein structures and may provide a good 
source for protein-ligand interaction studies (Young, 2009).  
Given the complexity of drug mechanisms, it is important to consider that computational 
models are becoming increasingly useful in the pharmacology field as their predictions are 
validated by experimental findings. Overall, homology modelling predicts a three-dimensional 
structure from the sequence of a target protein with an accuracy that is often comparable to the 
best outcomes attained experimentally and it provides invaluable insights into the molecular 
basis of putative protein functions (Krieger et al., 2003).  
Template identification, alignment, homology model building and validation 
The homology model process includes several steps: template identification, template-target 
alignment, building of the homology model and model validation. Briefly, in homology 
modelling, the primary sequence of the target protein is compared with primary sequences of 
proteins for which crystal structures are available (templates) in order to find regions that are 
identical to the target protein. In this regard, homology modelling (or template-based protein 
modelling) relies on evolutionary relationships between a target protein and templates with 
known experimental structures to ultimately build the target three-dimensional model (Young, 
2009). This principle is based on the fact that, during evolution, the three-dimensional structure 
of a protein has been more highly conserved than the associated amino acid sequence, so that 
similar evolutionary related sequences generally fold into similar structures and adopt 
comparable 3D structures (Chothia and Lesk, 1986). A crucial factor to consider in homology 
modelling is the sequence identity with the template, and the most accredited theory suggests 
that to obtain a reliable homology model, the sequence identity should be over 70% (Young, 
2009). Of course, higher sequence identity between the model and the template leads to better 
expected quality models (Arnold et al., 2006). The crystallographic coordinates for several 
segments of known evolutionary-related proteins are then used to build the three-dimensional 
geometry of the protein and the homology model is validated with tools (e.g. Rampage and 
Procheck) based on a comparison of a range of stereo-chemical parameters with those of trusted 
reference structures (Arnold et al., 2006).   
 
 
134 
 
SWISS-MODEL: computational tool for template identification, alignment and 
homology model building 
The online software ‘SWISS-MODEL’ provides a range of programmes and databases required 
for template identification; alignment; homology model building and access to updated protein 
sequence and structure databases (e.g. Protein Data Bank) (Arnold et al., 2006). In detail, the 
template structure database used by SWISS-MODEL (SMTL) is derived from the Protein Data 
Bank (Arnold et al., 2006). The sequence database search for template identification, provides 
an overview of the results organised in clusters of templates showing different percentages of 
identity. For each template, several information items are reported: PDB ID; name of the 
structure; experimental methods used to obtain the structure; resolution; the sequence identity 
to the target; the target sequence coverage; template search method used; oligomeric state; and 
description of ligands. The level of difficulty in identifying suitable templates for a target 
sequence may be low for well-characterised protein families or really high for proteins with 
unknown structure. To overcome this issue, SWISS-MODEL provides access to different 
methods to search for templates (BLAST, Iterative profile BLAST, HMM-based template 
library search) (Arnold et al., 2006). 
‘BLAST’ is a Basic Local Alignment Search Tool that compares a query protein sequence with 
the SWISS-MODEL library of sequences extracted from PDB and identifies high scoring 
sequence alignments between the query sequence and the templates in the database using a 
specific algorithm. When no suitable templates are identified, two additional approaches are 
provided: PSI BLAST and HMM-based template library search.  
‘PSI BLAST’ is a Position-Specific Iterative BLAST tool used to find more distant 
evolutionary templates compared to the query protein sequence. Initially, PSI BLAST produces 
a list of close evolutionary templates used to generate a ‘profile sequence’ which summarises 
significant analogies present in these templates. Then a query against the SWISS-MODEL 
library templates is performed using this ‘profile sequence’ and a wider group of proteins is 
identified. This group is then used to produce another ‘sequence profile’ and the process is 
repeated. This tool is more sensitive in identifying distant evolutionary relatives of the target 
sequence compared to BLAST (Arnold et al., 2006). 
Alternatively, ‘HMM-based template library search tool’ finds all the sequence homologues 
that match the submitted sequence. These templates are then assembled and converted   into a 
Hidden Markov Model (HMM) which is then scanned against the Hidden Markov model 
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library to find high score structural multiple alignments which are based only on geometric 
information of the proteins. Compared to PSI BLAST, this tool has higher sensitivity and 
generates more accurate alignments (Remmert et al., 2011). This tool may be use used as an 
alternative to PSI BLAST to identify distant evolutionary homologues of the target sequence. 
The SWISS-MODEL server uses the improved HMM methods named Hidden ‘HMM-HMM–
based lightning-fast iterative sequence search’ (HHblits; 
http://toolkit.genzentrum.lmu.de/hhblits/) (Remmert et al., 2011). HHBlits relies on the ‘kClust 
tool’ to cluster large protein sequence databases to below 30% sequence identity and it is ~1000 
times quicker than BLAST (Hauser et al., 2013). In detail, the query sequence is firstly 
converted into a first HMM which is scanned against the HMM database (NR). Sequences from 
matched HMMs below a statistical defined expected value (E value) threshold (pre-filter), are 
then added to the query sequence from which another HMM for the next search iteration is 
built. The pre-filter reduces the number of full HMM-HMM alignments considerably (by 
~2,500-fold) (Remmert et al., 2011). 
When the sequence analysis is complete, and the alignment is corrected accordingly, the 
software proceeds with the generation of the model. The steps followed by SWISS-MODEL 
include: backbone generation, loop modelling, side chain modelling, and model optimization. 
Once the models have been built the server usually outputs an assessment of model quality.  
This section provides the three-dimensional structure of the model, the target-template 
alignment, and the model coordinates available in PDB format. Additional information about 
the selected templates, oligomeric state and bound ligands are provided. The global model 
quality is assessed calculating the QMEAN, Q-MEAN4, Q-MEAN4 Z-score functions 
(Benkert, et al., 2011).  Regions that are poorly or highly modelled present different colours 
based on the QMEAN value, which is a scoring function referred to the geometrical properties 
of the entire structure and local regions of the model (each residue) and it consists of a 
combination of distinct structural parameters: torsion angle potential over three consecutive 
amino acids (local geometry); distance-dependent interaction potential among Cß in the 
polypeptide and among all atoms (long range-interactions); solvation potential and 
accessibility; terms reflecting the agreement between predicted and calculated secondary 
structure (Benkert et al., 2009). QMEAN4 score is the version of the scoring function based on 
normalised statistical potential scores. QMEAN4 Z-score is calculated by subtracting the 
normalized QMEAN4 from the average normalized QMEAN4 score described for high 
resolution proteins and divided by the standard deviation of the observed distribution. 
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Additionally, the SWISS-MODEL server generates a ‘local quality plot’ that shows the 
predicted similarity to the target for each residue, and a ‘comparison plot’ that provides a 
comparison of the quality scores (Q-MEAN Z-scores) of the model with those of experimental 
structures and indicates whether the quality of the model agrees with high-resolution crystal 
structures. Furthermore, the Global Model Quality Estimation (GMQE) score provided by 
SWISS-MODEL server, is an index of the accuracy of the model generated with a specific 
alignment (higher scores indicate higher quality estimation) 
(https://swissmodel.expasy.org/docs/help). 
Rampage and Procheck: computational tools for model validation 
Rampage 
Rampage is a free software (http://mordred.bioc.cam.ac.uk/~rapper/rampage.php) that 
produces 2-D Ramachandran plots for evaluating the stereochemical quality of a protein by 
investigating whether the distribution of backbone bond dihedral angles (φ / ψ) agrees with that 
found in high resolution structures (Lovell et al., 2003). In detail, φ angle denotes rotation 
around Cα –N bond while ψ angle signifies rotation around the Cα-C bond in the polypeptide. 
Torsion angles control protein folding and specifically φ and ψ angles provide the flexibility 
required for the backbone to adopt a specific fold. Especially in recent years, φ / ψ plots for 
individual homology models have become crucial in structure validation, because they provide 
a sensitive indicator of geometrical local issues. The approximate location of the most 
favourable low-energy regions in a protein was largely accepted and these φ / ψ criteria have 
become a crucial aspect of protein structure validation (Lovell et al., 2003). 
In detail, the input to Rampage is a single file containing the coordinates of the protein structure 
(PDB file).  After analysis, the Rampage software produces φ / ψ plots for glycine, proline, 
pre-proline and all the other residues. The horizontal axis shows φ values, while the vertical 
shows ψ values. The plot is divided into three regions: favoured, allowed, and outlier regions. 
Different type of secondary structures (α-helices and β-sheets) present different ranges of 
dihedral angles and the Ramachandran plot allows clear regional distinction between these two 
structures, showing clustering of dots in two different low-energy regions. Theoretically, the 
average φ and ψ values for α-helices and β-sheets should be clustered around -57, -47 and -80, 
+150, respectively in the Ramachandran plot (Kumar et al., 2016). By contrast, outlier regions 
show residues involved in forbidden torsion angles due to steric hindrance. This type of 
deviation indicates issues with the structure since high resolution proteins tend to have better 
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clustering within the allowed regions and tend to fold according to specific secondary 
structures: α-helices and β-sheets.   
φ / ψ plots for glycine proline, pre-proline residues are graphed separately because these amino 
acids do not follow the principle of clustering around the α- and β-regions. In this regard, the 
exceptional conformational flexibility of glycine and the unique conformational rigidity of 
proline make accessible otherwise forbidden dihedral angle distributions and affect the 
secondary structure of proteins. Glycine is indeed often found in loop regions, while proline 
typically functions as a helix disruptor and induces distortions that affect the pre-proline 
residues conformations as well (Lovell et al., 2003).  
To sum up, in good quality homology models, the distribution of backbone bond dihedral 
angles (φ / ψ) in the Ramachandran plot must agree with that found in high resolution structures 
which are characterised by high clustering within the favoured and allowed regions. By 
contrast, torsion angles in disallowed regions of the Ramachandran plot may indicate problems 
with the structure (bad geometry) that should be carefully analysed (Lovell et al., 2003).  
 
Procheck 
The web server Procheck (http://services.mbi.ucla.edu/PROCHECK/) analyses the 
stereochemical quality of a given protein structure, by investigating whether specific 
stereochemical indicators agree with those found in well refined and high-resolution structures. 
The parameters analysed by this server include: dihedral angles, main chain bond lengths and 
angles, chi angles, disulphide bonds, non-bonded contact distances, hydrogen bonds, planarity, 
chirality. Distinct outputs are produced for all these parameters and all the plots are output in 
PostScript format (Laskowski et al., 1993).  
 
Dihedral angles analysis:  Similarly to Rampage, Procheck generates a Ramachandran plot 
showing the distribution of torsion angles (φ / ψ) for all residues in a protein. The plot is 
subdivided into core, allowed, generously allowed and disallowed regions. These regions are 
those described by Morris et al. (1992) who tested numerous protein structures at high 
resolutions and found that 97% of the φ / ψ distributions clustered in the core and allowed 
regions. Core regions were defined those with more than 100 residues per pixel, while allowed 
regions those with around eight residues per pixel. 
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In the Ramachandran plot, different colours highlight distinct regions and the darker the area 
the more favourable the φ / ψ distributions. In detail, red indicates low-energy regions (core), 
yellow allowed regions, cream the generously-allowed regions and white disallowed regions. 
Glycine residues are identified by triangles while the other residues are represented as squares. 
Ideally, the homology model should have over 90% of the residues clustered in the core regions 
A (right handed α-helices), B (β-sheets), L (left-handed α-helices). By contrast poor models 
have no clustering and present many outliers (Morris et al., 1992). 
Main chain bond lengths and bond angles analysis: In protein structure, internal bond lengths 
and angles should conform to the stereochemical values described by Engh & Huber (1991) 
who performed a comprehensive analysis of around 80000 small-molecule structures. 
Differences greater than 0.05 Angstroms for bond lengths and 10 degrees for bond angles are 
highlighted (Laskowski et al., 1993).  
Chi (χ) angles analysis: The side chain torsion angles are typically named as χ1 (Cα-Cß), χ2 (Cß-
Cγ), χ3 (Cγ -Cδ), etc. Steric hindrance between γ side chain and main chain restricts χ1 angle. 
Preferred conformations of the side chain as a function of χ1 (-60º, +180º, +60º) are gauche (+), 
trans and gauche (-). Procheck generates a χ1 -χ2 plot for each residue and ideally the values for 
each residue should cluster in nine ideal positions, resulting from the combinations of the three 
preferred conformations for each angle χ1 and χ2.  Residues lying more than 3.0 standard 
deviations from ideal positions are labelled (Morris et al., 1992; Laskowski et al., 1993).  
Disulphide bonds analysis: Disulphide bonds originate from interactions between the SH 
groups of two adjacent cysteine residues in the three-dimensional structure. Ideally, the S-S 
distance in each disulphide bond should be 2 Angstroms, while the χ3 torsional angle defined 
by this bridge should be -85.8º in the left-handed conformation and 96.8º for a right-handed 
conformation. Significant deviations from these ideal values are highlighted (Laskowski et al., 
1993; Morris et al., 1992). 
Non-bonded contact distances analysis: Non-bonded atoms which are closer to 2.6 Angstroms 
(minimal accepted van der Waals separation) typically indicate bad contacts. This analysis 
excludes potential hydrogen bonding partners (H-bond acceptor and donors). Significant 
deviations from the ideal value are highlighted (Laskowski et al., 1993; Morris et al., 1992).  
Hydrogen bond analysis: The analysis of main hydrogen energies is evaluated using the Kabsch 
& Sander (1983) method. Ideal values should be around -8.50 kJ mol-l. Significant deviations 
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from this ideal value of -2.0 Kcal/mol are highlighted (Laskowski et al., 1993; Kabsch & 
Sander, 1983).  
Planarity analysis: Residues with large planarity deviations indicate issues in the protein 
structure caused by bad geometry (e.g. incorrect backbone, misplaced chain positioning). For 
residues containing aromatic rings, root mean squared (RMS) distances greater than 0.03 
Angstroms from the best fit plane are highlighted, while for the other residues the threshold 
value is 0.02 Angstroms. A negative value signalizes a D-amino acid. The planarity of the 
peptide bond is based on the measure of the ω torsion angles that ideally should be 180º 
(Laskowski et al., 1993; Morris et al., 1992). 
Chirality analysis: This analysis evaluates potential Cα tetrahedral distortions and it is based 
on the measure of the rotational zeta torsion angle defined by the atoms: Cα, N, C, Cß. The ideal 
value is 33.9 degrees. Significant deviations from this expected value are highlighted 
(Laskowski et al., 1993; Morris et al., 1992). 
Proline φ torsion angle analysis: The cyclic structure of proline’s side chain restricts the φ 
torsion angle to -65.4º. Proline along with glycine do not follow the Ramachandran plot. 
Significant deviations from this expected value are highlighted (Laskowski et al., 1993; Morris 
et al., 1992). 
φ / ψ torsion angles in α-helix analysis: In the α-helix all the amino acids have negative φ / ψ 
torsion angles and specifically the ideal values are -65.3º and -39.4º. Significant deviations 
from this expected value are highlighted (Laskowski et al., 1993; Morris et al., 1992). 
G-factor calculations: At the end of the analysis dihedral angles and main chain covalent forces 
are globally scored to produce G values. These G-factors are log-odds scores computed based 
on the observed mean and standard deviation values in the given structure compared to ideal 
values. G-factor values below -0.5 indicate unusual stereochemical properties of the model, 
while values below -1.0 indicate a highly unusual probability of conformation (Laskowski et 
al., 1993). 
6.3) Molecular Docking overview 
Molecular docking 
In parallel to the incessant synthesis of novel compounds, the urge to identify structural 
information about potential drug-target interactions has increased greatly over the last few 
years.  
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In this regard, molecular docking is a method widely used to computationally simulate the 
molecular recognition process and to predict the “best-fit” orientation of two interacting 
partners (ligand-target). To determine the energetically most favourable binding modes, 
molecular docking generates different ligand binding poses and uses a scoring function to 
estimate the strength of binding interactions and rank the generated ligand poses (Sousa et al., 
2006). 
In order to perform computational drug-target docking experiments, a sizeable body of 3D 
structure information of novel drugs and relevant drug targets (e.g. receptors, transporter 
proteins) is necessary to predict the 3D structure of a drug-target complex.  As regards to 
proteins, the most reliable sources are high-resolution crystal structures which are available in 
the Protein Data Bank (PDB). Alternatively, in the absence of experimental structures, good-
quality homology models may be used. On the other hand, the 2D-structure of the ligands may 
be drawn using ChemDraw software and then converted into 3D structures using Avogadro 
software. 
Docking approach 
The docking approach simulates the actual docking process in which the ligand fits into the 
protein’s binding site after a certain number of “moves” (translations, rotations, torsion angle 
rotations) and then the system's total energy is calculated.  
Docking protocols employ a combination of a search algorithm and a scoring function. The 
search algorithms allow the degrees of freedom of the target–ligand system to be sampled in 
order to generate the best binding mode, while the scoring functions have been designed to 
rank different potential protein–ligand complexes based on the strength of their intermolecular 
interactions (Sousa et al., 2006). 
Docking algorithm 
Finding the best binding pose is crucial in a docking protocol and it is typically predicted by 
calculating the root-mean-square deviation (RMSD) between the experimentally observed 
atom positions of the ligands and the one(s) predicted by the algorithm. In this regard, the 
flexibility of the system and number of degrees of freedom included in the conformational 
search is a crucial aspect in the docking efficiency. Because of the huge number of degrees of 
freedom associated with the real biological system, the dimensionality of the issue is reduced 
through the application of different levels of approximations and different docking methods 
characterised by increasing complexity can be used: 
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• Rigid receptor and ligand approach: both the ligand and the receptor are treated as rigid 
entities and only the degrees of translational and rotational freedom are explored.  
• Flexible ligand approach: the ligand is regarded as a flexible body while the receptor is 
kept rigid.  
• Flexible ligand and receptor approach: both the ligand and the protein are treated as 
flexible entities and relies on the most complex algorithms that consider alternative 
conformational changes taking place between the ligand and the protein. Notably, the 
extent of flexibility of both protein and ligand is necessarily simplified (Sousa et al., 
2006).  
Specifically, three general categories of methods have been devised to treat ligand flexibility:  
1. Systematic methods 
2. Random or stochastic methods 
3. Molecular Dynamics simulation methods (Sousa et al., 2006) 
 
Systematic methods 
Systematic docking methods can be divided into:  
 
✓ Conformational search algorithm approach: all degrees of freedom in a molecule are 
explored by rotating all rotatable bonds in the ligand through 360° until the achievement 
and evaluation of possible combinations. 
✓ Fragmentation approach: the ligand is initially fragmented into different rigid parts and 
then grown by placing each fragment in the active binding site. Alternatively, the 
fragments are docked into the binding site and then linked covalently to generate the 
initial ligand (Sousa et al.,2006). 
 
Random or stochastic algorithm-based methods 
Random algorithm-based methods sample the conformational space by applying random 
changes to the ligand. There are different types of methods based on random algorithms: 
Monte Carlo methods and Genetic Algorithm methods. 
✓ Monte Carlo algorithm method: docking calculations consist of a number of 
independent runs starting from random conformations. Each of these steps involves a 
random perturbation of the conformation (random atomic movements) and a selection 
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in which the new conformation is evaluated according to the metropolis criterion 
(thermodynamical exploration characterised by simulation of changes in temperature) 
and checked against some probability of acceptance according to the Boltzmann 
probability distribution (by which a system at a low energy has a small probability of 
being at a high energy state).  
If the random atomic movement causes a decrease in the energy of the system, then the 
new assembly is accepted. An example of a program that employs MC-based algorithm 
is Autodock Vina.  In detail, this docking programme employs Monte Carlo algorithm 
to perform a global search and it additionally employs a local search (iterated global 
local optimizer) to increase the likelihood to find the global minimum of the conformers 
(Sousa et al., 2006). 
 
✓ Genetic Algorithm method: according to this method, randomly-generated ligand poses 
are regarded as chromosomes; each state variable (translation, orientation, rotation) is 
treated as a gene, each ligand’s state corresponds to the ‘genotype’ and ligand’s atomic 
coordinates are regarded as ‘phenotype’. Each ligand pose is then evaluated on the base 
of the ‘fitness score’ resulting from the total interaction energy (intermolecular energy, 
internal energy, torsional energy, unbound energy) of the protein-ligand system. 
Changes in state variables (mutations) are applied to the population of ligand poses 
(chromosomes) to sample a new pose space (offspring/descendant generation). 
Selection of specific new-generation ligand poses is based on the fitness score, by 
which ligand poses (chromosomes) with the best scores are preserved for propagation 
into new generation to enable the evolution of optimal solutions (correct binding 
modes) (Morris et al., 1998). An example of Genetic Algorithm-based docking program 
is Autodock 4.0. In detail, this docking program employs the Genetic Algorithm to 
perform a global search and it additionally employs a local search method based on the 
Amber force field to increase the likelihood to find the global minimum of the 
conformers. 
 
 
 
 
143 
 
Molecular dynamics simulation methods 
Molecular dynamics methods are computer simulations where the molecules are allowed to 
interact for a specific period of time, in order to obtain a view of the dynamic evolution of the 
docking process. In this approach, forces between atoms/molecules and their energies are 
calculated using molecular mechanics force fields, while the trajectories of atoms and 
molecules are determined by employing Newton's equations of motion. Molecular dynamics 
simulations allow one to describe several events occurring in a dynamic molecular system: 
solvation of the molecules; motions of molecules at various temperatures and pressures; drug 
binding; conformational changes critical to protein function; membrane transport; local 
rearrangement of side chains; small motion of loops.  The study of protein dynamics is a very 
challenging, expensive, and time-consuming process. However, different algorithms and force 
fields are being used to provide some insights on computational dynamic structural biology 
(Sousa et al., 2006). 
Scoring functions 
Scoring functions are mathematical methods used to identify the best binding pose of a ligand 
(goodness of fit) on the protein binding pocket by accurately predicting the binding free energy 
of the complex and the strength of the non-covalent interaction between two molecules (e.g. 
ligand and target). An important application of the scoring function is to identify the potential 
drug leads for a given protein target by searching a large NPS database (i.e. virtual database 
screening). A reliable scoring function should be able to rank NPS drugs according to their 
binding scores.  
Since a very sophisticated scoring function would be computationally too expensive and too 
time-consuming, a number of simplifications and approximations are included with a natural 
cost in terms of accuracy (Sousa et al., 2006).  
Scoring functions are typically classified as:  
✓ force-field-based 
✓ empirical-based 
✓ knowledge-based 
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Force-field based scoring functions 
Force-field scoring has long been employed in many successful docking programs including 
Autodock 4.0. The potential energy of the system is estimated by summing the strength of 
intermolecular van der Waals and electrostatic interactions between all atoms of the receptor 
and the ligand in the complex and the internal energy of the ligand and the protein using a force 
field.  However, important contributions to the binding free energy such as solvation, entropic 
terms are often ignored or implicitly added, highlighting some traditional limitations of force 
field scoring functions (Sousa et al., 2006). The various contributions to binding can be written 
with the following equation: 
ΔGbinding = ΔGsolvent + ΔGint + ΔGconf + ΔGmotion 
ΔGbind= free energy of binding between a ligand and a receptor 
ΔGsolvent= desolvation free energy of both ligand and receptor upon binding 
ΔGint= interaction free energy involving direct contact of ligand with protein (e.g. van der 
Waals interactions, electrostatic interactions, and hydrogen bonds) 
ΔGconf = conformational strain loss upon binding 
ΔGmotion= entropy loss upon binding (internal rotation and vibration) (Smith et al., 2009). 
 
Docking programs such as Autodock 4.0 use a semi-empirical free energy force field to 
evaluate different conformations during docking simulations. 
The force field is parameterized using a wide number of well-known protein-inhibitor 
complexes. The force field assesses binding in two steps: in the first step, the internal energies 
of the protein and ligand are estimated for the transition from the unbound states to the bound 
state; in the second step the intermolecular energies obtained combining the ligand and protein 
in their bound conformation are assessed (http://autodock.scripps.edu/faqs-
help/manual/autodock-4-0-user-guide/AutoDock4.0_UserGuide.pdf). 
 
The force field includes: 
✓ six pair-wise assessments (V) where L refers to the “ligand” and P refers to the 
“protein”  
✓ an estimation of the conformational entropy lost upon binding (ΔSconf):  
 
 ΔG = (Vbound L−L −Vunbound L−L )+(Vbound P−P −Vunbound P−P )+(Vbound P−L −Vunbound P−L +ΔSconf) 
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Each of the pair-wise energetic terms includes assessments for dispersion/repulsion, 
electrostatics, hydrogen bonding terms and desolvation. In detail, van der Waals energy terms 
are described with a Lennard-Jones potential, while the electrostatic term is given by a 
Coulombic formulation. 
 
Empirical Scoring Functions 
Empirical scoring functions are based on empirical data and are used to determine the binding 
affinity between the ligand and the target. In detail, these scoring functions assume that binding 
energies can be approximated by a sum of several interaction terms derived from weighted 
structural parameters. The individual weights are obtained by fitting the scoring function to 
experimental binding parameters of a set of protein-ligand complexes with known structures 
(regression analysis). Several terms (e.g. hydrogen bonds, ionic and lipophilic interactions, loss 
of entropy upon binding) form the basis of the scoring functions. The various contributions to 
binding can be written with the following equation: 
ΔG = Σi Wi ΔGi 
ΔG= free energy of binding 
Wi= coefficient determined by fitting the binding affinity data of a set of well-known protein-
ligand complexes 
ΔGi= includes different energy terms (hydrogen bond, entropy, desolvation, electrostatics, 
hydrophobicity). 
These scoring functions are fast, but their accuracy depends entirely on the experimental data 
set used in the parameterization process (Sousa et al., 2006) 
Knowledge-based scoring function 
This scoring function is based on statistical observations of intermolecular interactions of 
experimentally known complex structures and represent the binding affinity as a sum of 
protein-ligand atom pair interactions which are used to derive distance-dependent interaction 
free energies of protein-ligand atom pairs ("potentials of mean force"). This method is founded 
on the assumption that close intermolecular interactions that occur more frequently are likely 
to be energetically favourable and therefore contribute to binding affinity. In detail, pairwise 
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potentials are obtained from the frequency of occurrence of atom pairs in a database, according 
to the inverse Boltzmann relation.  
In protein-ligand studies, the potentials are calculated by the following equation: 
wr=-KbT ln[p(r)/p*(r)] 
wr=pairwise potentials 
Kb= Boltzmann constant 
T=absolute temperature of the system 
p(r)= number density of the protein-ligand atom pair at distance r 
p*(r)= pair density in a reference state where the interatomic interactions are zero (Huang et 
al., 2010) 
Some docking programs use a mix of different scoring functions. Autodock Vina for example 
uses hybrid empirical/ knowledge-based scoring functions to determine the binding affinity 
between the ligand and the target. Indeed, it uses empirical information from both the 
conformational preferences of the receptor-ligand complexes and the experimental affinity 
calculation (Trott and Olson, 2009). 
Over the years, docking has been applied successfully in different types of virtual screening. 
Among them, PyRx 0.9.4 is a virtual screening with an easy-to-use user interface for AutoDock 
4.0 and AutoDock Vina software, which makes it a valuable and popular tool in computational 
science as it does not require extensive expert and technical knowledge from users. This 
software is typically used to dock small molecules (e.g. drugs) to a macromolecule (e.g. 
receptor) to acquire some insights into the pharmacological activity of certain compounds 
(Dallakyan and Olson, 2015). 
 
Computational docking programmes: Autodock 4.0 and Autodock Vina 
Autodock 4.0 and Autodock Vina are computational docking programs that have been 
developed in parallel to answer to different needs. Different scoring functions (approximate 
mathematical methods) are used by these two programs to predict the strength of non-covalent 
interactions after docking and score each one of a set of different ligand binding poses. 
In detail, Autodock uses semi-empirical force-field scoring functions based on physical atomic 
interactions (e.g. van der Waals interactions, electrostatic interactions, and bond 
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stretching/bending/torsional forces) derived from both experimental data and quantum 
mechanical calculations (Huang et al., 2010; Sousa et al., 2006).  
On the other hand, Autodock Vina uses hybrid empirical/knowledge-based scoring functions 
that score ligand binding poses by applying rules based on preferred and non-preferred atom 
pair interactions found in experimentally determined protein-ligand complexes. These rules are 
then interpreted as scoring functions and used to score ligand binding poses (Mohan et al., 
2005).  
Autodock 4.0 and Autodock Vina both adopt the flexible ligand docking approach, but they 
use different algorithms to explore the potential rotation, translation and orientation space 
searches of the ligand being docked to generate the best binding pose (binding-mode of a ligand 
in a protein binding site). The number of degrees of freedom (number of independent motions) 
included in the conformational space is a challenging aspect that influences the searching 
efficiency (Sousa et al., 2006).  
The specific search algorithm used by Autodock 4.0 is the random or stochastic Lamarckian 
genetic algorithm search. On the other hand, Autodock Vina relies on the Markov chains 
modified Monte Carlo algorithm.  
The Lamarckian genetic algorithm search used by Autodock 4.0, is an algorithm based on the 
principle of evolution associated to a local search method during optimization that generates 
low-energy conformations and orientations of the ligand (Morris et al., 1998). 
The local search method adopted during optimization, allows one to perform energy 
minimization by performing local energy assessments using a method based on the ‘AMBER’ 
force field. According to this method, energy calculations are performed by generating a three-
dimensional grid within which the receptor protein is placed, and various ligand atoms are 
allowed to systematically visit every grid point. For each ligand’s atom, different types of 
energies are calculated (hydrogen-bonding energies, electrostatic potentials, 
dispersion/repulsion energies) considering all receptor atoms near the grid points (8Å). Ligand 
atoms are given energy values which can later be sampled by the main docking programme to 
generate the best binding pose (Morris et al., 1998).  
To enhance algorithm search performance, the local energy assessment is coupled with a 
conformational space search based on a genetic algorithm (Lamarckian genetic algorithm 
search).  
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Autodock Vina relies on the random approach method Markov chains modified Monte Carlo 
algorithm (simulated annealing) by which random changes in the ligand conformation are 
generated and a thermodynamical exploration of different states is performed in order to  select 
energetically favourable states (global energy minimum) of the conformers. Changes in 
temperature are involved during the run for every conformation (Siavoush, 2016). To perform 
the local optimization, Vina employs the Iterated Global Local optimizer which uses multiple 
steps consisiting of a mutation followed by local optimization performed using the algorithm 
of Broyden-Fletcher-Goldfarb-Shanno (quasi-Newton method). This algorithm uses the value 
of the scoring function  along with its gradient (multi-variable generalization of the derivatives 
of the scoring function with respect to orientation, position of the ligand and torsion of the 
rotatable bonds) and performs successive measurements of the gradient to find the global 
energy minimum of the conformers. By using multithreading (the ability of a central processing 
unit (CPU) to execute multiple processes or threads concurrently) the execution of the docking 
process in Vina is speeded up considerably (Trott and Olson, 2009). 
6.4) SCs and in silico CB1 receptor studies, aim and goals 
The overall in silico CB1 receptor study conducted by our research group, aimed at providing 
a rationale for different biological effects that a range of novel SCs exert by investigating their 
CB1R binding properties. In detail, this study branched into two different analyses: docking of 
novel SCs against the homology model of the CB1 receptor (Rattus Norvegicus) and docking 
of novel SCs against the crystal structure of the human CB1 receptor. 
• Docking of novel SCs against the homology model of the CB1 receptor: since no crystal 
structure of the rodent CB1 receptor was available at the time of our study, a homology 
model of this receptor was built and used for molecular docking investigations. In a 
first instance, the docking approach (Autodock Vina) was validated by performing a 
comparative analysis of the relevant binding interactions of a series of referent 
compounds against the homology model of the CB1 receptor (Rattus Norvegicus) and 
those described in CB1 receptor mutation studies. The compounds used for validation 
were the same as those used in the CB1 computational study described by Hua et al., 
2016 and included a range of CB1 agonists (e.g. anandamide, 2-AG, Δ9‐THC, CP-
55,940, WIN-55,212-2, JWH-018) and CB1 antagonists (e.g. rimonabant, AM-251, 
AM-6358, Otenabant, Taranabant). After validation, the same docking software 
(Autodock Vina) was engaged to explore and detect the crucial binding interactions of 
149 
 
a range of index novel SCs (BB-22, 5F-PB-22, 5F-AKB-48, STS-135) against the 
above-mentioned homology model.  
• Docking of novel SCs against the crystal structure of the human CB1 receptor: once the 
crystal structure of the human CB1 receptor has been made available (Hua et al., 2016), 
the relevant key interactions of the above-mentioned referent compounds were 
investigated against the crystal structure of the human CB1 receptor by employing two 
different docking software packages (Vina and Autodock 4.0). The docking methods 
were then validated by performing a critical comparative analysis of our findings 
against those obtained from available evidence-based literature on CB1 receptor 
mutation studies. After validation, the same docking software packages were engaged 
to explore and detect the crucial binding interactions of the above-mentioned novel SCs 
against the crystal structure of the human CB1 receptor. An additional comparative 
analysis of the outcomes produced by different docking software (Vina and Autodock 
4.0) was undertaken, and the more consistent the results given by these software 
packages, the higher the reliability of their outcomes (further validation of the docking 
approach). Furthermore, relevant ligand interactions against the homology model 
(Rattus Norvegicus) and the crystal structure of the human CB1 receptor were 
analytically compared and discussed.  
 
6.5) CB1 receptor homology modelling studies: methods  
Template identification, alignment, homology model building and validation 
The in silico homology model of the rodent CB1 receptor was generated using the SWISS-
MODEL server (https://swissmodel.expasy.org/ provides). This server was fully automated 
from the sequence search and alignment to structure generation and evaluation. X-ray 
structures of the proteins in the Protein Data Bank with highest sequence similarity were 
selected as template structures. An expected molecular model was generated and a global 
model quality estimation (GMQE) score was used by the SWISS-MODEL server for quality 
estimation of the generated model.  
The primary sequence (FASTA) of the CB1 receptor (Rattus Norvegicus) (Accession ID: 
NP_036916.1) was retrieved from the NCBI website (https://www.ncbi.nlm.nih.gov/protein) 
using the NCBI’s own search engine ‘Entrez’ and it was used to build the model, according to 
the recognised evolutionary relationship between the Rattus Norvegicus species and the strains 
of laboratory rats employed in our preclinical studies (Hedrich, 2000). 
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According to SWISS-MODEL report, the template search was performed with Blast (Basic 
Local Alignment Search Tool) (Altschul et al., 1997) and HHblits (‘HMM-HMM–based 
lightning-fast iterative sequence search’) (Remmert et al., 2011) against the primary amino acid 
sequence contained in the Swiss-Model Template Library (SMTL) (last update: 2017-07-19, 
last included PDB release: 2017-07-14). An initial HHblits profile was built using the 
procedure outlined in Remmert et al. (2011), followed by one iteration of HHblits against NR 
(HMM database). The obtained profile was then searched against all profiles of the SMTL. The 
model was then built based on the target-template alignment using ProMod3 that generated the 
actual model coordinates according to the input alignment (Bienert et al., 2017). An insertion 
and deletion fragment modelling approach was performed using the fragment library; side 
chains were rebuilt, and loops were modelled with ProMod3. Finally, the geometry of the 
model was optimised by using a force field, and the global model quality was assessed 
calculating the QMEAN, Q-MEAN4, Q-MEAN4 Z-score functions (Benkert, et al., 2011).   
To further investigate the stereochemical quality of our CB1 receptor (Rattus Norvegicus) 
homology model, the PDB containing the coordinates of our protein structure was submitted 
to different structure assessment methods: Rampage 
(http://mordred.bioc.cam.ac.uk/~rapper/rampage.php) and Procheck 
(http://services.mbi.ucla.edu/PROCHECK).   
6.6) CB1 receptor homology modelling studies: results and discussion 
Overall 36 highest quality templates ranked by a predicted global quality estimate, have been 
retrieved by the SWISS-MODEL server. Among them, the crystal structure (X-RAY 
diffraction 2.80 Å) of the monomer 5tgz.1.A (452 amino acids) (Human Cannabinoid receptor 
1, flavodoxin) was selected to build the three-dimensional structure of the protein (sequence 
identity: 89.24%). After model building, the SWISS-MODEL server provided the target-
template alignment (see Figure 37), a view of the three-dimensional structure of the model (see 
Figure 38), and the model coordinates available in PDB format. The resolution of our model 
was 1.5 Angstrom (high resolution) and the total number of residues was 312.  
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Figure 37: Target-template alignment : CB1 receptor sequence (Rattus Norvegicus)-5TGZ1.A  sequence 
The Q-MEAN4 Z-score for the CB1R homology model (Rattus Norvegicus) was satisfactory 
(-3.06), and indicated a tolerable geometry of the model (see Figure 38).  From the analysis of 
the comparison plot emerged the fact that the structure of our homology model agreed with 
that of high-resolution proteins with a Q-MEAN Z-score>2 (light grey spots) while the majority 
of experimentally elucidated structures with high resolution shows a Q-MEAN Z-score<1 
(dark spots). Notably, in this plot the algebraic signs of the calculated Z-scores were 
standardised (see Figure 38). From a general observation of the local quality plot, emerged that 
some residues presented score values below 0.6 which indicates low quality (see Figure 38). A 
detailed analysis using Rampage and Procheck was necessary to examine eventual issues 
related to these residues. Overall, the Global Quality Estimation (GMQE) calculated for our 
homology model was 0.6, which indicated an acceptable accuracy of the model.  
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Figure 38: Top left: Three-dimensional structure of the CB1 receptor homology model (Rattus Norvegicus); top 
right: global quality plot; bottom left: comparison plot; bottom right: local quality plot. 
6.7) Quality estimation of the CB1 receptor homology model 
Rampage analysis: results and discussion 
According to our findings, 97.4% of residues were found in favoured regions (304 amino acids, 
dark spots), 2.2% in allowed regions (Glu 107, Trp 256, Leu 271, Arg 308, Ser 317, Thr 322: 
orange squares and Gly 255: orange cross) and 0.3% in outlier regions (Lys 316, red square) 
(see Figure 39). Since the φ / ψ dihedral angle distributions were consistent with those found 
in high resolution structures (Lovell et al., 2003) these results suggested that the stereochemical 
quality of our model was acceptable. However, one single amino acid (Lys 316) showed torsion 
angle distributions in outlier regions of the Ramachandran plot, highlighting the presence of a 
local geometrical issue that was carefully examined using the Procheck assessment method. 
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Figure 39: Ramachandran plot, generated by Rampage server, of the CB1 receptor homology model (Rattus 
Norvegicus). 
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Procheck analysis: results and discussion 
Dihedral angles analysis outcomes:  Similarly to Rampage, Procheck generated a 
Ramachandran plot showing the distribution of torsion angles (φ / ψ) for all residues in our 
homology model (see Figure 40).  In detail:    
• 95.5% of the residues were found in the most favoured regions marked with the letters 
A (right-handed alpha helices), B (beta strands), L (left-handed alpha helices) and 
indicated in red colour;   
• 3.8% in allowed regions marked with the letters a (right-handed alpha helices), b (beta 
strands) l (left-handed alpha helices), p (allowed epsilon) and indicated in yellow; 
• 0.3% in generously allowed regions marked with the letters ~a, ~b, ~l, ~p and indicated 
in cream (Leu 271); 
• 0.3% in disallowed regions indicated in white (Lys 316). 
 
These results were consistent with those obtained with Rampage, by which only one amino 
acid (Lys 316) was found in outlier regions. Additionally, the Ramachandran plots for all 
residue types, showed some residues found in unfavourable conformations (Lys 316, Gly 255, 
Leu 271 and Ser 317) that needed further examination. Overall, since our homology model 
showed over 90% of the residues clustered in the core regions A, B, L, it could be considered 
a good quality model.  
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Figure 40: Ramachandran plot of the CB1 receptor homology model (Rattus Norvegicus) generated by Procheck 
software. 
Main chain parameters analysis: Overall, Procheck analyses five main chain properties of the 
structure (peptide bond planarity; measure of bad non-bonded interactions; alpha carbon 
tetrahedral distortion; hydrogen bond energies; overall G-factor) and generates plots for each 
parameter, making a comparison with main chain properties found in well refined structures 
(see Figure 41). The blue band in each plot represents the outcomes from well refined structures 
and the width of the band corresponds to a variation of one standard deviation from the mean. 
The plots in the Figure 41 shows the resolution of our homology model and other well-refined 
proteins against: the percentage of residues found in the most favoured regions; the planarity 
of the peptide bond (standard deviation of the ω torsion angle expressed in degrees); the number 
of bad contacts per 100 residues; the Cα tetrahedral distortion (standard deviation of the Z angle 
expressed in degrees); the standard deviation of the hydrogen bonds energies expressed in 
Kcal/mol. According to these analyses, our homology model (dark square) lies inside the band 
for each one of the five parameters considered. In detail, its position is indicated as ‘better’ 
(which specifies a variation from the mean<1 standard deviation) for all designed parameters 
and suggests a good agreement with well refined structures (see Figure 41).  
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Figure 41: Main chain parameters of the CB1 receptor homology model (Rattus Norvegicus) generated by 
Procheck. 
Residue by residue Chi (χ) angle analysis: As previously described, Procheck generates a χ1 -
χ2 plot for each residue and preferably the values for each residue should cluster in nine ideal 
positions, resulting from the combinations of the three preferred conformations for each angle 
χ1 and χ2. The three preferred conformations are gauche (+), trans and gauche (-) (Morris et 
al., 1992; Laskowski et al., 1993). According to this analysis, four residues of our homology 
model (Asp 404, Ile 157, Leu 389, Trp 256) showed unfavourable conformations (score < -
3.00) and needed careful examination.  
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Overall side chain properties analysis: Five different side chain properties are analysed by 
Procheck which ultimately generates different plots showing the resolution of our homology 
model and other well refined proteins against the standard deviation expressed in degrees of   
χ1 gauche (-), χ1 trans, χ1 gauche (+), pooled χ1 torsion angles and χ2 trans. According to these 
analyses, our homology model (dark square) lies inside the band and its position is indicated 
as ‘better’ for all designed parameters, suggesting a good consistency with well refined 
structures (see Figure 42). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42: Overall side chain properties of the CB1 receptor homology model (Rattus Norvegicus) generated by 
Procheck.   
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Other residue by residue properties: Procheck for each residue, analyses other parameters 
including: (a) the absolute deviation from mean χ1 value; (b) absolute deviation from mean of 
omega torsion; (c) Cα chirality (absolute deviation of zeta torsion). Residues that deviate by 
more than 2 standard deviations from ideal values are indicated as red bars (see Figure 43). 
Additionally, the server generated (d) the schematic picture of the secondary structure, (e) the 
protein sequence along with the region of the Ramachandran plot where the residues are 
located, (f) each residue’s maximum deviation from ideal values considering several 
parameters (see Figure 43). According to the residue by residue analysis 21 residues showed 
maximum deviation higher than 2 standard deviations from ideal values. In detail: Glu 101, 
Asp 185, Ala 306, His 321 (issues with the omega  angle), Leu 148, Tyr 154, Phe 178, His 179, 
Arg 227, Leu 251,  Leu 254, Leu 261, His 303, Leu 389, Arg 401 (issues with Phi helix), Arg 
149, Tyr 154, His 179, Arg 227, Leu 251, Leu 254, Leu 261, His 303, Leu 389, Val 328 (issues 
with Psi helix), Leu 165, Leu 251, Arg 401, Arg 406 (issues with χ2 trans), Leu 254 (issues 
with χ1 gauche minus ), Trp 256, Asn 257, Val 328  (issues with dihedral trans gauche plus), 
Ala 306 (issues with H bond energy), Lys 316 (issues with Cα chirality, D amino acid). 
Bond length and bond angle analysis: From the bond length analysis, 99.9% of the residues 
were within limits and only one residue was highlighted (Gly 100: NCα length issue). As 
regards to the bond angles, 96.2% of the residues were within limits, while 3.8% were 
highlighted. Specifically, 24 residues showed bond angle values >2.0 standard deviations from 
mean including: Met 104, Glu 107, Asn 113, Thr 126, Arg 151, Asp 177, Ser 186, Arg 221, 
Arg 231, Leu 251, Pro 252, Asn 257, Phe 269, Asn 257, Phe 269, Thr 322, Arg 332, Ile 340, 
Gly 358, Asp 367, Val 368, Thr 392, Asn 394, Asp 404, Phe 413. These residues are worth 
investigating further. 
Planarity analysis: Residues with large planarity deviations indicate issues in the protein 
structure caused by bad geometry. For residues containing aromatic rings, RMS distances 
greater than 0.03 Angstroms from the best fit plane are highlighted, while for the other residues 
the threshold value is 0.02 Angstroms. A negative value signals a D-amino acid (Laskowski et 
al., 1993; Morris et al., 1992). According to the analysis 84.9% of residues were within limits 
and 15.1% highlighted. Specifically, 12 amino acids showed distorted geometry, including: 
Tyr 154, His 155, Phe 175, Phe 190, Tyr 276, Trp 280, Phe 290, Tyr 293, Asp 339, Tyr 398 
(see Figure 44). 
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Figure 43: Residue by residue properties of the CB1 receptor homology model (Rattus Norvegicus) generated by 
Procheck. 
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Figure 44: Residues of the CB1 receptor homology model (Rattus Norvegicus) with planarity deviations according 
to Procheck.  
 
G-factor calculations: At the end of analysis, Procheck generated G-factors which are log-odds 
scores computed based on the observed mean and standard deviation values in the given 
structure compared to ideal values. G-factor values for dihedral angles in our homology model 
was: -0.05, while for covalent bonds was: 0.04. Since, ideally scores should be above -0.5 
(Laskowski et al., 1993), G-Factor values related to our homology model were acceptable.   
 
6.8) Homology model refinement and preparation for docking process 
Prior to docking, the homology model structure underwent some refinement operations. In 
detail, the protein was prepared using the protein preparation wizard tool in Maestro 10.4. 
(https://www.schrodinger.com/maestro). During this process, all hydrogens were added and 
protonation states of ionisable groups optimized for pH=7; water molecules were deleted, and 
issues associated with the workspace structure were fixed. After optimization, the PDB file was 
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converted into a format (.pdbqt) suitable for docking in the virtual screening software PyRx 
0.9.4.  
6.9) Ligand building and preparation for docking process 
All ligands were prepared to create 3D geometries which were optimised prior to virtual 
screening. In detail, the SMILES (Simplified Molecular Input Line Entry System) of each 
ligand was retrieved from Pub Chem (https://www.ncbi.nlm.nih.gov/pccompound) and pasted 
into Chem Draw Professional 15.0 
(http://www.cambridgesoft.com/Ensemble_for_Chemistry/ChemDraw/ChemDrawProfession
al/) in order to obtain the 2D-structure (.mol file). The structure was then uploaded into 
Avogadro where the hydrogens were removed and added for pH=7.0 and the geometry was 
optimised using  setup force field MMFS and number of steps: 10000 minimization steps. After 
optimization, each ligand was saved as mol.2 file and converted into a .pdbqt file format 
suitable for docking in the virtual screening PyRx 0.9.4. 
(https://sourceforge.net/p/pyrx/news/2016/02/pyrx-094-release-announcement/). 
6.10) Docking of referent compounds against the homology model of the rodent CB1 
receptor, approach validation: methods 
In the docking approach validation, the key binding interactions of a range of referent 
compounds against the homology model of the rodent CB1 receptor were analysed. PyRx 0.9.4 
was used as virtual screening software and the docking programme employed was Autodock 
Vina. This programme adopts a flexible ligand docking approach, and generates the best 
binding pose by comparing the root-mean-square deviation (RMSD) between the 
experimentally observed atom positions of the ligands and the one(s) predicted by the Markov 
chains modified Monte Carlo algorithm (Sousa et al., 2006). Vina search space coordinates 
used in our study were established according to previous experimental studies and were as 
follows: centre, X:41, Y:29, Z:317; dimensions, X: 25 Å, Y: 25 Å, Z: 25 Å. These parameters 
efficiently restricted where the movable atoms lay during the docking process. After docking, 
the ligand binding energy (Kcal/mol) and two variants of RMSD values were provided: rmsd/lb 
(RMSD lower bound) which matches identically labelled atoms and ignores any symmetry of 
the ligands, and rmsd/ub (RMSD upper bound) which considers alternative symmetric 
conformations of the ligands. The compounds used for validation were the same as those used 
in the CB1 computational study described by Hua et al. (2016) and included a range of CB1 
agonists (e.g. anandamide, 2-AG, Δ9‐THC, CP-55,940, WIN-55,212-2, JWH-018) and CB1 
antagonists (e.g. rimonabant, AM-251, AM-6358, Otenabant, Taranabant). Overall, eight 
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binding modes for each ligand were generated and the pose with the lowest binding energy 
(expressed in Kcal/mol) was selected to study the key binding interactions.  
A comparative analysis of the relevant ligand binding interactions described in CB1 receptor 
mutation studies and those found with our computational docking approach, was undertaken. 
The computational findings were then debated against the experimental ones and possible 
consistencies were highlighted to support our docking approach. For each referent compound, 
the lowest binding affinity values obtained using the docking programme Vina, were compared 
against the experimentally-obtained Ki values retrieved from the literature. Possible 
inconsistencies between computational and experimental binding affinity findings were 
analysed, and some limitations of the study were highlighted and discussed.  
6.11) Docking of representative CB1R agonists and antagonists against the CB1 receptor 
(Rattus Norvegicus) homology model: results and discussion 
Binding modes of representative CB1 receptor agonists 
According to the outcomes generated by the Vina docking programme, the indole group of the 
aminoalkylindole derivative JWH-018 (1-pentyl-3-(1-naphthoyl)indole) showed mainly 
hydrophobic interactions with residues placed on the N-terminal group of the protein (Met 105, 
Met 103, Phe 102); its pentyl tail formed mostly alkyl interactions with residues located on the 
helix 3 (Phe 189) and  in the second extracellular loop (ECL2) (Phe 268, Pro 269); while its 
naphthoyl group interacted primarily through hydrophobic interactions with helix 2 (Phe 170), 
helix 3 (Val 196), helix 6 (Trp 356), helix 7 (Leu 387, Cys 386) (see Figures 45 and 46). The 
binding mode of JWH-018 was supported by mutation studies on helix 6 (Trp 356) and 3 (Phe 
189) and structure–activity relationship (SAR) studies of N-alkyl chain length (Mc Allister et 
al., 2003; Shim et al., 2006; Aung et al., 2000).  
The aminoalkylindole derivative WIN-55,212-2 (2,3-dihydro-5-methyl-3((4-
morpholinyl)methyl)pyrrolo(1,2,3,-de)-1,4-benzoxazin-6-yl)-1-naphthalenyl methanone) 
formed mainly pi-sulphur interactions with residues placed on the N-terminal group of the 
receptor (Cys 107, Met 109); and hydrophobic and van der Waals interactions with the helix 7  
(Met 384, Phe 381) and helix 2 (Phe 170, 174) (see Figures 44 and 46). The binding mode of 
this ligand was supported by relationship (SAR) study of N-alkyl chain length (Mc Allister et 
al., 2003) and computational studies where Phe 170 and Phe 174 (helix 2) were described as 
interacting residues for WIN-55,212-2 binding (Hua et al., 2016).  
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The endocannabinoids anandamide (N-arachidonoyl-2-hydroxyethylamide) and 2-AG (2-
Arachidonylglycerol), adopted a C-shaped conformation forming interactions with the N-
terminal loop and the ECL2, with their long aliphatic tails interacting with the 2, 3, 5, 6, 7 
helices (see Figures 45 and 46). These results were in line with those described by Hua et al. 
(2016) and were in accordance with mutation studies by which Tyr 275 is a key residue for 
anandamide and 2-AG binding (Mc Allister et al., 2003).  
Δ9‐THC (Δ9-tetrahydrocannabinol) and CP-55,940 (3-(2-hydroxy-4-(1,1-
dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol) had their rings placed between the 
N-terminal loop and the extracellular loop (ECL2) (Phe 268). Other interacting residues were 
mainly located in the 3, 6, 7 helices (Δ9‐THC and CP-55,940) and in the helix 5 (CP-55940) 
and formed mostly hydrophobic interactions with the ligands (see Figures 45 and 46). These 
results were supported by those described by Hua et al. (2016) and were in accordance with 
mutation studies by which Tyr 275, Phe 189, Ser 383, Phe 268, were described as key residues 
for CP-55,940 binding (Shim et al., 2006), while Ser 383 was described crucial for Δ9‐THC 
recognition (Shao et al., 2016).  
In this analysis, the residues were re-numbered according to the alignment with the target 
protein. The ligand protein interaction diagrams of the agonists complexed with the CB1 
receptor homology model are in the Figure 45. The lists of interactions observed between 
agonists and the CB1 receptor (Rattus Norvegicus) homology model are in the Figure 46.  
Binding modes of representative CB1 receptor antagonists 
Referring to the CB1 antagonists, AM-251 (1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-
methyl-N-piperidin-1-ylpyrazole-3-carboxamide) principally interacted with residues placed 
in the N-terminal loop, in the ECL2, and in the 2, 3, 6, 7 helices of the homology model.  
In detail, the dichlorophenyl group interacted with the 2, 6, 7 helices and the N-terminal loop; 
the iodophenyl group formed interactions with 3, 6, 7 helices and ECL2; and the pyrazole ring 
mainly interacted with the N-terminal loop (see Figures 47 and 48). Since AM-251 is 
structurally very close to rimonabant, it showed interactions with some residues considered 
crucial for rimonabant binding recognition, including: Phe 379, Phe 170, Cys 386, Phe 174, 
Trp 356 (Mc Allister et al., 2003; Shim, 2010; Shim et al., 2012). 
The antagonist rimonabant (5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-
1-ylpyrazole-3-carboxamide) shared several identical interacting residues with AM-251 and 
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principally interacted with amino acids placed in the N-terminal loop, ECL2, and in the 3, 6, 7 
helices, mainly through hydrophobic interactions. In detail, the chlorophenyl groups formed 
interaction with the 3, 6, 7 helices and ECL2, while the pyrazole ring mainly interacted with 
the N-terminal loop (see Figure 47 and 48). Consistent with mutation studies, rimonabant 
showed interactions with residues considered crucial for binding recognition, including Leu 
193, Phe 170, Cys 386 (Shim, 2010; Mc Allister et al., 2003). Additionally, these results were 
in line with those described by Hua et al. (2016) by which Cys 386, Val 196, Phe 170, Phe 174, 
Trp 356, Leu 359, Ser 383 and Phe 268 directly interacted with rimonabant.  
The antagonists otenabant (1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-4-
(ethylamino)piperidine-4-carboxamide) and taranabant (N-(3-(4-chlorophenyl)-2-(3-
cyanophenyl)-1-methylpropyl)-2-methyl-2((5(trifluoromethyl)pyridin2yl)oxy)propenamide), 
showed interactions with some residues considered crucial for rimonabant binding recognition 
(Shim, 2010; Mc Allister et al., 2003) and in line  with those described by Hua et al. (2016), 
including Phe 268, Leu 359, Ser 383, Val 196, Trp 356, Phe 170, Phe 174, His 178 (otenabant 
interacting residues) and Cys 386, Val 196, Phe 170, Phe 174, Ser 383 (taranabant interacting 
residues) (see Figure 47 and 48).  
The compound AM-6358 formed mainly hydrophobic interactions with the N-terminal loop, 
the ECL2 and the 2, 3, 5, 6, 7 helices; with the pyrazole ring interacting with the N-terminal, 
and the dichlorophenyl group mainly forming interactions with the 2 and 7 helices (see Figures 
47 and 48). The interactions with Leu 387, Leu 359, Cys 386, Trp 356, Val 196, Gly 166, Ser 
167, Phe 170, Phe 174, Ile 119, Met 384, Ile 105, Ser 383, Met 103, Phe 379, Phe 102, Phe 
268, Leu 193, Thr 197 were in line with those described by Hua et al. (2016), and some of them 
were supported by previous studies by which mutagenesis of Phe170 and Phe 174 resulted in 
dramatically decreased functional affinity for AM-6538 (Mc Allister et al., 2003; Hua et al., 
2016).  
In this analysis, the residues were renumbered according to the alignment with the target 
protein. The ligand protein interaction diagrams of the antagonists complexed with the CB1 
receptor homology model are in the Figure 47. The lists of interactions observed between 
antagonists and the CB1 receptor (Rattus Norvegicus) homology model are in the Figure 48.  
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6.12) Vina binding energies against experimental Ki values for representative CB1 
receptor agonists and antagonists 
In our analysis, the lowest Vina binding energy (expressed in Kcal/mol) related to the best 
binding pose for each referent compound, was compared with the Ki value (expressed in 
nanomoles) obtained with experimental bioassay studies. The Ki value is reflective of the 
binding affinity and the smaller the Ki value, the greater the binding affinity of the compound; 
while the lowest the binding energy generated by the docking programme Vina, the higher the 
binding affinity.  
As observed in the Table 3, there was no correlation between Vina binding energies and 
experimental Ki values (lower energies should be related to lower Ki values). The reasons for 
these inconsistencies could be related to the use of a homology model of the CB1 receptor, 
characterised by some chemical and geometrical different features compared to the real CB1 
receptor, and to some limitations inherent to our docking approach.  
First of all, the docking software Vina employs a simplified scoring function based on empirical 
free energies of binding with implicit hydrogens, no electrostatic contribution or atomic 
charges, to score poses more quickly; secondly, it reduces the conformational space search by 
employing a rigid model for the receptor which often leads to improper results. Additionally, 
it may be possible that scoring function needs to be optimized, especially for molecules 
containing fluorine or chlorine atoms, which may not be considered adequately (Forli et al., 
2016). However, Vina docking software should perform sufficiently well for the prediction of 
bound complexes for drug-sized molecules, with errors on estimated energies around 2–3 
Kcal/mol (Forli et al., 2016).  
More advanced tools (such as molecular dynamics) with more sophisticated and 
computationally-intensive parameterizations of the system, are potentially needed to predict 
conformation and energy more accurately.  
 
166 
 
Table 3: Vina binding energies related to the best binding poses of representative CB1R agonists and antagonists 
at the CB1R homology model (Rattus Norvegicus) against experimental Ki values. 
6.13) Conclusions of the docking approach validation 
Overall, the outcomes generated by the docking programme Vina seemed to be sufficiently 
reliable in terms of ligand interactions, as most of the residues found to be involved in ligand 
binding were consistent with those considered crucial according to mutation studies and 
previous computational studies.  
By contrast, in the light of the above-mentioned limitations of the docking approach, the 
binding energy values were approached with caution since no specific correlation between Ki 
values and binding energies was found. 
The same methods were employed in the analysis of the binding interactions of the novel SCs 
BB-22, 5F-PB-22, 5F-AKB-48, STS-135 against the CB1 receptor (Rattus Norvegicus) 
homology model. However, all the results were regarded as preliminary findings requiring 
further refinement and optimization with more sophisticated tools.  
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Figure 45: Ligand protein interaction diagrams of JWH-018, WIN-55,212-2, Anandamide, 2-AG, CP-55,940, 
Δ9‐THC complexed with the CB1R (Rattus Norvegicus) homology model. The complexes shown are the most 
favourable poses obtained using the molecular docking software Vina.  
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Figure 46: Lists of interactions observed between JWH-018, WIN-55,212-2, 2-AG, Anandamide, CP-55,940, 
Δ9‐THC and the CB1R (Rattus Norvegicus) homology model and obtained using the molecular docking 
software Vina. 
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Figure 47: Ligand protein interaction diagrams of AM-251, AM-6358, Otenabant, rimonabant, taranabant 
complexed with the CB1R (Rattus Norvegicus) homology model. The complexes shown are the most favourable 
poses obtained using the molecular docking software Vina.  
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Figure 48: Lists of interactions observed between AM-251, AM-6358, otenabant, rimonabant, taranabant and the 
CB1 receptor (Rattus Norvegicus) homology model obtained using the molecular docking software Vina. 
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6.14) Docking of a range of novel synthetic cannabinoids against the CB1 receptor 
(Rattus Norvegicus) homology model: methods 
In this analysis, the key binding interactions of a range of novel SCs (BB-22, 5F-PB-22, 5F-
AKB-48, STS-135) against the homology model of the rodent CB1 receptor were analysed. The 
methods used were the same applied with the referent compounds. In detail, PyRx 0.9.4 was 
used as virtual screening software and the docking programme employed was Vina. Search 
space coordinates used in our study were established according to previous experimental 
studies and were as follows: centre, X:41, Y:29, Z:317; dimensions, X: 25 Å, Y: 25 Å, Z: 25 
Å. Overall, eight binding modes for each ligand were generated and the pose with the lowest 
binding energy (expressed in Kcal/mol) was selected to study the key binding interactions.  
A comparative analysis of the relevant ligand binding interactions described in CB1 receptor 
mutation studies and those found with our computational docking approach, was undertaken. 
The computational findings were then compared with the experimental ones and possible 
consistencies were highlighted to support our docking approach.   
 
6.15) Docking of the novel synthetic cannabinoids against the CB1 receptor (Rattus 
Norvegicus) homology model: results 
According to Vina docking outcomes, the novel aminoalkylindole derivatives under study (BB-
22, 5F-PB-22, 5F-AKB-48, STS-135) shared some identical interacting residues including: 
Leu 359 (helix 6), Met 103 (N-terminal loop), Phe 102 (N-terminal loop), Phe 170 (helix 2), 
Phe 268 (extracellular loop), Phe 379 (helix 7), Ser 383 (helix 7), Val 196 (helix 3). This 
evidence demonstrated that all novel SCs act at the level of the same binding pocket, showing 
mainly hydrophobic interactions with the 2, 3, 6, 7 helices, the ECL2 and the N-terminal loop 
(see Figures 49 and 50). 
In detail, the indole group of BB-22 formed hydrogen bond and hydrophobic interactions with 
residues placed on the N-terminal loop; its cyclohexyl methyl group interacted through alkyl 
interactions with the 2, 3, 7 helices; while its quinolinyl group formed mostly hydrophobic 
interactions with ECL2 and with the N-terminal loop (see Figures 47 and 48). 
On the other hand, the indole group of 5F-PB-22 interacted with the N-terminal loop through 
hydrogen bond and hydrophobic interactions; its fluorinated pentyl tail interacted with the 3, 5 
and 6 helices; while its quinolinyl group formed hydrophobic interactions with helix 2 and the 
N-terminal loop (see Figures 49 and 50).   
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When complexed with the homology model, 5F-AKB-48 and STS-135 presented almost 
identical binding poses. In detail, their indazole and indole groups respectively, formed mainly 
hydrophobic interactions with the N-terminal group of the receptor and the helix 3; their 
fluorinated pentyl tail interacted mainly through alkyl interactions with the helix 6 and through 
van der Waals interactions with helix 7; while their adamantyl groups mostly formed alkyl 
interactions with the 3, 5 and 6 helices (see Figures 49 and 50).  
Notably, some of the novel aminoalkylindole derivatives under study, interacted with residues 
that, according to mutation studies, were considered crucial for aminoalkylindole binding 
recognition (Mc Allister et al., 2003; Shim et al., 2006). Among them, Phe 200 (helix 3) 
interacted with 5F-PB-22 (pi-alkyl interaction); Trp 279 (helix 5) interacted with 5F-AKB-48, 
5F-PB-22, STS-135 (pi-alkyl interactions); Trp 356 (helix 6) interacted with 5F-AKB-48, 5F-
PB-22, STS-135 (pi-alkyl interactions) (see Figures 49 and 50). 
Interestingly, all novel SCs under study, showed interactions with residues considered crucial 
for rimonabant binding recognition (Mc Allister et al., 2003, Shim et al., 2012). Specifically, 
BB-22 interacted with Phe 170 (helix 2), Phe 189 (helix 3), Phe 379, Cys 386 (helix 7); 5F-
PB-22 interacted with Phe 170 (helix 2); Phe 189, Thr 197 and Phe 200 (helix 3); Trp 279 
(helix 5), Trp 356 (helix 6), Phe 379 (helix 7); 5F-AKB-48 and STS-135 formed interactions 
with Phe 170, Thr 197, Leu 193, Trp 279, Trp 356, Phe 379, Cys 386. 
In this analysis, the residues were renumbered according to the alignment with the target 
protein. The ligand protein interaction diagrams of the novel SCs complexed with the CB1 
receptor homology model are in the Figure 49. The lists of interactions observed between the 
novel SCs and the CB1 receptor (Rattus Norvegicus) homology model are in Figure 50. 
6.16) Vina binding energies against experimental Ki values for each third generation SC 
under study 
According to the results generated by the Vina docking programme, BB-22 showed the lowest 
binding energy (-9.6 Kcal/mol) compared to the other novel compounds under study, while no 
relevant differences were observed among 5F-PB-22, 5F-AKB-48, STS-135 (see Table 4). 
These findings were partially supported by those obtained with experimental competition 
binding assay studies, by which BB-22 and 5F-PB-22 exhibited higher binding affinities 
compared to 5F-AKB-48 and STS-135. However, the experimental rank of order of CB1 
receptor affinity (BB-22, Ki 0.11) = (5F-PB-22, Ki 0.13)> (5F-AKB-48, Ki 0.87)> (STS-135, 
Ki 1.93) (De Luca et al., 2016), did not fully correlate with our computational findings (BB-
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22, -9.6 Kcal/mol) > STS-135 (-9.0 Kcal/mol) ≃ 5F-PB-22 (-8.8 Kcal/mol) = 5F-AKB-48 (-
8.8 Kcal/mol) (see Table 4). 
 
 
 
 
 
 
 
 
Table 4: Vina binding energies related to the best binding poses of BB-22, 5F-PB-22, 5F-AKB-48, STS-135 at 
the CB1R homology model (Rattus Norvegicus) against experimental Ki values. 
 
The lack of correlation between Vina binding energies and experimental Ki values (lower 
energies should be related to lower Ki values) could be potentially related to: 
➢ some different chemical, geometrical and three-dimensional features inherent to the 
homology model compared to the real CB1 receptor; 
➢ some limitations inherent to our docking approach (potential inability of the docking 
programme to detect small differences in terms of binding affinity; simplified scoring 
function, rigid model of the receptor, potential errors on estimated energies around 2–
3 Kcal/mol, molecules containing atomic charges which may not be considered 
satisfactorily) (Forli et al., 2016) (see Chapter 6; Paragraph 12 for details). 
 
Overall, the problem of predicting the affinity that a compound has for a protein is a challenging 
one in docking studies. The issue could have been potentially overcome employing a consensus 
scoring method (which is a more accurate method whereby the binding affinities are predicted 
by combining the results of several different scoring algorithms) (Houston and Walkinshaw, 
2013), or by using more advanced tools (such as molecular dynamics) with more sophisticated 
parameterizations of the system (Forli et al., 2016). 
Alternatively, we decided to perform further docking studies against the crystal structure of the 
human CB1 receptor (made recently available in the protein data bank) and more accurate 
results were expected compared to those obtained with the CB1R homology model. An 
additional comparative analysis of the outcomes produced by different docking software 
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packages (Vina and Autodock 4.0) was undertaken, and the more consistent the results given 
by these software packages, the higher the reliability of their outcomes.  
 
Figure 49: Ligand protein interaction diagrams of BB-22, 5F-PB-22, 5F-AKB-48, STS-135 complexed with the 
CB1R (Rattus Norvegicus) homology model. The complexes shown are the most favourable poses obtained using 
the molecular docking software Vina.  
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Figure 50: Lists of interactions observed between BB-22, 5F-PB-22, 5F-AKB-48, STS-135 and the CB1R (Rattus 
Norvegicus) homology model obtained using the molecular docking software Vina. 
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6.17) Docking of representative CB1R agonists and antagonists against the crystal 
structure of the human CB1 receptor: approach validation  
Methods 
The crystal structure of the human CB1 receptor (452 amino acids, 2.0 Angstroms of resolution) 
was retrieved from the Protein Data Bank (ID:5TGZ) and then underwent some refinement 
operations, while ligands were prepared to create 3D geometries which were optimised prior 
to virtual screening. The quality of the receptor structure employed plays a crucial role in 
determining reliable docking outcomes. In general, the higher the resolution of the crystal 
structure, the more reliable the docking results obtained (Mohan et al., 2005). The protein was 
prepared using the protein preparation wizard tool in Maestro 10.4. During this process, all 
hydrogens were displayed and optimized for pH=7; water molecules were deleted, issues 
associated with the workspace structure were fixed and bound ligands were removed. After 
optimization, the PDB file was converted into a format (.pdbqt) suitable for docking in the 
virtual screening PyRx 0.9.4.  
The preparation phase of the ligands was the same described in the Chapter 6, Paragraph 9. 
After preparation, each ligand was converted into a .pdbqt file format suitable for docking. 
PyRx 0.9.4 was used as virtual screening software and Autodock Vina and Autodock 4.0 were 
the docking programs employed. Vina’s search space coordinates were set as follows: centre, 
X:41, Y:29, Z:317; dimensions X: 25 Å, Y: 25 Å, Z: 25 Å. Overall, eight binding modes for 
each ligand were generated and the pose with the lowest binding energy (expressed in 
Kcal/mol) was selected to study the relevant key binding interactions. In Autodock 4.0, the 
search space coordinates used were the following: centre, X:41, Y:29, Z:317; number of points 
X: 184, Y: 230, Z: 294, spacing: 0.12 Å. For each pose the estimated free energy of binding 
resulted from the total interaction energy (intermolecular energy, internal energy, torsional 
energy, unbound energy) was calculated. In total, ten binding modes for each ligand were 
generated and the pose with the lowest estimated free energy of binding (expressed in 
Kcal/mol) was selected to study the relevant key binding interactions. 
The key binding interactions of the same referent compounds used in our homology modelling 
studies were analysed against the crystal structure of the human CB1 receptor (5TGZ).  
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6.18) Docking of representative CB1R agonists and antagonists against the crystal 
structure of the human CB1 receptor: results and discussion 
Binding modes of representative CB1 receptor agonists 
Overall, Vina and Autodock 4.0 results were highly consistent for all referent compounds 
tested. In detail, according to both software docking programs, the indole group of the 
aminoalkylindole derivative JWH-018 (1-pentyl-3-(1-naphthoyl)indole) showed mainly 
hydrophobic and van der Waals interactions with residues placed on the N-terminal group of 
the protein (Ile 105, Met 103) and sulphur interactions with the helix 7 (met 384); its pentyl 
tail formed mostly alkyl interactions with residues located on the helix 3 (Phe 189) and  on the 
second extracellular loop (ECL2) (Pro 269); while its naphthoyl group interacted primarily 
through hydrophobic interactions with the helix 2 and  3 (Phe 170, Val 196); van der Waals 
interactions with the helix 6 (Trp 356) and sulphur interactions with the helix 7 (Cys 386) (see 
Figures 51, 52, 53 and 54). The binding modes of JWH-018 obtained with both docking 
programs, were supported by mutation studies on helices 6 (Trp 356) and 3 (Phe 189) and 
structure–activity relationship (SAR) study of N-alkyl chain length (Mc Allister et al., 2003; 
Shim et al., 2006; Aung et al., 2000). 
The aminoalkylindole derivative WIN-55,212-2 (2,3-dihydro-5-methyl-3((4-
morpholinyl)methyl)pyrrolo(1,2,3,-de)-1,4-benzoxazin-6-yl)-1-naphthalenyl methanone) 
mainly formed interactions with residues placed on the N-terminal group of the receptor (Met 
103, Ile/Met 105); and interactions with the helix 7 (Ser 383) and helix 2 (Phe 170) (Vina and 
Autodock 4.0 outcomes). Additionally, according to Autodock 4.0 findings, WIN-55,212-2 
interacted with Phe 268 (ECL2) Trp 356 (helix 6), Phe 379 (helix 7), through hydrophobic 
interactions; while according to Vina outcomes, it interacted with Phe 174 (helix 2) as well 
(see Figures 51, 52, 53 and 54).The binding modes of this ligand were supported by relationship 
(SAR) study of N-alkyl chain length; mutation studies by which Trp 356 was described as a 
key residue for WIN-55,212-2 binding recognition (Mc Allister et al., 2003; Aung et al., 2000); 
and molecular modelling studies by which Phe 170, Phe 174 (helix 2) and Phe 379 (helix 7) 
were described as interacting residues for WIN-55,212-2 binding (Hua et al., 2016). 
The agonists anandamide (N-arachidonoyl-2-hydroxyethylamide) and 2-AG (2-
Arachidonylglycerol) formed interactions with the N-terminal group and the extracellular loop 
ECL2, and their long aliphatic tails interacted with the 3, 5, 6 and 7 helices (see Figures 51, 52, 
53 and 54). These results were in line with those described by Hua et al. (2016) and were in 
accordance with mutation studies by which Tyr 275 (consistent with Vina and Autodock 4.0 
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outcomes) and Phe 189 (consistent with Autodock 4.0 outcome) were key residues for 
anandamide binding (Mc Allister et al., 2003). 
Δ9‐THC (Δ9-Tetrahydrocannabinol) and CP-55,940 (3-(2-hydroxy-4-(1,1-
dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol) had their rings placed between the 
N-terminal loop and the extracellular loop (ECL2) (Phe 268). Other interacting residues were 
mainly located in the 3, 6, 7 helices (Δ9‐THC and CP-55,940) and in the helix 5 (CP-55940) 
and formed mostly hydrophobic interactions with these ligands (see Figures 51, 52, 53 and 54). 
These results were supported by those described by Hua et al. (2016) and were in accordance 
with mutation studies by which Phe 189, Ser 383, Phe 268 (consistent with Vina and Autodock 
4.0 outcomes) and Ile 271, Tyr 275 (in line with Vina outcomes) were described as key residues 
for CP-55,940 binding; while Ser 383, Phe 174 (consistent with Vina and Autodock 4.0 
outcomes) and Leu 193 (in line with Autodock 4.0 outcome) were reported to be crucial 
residues for Δ9‐THC binding recognition (Shim et al., 2006; Shao et al., 2016).  
The ligand protein interaction diagrams of the agonists complexed with the crystal structure of 
the CB1 receptor obtained using the molecular docking software Vina and Autodock 4.0 are in 
the Figures 51 and 53 respectively. The lists of interactions observed between agonists and the 
CB1 receptor (crystal structure) obtained using the molecular docking software Vina and 
Autodock 4.0, are in the Figures 52 and 54 respectively. 
Binding modes of representative CB1 receptor antagonists 
As regards to the CB1R antagonists, AM-251 (1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-
methyl-N-piperidin-1-ylpyrazole-3-carboxamide) principally interacted with residues placed 
in the N-terminal loop, in the ECL2, and in the 2, 3, 6, 7 helices. As expected, it showed 
interactions with some residues considered crucial for rimonabant binding recognition, 
including: Leu 193, Phe 379, Phe 170, Trp 356, Cys 386 (Vina and Autodock 4.0 outcomes) 
and Phe 189, Trp 279, Thr 197 (Autodock 4.0 outcomes) (see Figures 55, 56, 57, and 58). 
The antagonist rimonabant (5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-
1-ylpyrazole-3-carboxamide) shared similar interacting residues with AM-251 and principally 
interacted with residues placed in the N-terminal loop, ECL2, and in the 2, 3, 6, 7 helices, 
forming mainly hydrophobic interactions. Consistent with mutation studies (Shim, 2010; Mc 
Allister et al., 2003), rimonabant showed interactions with residues considered crucial for 
rimonabant binding recognition, including Leu 193, Phe 379, Phe 170, Cys 386 (Vina and 
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Autodock 4.0 outcomes) and Phe 189, Trp 279 (Autodock 4.0 outcomes) (see Figures 55, 56, 
57, and 58). Additionally, these results were in line with those described by Hua et al. (2016) 
by which Phe 268, Leu 359, Cys 386, Trp 356, Val 196, Ser 383, Phe 170, directly interacted 
with rimonabant. 
The antagonist otenabant (1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-4-
(ethylamino)piperidine-4-carboxamide) interacted with the same residues described by Hua et 
al. (2016), including Phe 268, Leu 359, Cys 386, Trp 356, Val 196, Ser 383, Phe 170, Phe 174, 
His 178, and it showed interactions with some residues considered crucial for rimonabant 
binding recognition (Vina and Autodock 4.0 outcomes) (Mc Allister et al., 2003; Shim et al., 
2012) (see Figures see Figures 55, 56, 57, and 58). 
Similarly to otenabant,  the antagonist taranabant (N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-
1-methylpropyl)-2-methyl-2((5(trifluoromethyl)pyridin2yl)oxy)propenamide) showed 
interactions with some residues considered crucial for rimonabant binding recognition (Shim, 
2010; Mc Allister et al., 2003) and in line  with those described by Hua et al. (2016) including  
Phe 268, Leu 359, Cys 386, Trp 356, Val 196, Ser 383, Phe 170, Phe 174, His 178 (Vina 
outcomes) and Phe 170, Phe 174, His 178 (Autodock 4.0 outcomes) (see Figures 55, 56, 57, 
and 58). 
The antagonist AM-6358 formed mainly hydrophobic interactions with the N-terminal loop, 
the ECL2 and the 2, 3, 6, 7 helices. In detail, several interacting residues were in line with those 
described by Hua et al. (2016), and included: Leu 387, Leu 359, Cys 386, Trp 356, Val 196, 
Gly 166, Ser 167, Phe 170, Phe 174, Ile 119, Met 384, Ile 105, Ser 383, Met 103, Phe 379, Phe 
102, Phe 268, Leu 193, Thr 197 (Vina and Autodock 4.0 outcomes) (see Figures 55, 56, 57, 
and 58). 
The ligand protein interaction diagrams of the antagonists complexed with the crystal structure 
of the CB1 receptor obtained using the molecular docking software programs Vina and 
Autodock 4.0 are in the Figures 55 and 57, respectively. The lists of interactions observed 
between antagonists and the CB1 receptor (crystal structure) obtained using the molecular 
docking software Vina and Autodock 4.0, are in Figures 56 and 58, respectively.  
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6.19) Vina and Autodock 4.0 binding affinities against experimental Ki values for 
representative CB1 receptor agonists and antagonists 
In our analysis, the lowest Vina and Autodock 4.0 binding energies (expressed in Kcal/mol) 
related to the best binding pose for each referent compound, were compared with the Ki value 
(expressed in nanomoles) obtained with bioassay studies.  
As observed in the Table 5, there is no correlation between Vina and Autodock 4.0 binding 
energies against experimental Ki values (lower energies should be related to lower Ki values). 
The reasons for these inconsistencies may be related to some limitations inherent to our 
docking approaches. Vina and Autodock 4.0 currently employ some simplifications that may 
affect the outcomes generated. Firstly, they both use a rigid receptor, and this may be a serious 
limitation if the real system includes significant receptor motion (Forli et al., 2016). To 
overcome this issue, we used a receptor structure taken from a receptor-ligand complex, where 
the receptor should be in the relevant conformation (Hua et al., 2016). Additionally, Vina and 
Autodock 4.0 scoring functions are highly approximated and the number of degrees of freedom 
for the ligands is necessarily limited (Forli et al., 2016).  Furthermore, both methods require a 
simplified typing of atoms (identification of aromatic and aliphatic carbon atoms) and 
molecules containing fluorine or chlorine atoms may not be considered adequately. Obviously, 
better results would have been obtained employing more sophisticated and computationally-
intensive programs or using complementary tools that would have helped to predict the binding 
energies more accurately. This improvement could represent the next goal in our study.   
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Table 5: Vina and Autodock 4.0 binding energies related to the best binding poses of representative CB1R agonists 
and antagonists at the CB1R crystal structure, against experimental Ki values. 
6.20) Conclusions of the docking approach validation 
Globally, the outcomes generated by the docking programs employed, were considered reliable 
in terms of ligand interactions, as most of the residues found to be involved in ligand binding 
were in line with those considered crucial in previous mutation studies and computational 
analyses.  
By contrast, since no specific correlation between Ki values and binding energies was found,  
the binding energy values were approached with caution. The same methods were employed 
in the analysis of the binding interactions of the index SCs BB-22, 5F-PB-22, 5F-AKB-48, 
STS-135 against the crystal structure of the human CB1 receptor. However, all the results were 
regarded as preliminary findings requiring further optimization with more sophisticated tools.  
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Figure 51: Ligand protein interaction diagrams of JWH-018, WIN-55,212-2, Anandamide, 2-AG, CP-55,940, Δ9‐
THC complexed with the CB1R crystal structure. The complexes shown are the most favourable poses obtained 
using the molecular docking software Vina. 
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Figure 52: Lists of interactions observed between JWH-018, WIN-55,212-2, 2-AG, Anandamide, CP-55,940, 
Δ9‐THC and the CB1R crystal structure and obtained using the molecular docking software Vina. 
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Figure 53: Ligand protein interaction diagrams of JWH-018, WIN-55,212-2, Anandamide, 2-AG, CP-55,940, Δ9‐
THC complexed with the CB1R crystal structure. The complexes shown are the most favourable poses obtained 
using the molecular docking software Autodock 4.0. 
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Figure 54: Lists of interactions observed between JWH-018, WIN-55,212-2, 2-AG, Anandamide, CP-55,940, Δ9‐
THC and the CB1R crystal structure and obtained using the molecular docking software Autodock 4.0. 
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Figure 55: Ligand protein interaction diagrams of AM-251, AM-6358, otenabant, rimonabant, taranabant 
complexed with the CB1R crystal structure. The complexes shown are the most favourable poses obtained using 
the molecular docking software Vina.  
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Figure 56: Lists of interactions observed between AM-251, AM-6358, otenabant, rimonabant, taranabant and the 
CB1 receptor crystal structure obtained using the molecular docking software Vina. 
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Figure 57: Ligand protein interaction diagrams of AM-251, AM-6358, Otenabant, rimonabant, taranabant 
complexed with the CB1R crystal structure. The complexes shown are the most favourable poses obtained using 
the molecular docking software Autodock 4.0.  
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Figure 58: Lists of interactions observed between AM-251, AM-6358, otenabant, rimonabant, taranabant and the 
CB1 receptor crystal structure obtained using the molecular docking software Autodock 4.0. 
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6.21) Docking of a range of novel synthetic cannabinoids against the crystal structure of 
the human CB1 receptor: methods 
In this analysis, the key binding interactions of a range of novel SCs (BB-22, 5F-PB-22, 5F-
AKB-48, STS-135) against the crystal structure of the human CB1 receptor were analysed. The 
methods used were the same applied with the referent compounds. PyRx 0.9.4 was used as 
virtual screening software and Autodock Vina and Autodock 4.0 were the docking programmes 
employed. Vina’s search space coordinates were set as follows: centre, X:41, Y:29, Z:317; 
dimensions X: 25 Å, Y: 25 Å, Z: 25 Å. Overall, eight binding modes for each ligand were 
generated and the pose with the lowest binding energy (expressed in Kcal/mol) was selected to 
study the relevant key binding interactions. In Autodock 4.0, the search space coordinates used 
were the following: centre, X:41, Y:29, Z:317; number of points X: 184, Y: 230, Z: 294, 
spacing: 0.12 Å. For each pose the estimated free energy of binding resulted from the total 
interaction energy (intermolecular energy, internal energy, torsional energy, unbound energy) 
was calculated. In total, ten binding modes for each ligand were generated and the pose with 
the lowest estimated free energy of binding (expressed in Kcal/mol) was selected to study the 
relevant key binding interactions. 
6.22) Docking of a range of novel synthetic cannabinoids with the crystal structure of 
the human CB1 receptor: results and discussion 
According to Vina findings, the novel aminoalkylindole derivatives under study (BB-22, 5F-
PB-22, 5F-AKB-48, STS-135) shared some identical interacting residues including: Ile 105, 
Met 103, Phe 102 (N-terminal loop), Phe 170 (helix 2), Phe 379, Ser 383 (helix 7). However, 
according to the outcomes generated by Autodock 4.0, the interacting residues shared by all 
novel SCs, were many more and included: Ile 105, Met 103, Phe 102, (N-terminal loop), Phe 
170, Phe 268, Pro 269 (helix 2), Phe 189, Val 196 (helix 3), Phe 379, Ser 383 (helix 7), Ile 267 
(ECL2) (see Figures 57, 58, 59 and 60).  
Referring to Vina outcomes, the indole core of BB-22 formed alkyl interactions with the N-
terminal loop; its quinolinyl group formed a sulphur interaction with helix 7 (Cys 386), and 
alkyl interactions with helix 3 (Val 196) and helix 7 (Leu 387); while its cyclohexyl methyl 
group interacted with both, the ECL2 (Phe 268) and the N-terminal loop (Ile 105) through alkyl 
interactions. On the other hand, the best binding pose of BB-22 generated by Autodock 4.0 
programme, showed slight different type of interactions, with its indole group forming pi-pi 
and sulphur interactions with helix 7 (Phe 379, Cys 386 respectively); its cyclohexyl methyl 
group forming alkyl interactions with the 2, 3, 7 helices and its quinolinyl group interacting 
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with both, the ECL2 (pi-pi interactions) and the N-terminal loop (alkyl and hydrogen bond 
interactions) of the receptor (see Figures 59, 60, 61 and 62). 
According to Vina outcomes, the indole group of 5F-PB-22, interacted mainly with the N-
terminal loop of the protein through pi-pi (Phe 102) and sulphur interactions (Met 103); its 
quinolinyl group formed primarily alkyl interactions with the N-terminal loop and the ECL2; 
while its fluorinated pentyl tail interacted mainly with the 2, 3, 5, 6 and 7 helices of the receptor. 
On the other hand, the best binding pose of 5F-PB-22 generated by Autodock 4.0 programme, 
showed slight different type of interactions, with the indole group interacting with the N-
terminal loop and ECL2; the quinolinyl group forming mainly alkyl interactions with helix 3 
and van der Waals interactions with helix 7; and the fluorinated pentyl tail interacting with the 
N-terminal loop, the ECL2 and helix 7 (see Figures 59, 60, 61 and 62). 
Referring to Vina outcomes, the indazole and indole groups of 5F-AKB-48 and STS-135 
respectively, interacted mainly with the N-terminal loop; their adamantyl groups formed 
mostly hydrophobic interactions with the 2 and 7 helices; while their fluorinated pentyl tails 
formed halogen interactions with the helix 7 (Ser 383) (Vina outcomes). On the other hand, the 
best binding poses of 5F-AKB-48 and STS-135 generated by Autodock 4.0 programme, 
showed slight different type of interactions, with the indole group of 5F-AKB-48 interacting 
with the helix 3 and the N-terminal loop; and the indazole group of STS-135 forming 
interactions with the N-terminal loop, and the 3 and 7 helices. Additionally, their adamantyl 
groups primarily interacted with the ECL2 ant the N-terminal loop, while the fluorinated pentyl 
tails mainly interacted with the 3 and 6 helices (see Figures 59, 60, 61 and 62). 
Notably, according to Vina outcomes, only the novel aminoalkylindole derivatives BB-22 and 
5F-PB-22 interacted with residues that, according to mutation studies, were considered crucial 
for aminoalkylindole binding recognition (Mc Allister et al., 2003, Shim et al., 2006). In this 
regard, Phe 200 (helix 3) and Trp 279 (helix 5) interacted with 5F-PB-22 (pi-alkyl interaction); 
while Trp 356 (helix 6) interacted with both BB-22 and 5F-PB-22 (van der Waals and pi-alkyl 
interactions respectively). On the other hand, according to Autodock 4.0 outcomes, only STS-
135 interacted with a residue (Trp 356) referred as crucial for aminoalkylindole binding 
recognition (see Figures 59, 60, 61 and 62). 
Interestingly, the index novel SCs in our study, showed interactions with residues considered 
crucial for rimonabant binding recognition (Mc Allister et al., 2003; Shim et al., 2012). 
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The ligand protein interaction diagrams of the novel SCs complexed with the CB1R crystal 
structure according to Vina and Autodock 4.0 programs are in the Figures 59 and 61 
respectively, while the lists of interactions are in the Figures 60 and 62. 
6.23) Vina and Autodock 4.0 binding affinities against experimental Ki values for each 
novel SC under study 
According to the results generated by the docking programme Vina, BB-22, STS-135, 5F-
AKB-48, 5F-PB-22 showed comparable binding energies (-9.6, -9.6, -9.5, -9.1 Kcal/mol 
respectively). On the other hand, according to Autodock 4.0 outcomes, the rank of order of the 
estimated free energy of binding was as follows: BB-22 (-11.48 kcal/mol), STS-135 (-11.2 
Kcal/mol), 5F-AKB-48 (-10.93 Kcal/mol), and 5F-PB-22 (-9.53 kcal/mol) (see Table 6). 
Overall, there was no correlation between both Vina and Autodock 4.0 binding energies against 
experimental Ki values (lower energies should be related to lower Ki values). The reasons for 
these inconsistencies may be related to some limitations inherent to our docking approaches 
(for details see paragraph 6.19).  
 
Table 6: Vina and Autodock 4.0 binding energies related to the best binding poses of BB-22, 5F-PB-22, 5F-AKB-
48, STS-135 at the CB1R crystal structure, vs experimental Ki values. 
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Figure 59: Ligand protein interaction diagrams of BB-22, 5F-PB-22, 5F-AKB-48, STS-135 complexed with the 
CB1R crystal structure. The complexes shown are the most favourable poses obtained using the molecular docking 
software Vina.  
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Figure 60: Lists of interactions observed between BB-22, 5F-PB-22, 5F-AKB-48, STS-135 and the CB1R crystal 
structure obtained using the molecular docking software Vina. 
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Figure 61: Ligand protein interaction diagrams of BB-22, 5F-PB-22, 5F-AKB-48, STS-135 complexed with the 
CB1R crystal structure. The complexes shown are the most favourable poses obtained using the molecular docking 
software Autodock 4.0. 
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Figure 62: Lists of interactions observed between BB-22, 5F-PB-22, 5F-AKB-48, STS-135 and the CB1R crystal 
structure obtained using the molecular docking software Autodock 4.0. 
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6.24) Comparison among docking outcomes obtained using the CB1 receptor homology 
model (Rattus Norvegicus) and the crystal structure of the human CB1 receptor 
Binding modes of representative CB1 receptor agonists 
Overall, the type of interactions and the binding poses generated for each agonist, changed 
slightly according to the docking programme used (Vina or Autodock 4.0) and the receptor 
involved (CB1 homology model or crystal structure). However, the consistency obtained using 
the same docking program Vina and different receptors (CB1 homology model or crystal 
structure) seemed higher compared to that obtained using different docking programs (Vina 
and Autodock 4.0) and the same receptor (CB1R crystal structure).  
According to Vina outcomes, the indole group of JWH-018 interacted through pi-sigma and 
alkyl interactions with residues placed on the N-terminal group (Met 103, Met 105) of the 
homology model (see Figures 45 and 46); and through alkyl and van der Waals interactions 
with amino acids (Met 103, Ile 105) placed on the N-terminal group of the crystal structure 
(see Figures 51 and 52). Additionally, the residue Ser 383 of either receptor (homology model 
or crystal structure) formed hydrogen bond or van der Waals interactions with the indole group 
of the ligand; while the same type of interaction (pi-sulphur) was observed between Met 384 
and the indole group of the ligand in both ligand-protein complexes. Additionally, the pentyl 
tail of JHW-018 formed alkyl interactions with the helix 3 (Phe 189) and the ECL2 (Pro 269) 
of either protein; while its naphthoyl group formed hydrophobic interactions with the helix 2 
(Phe 170); van der Waals interactions with Trp 356 and alkyl/pi-sulphur interactions with other 
residues placed on the helix 7 of either receptor. Furthermore, the type of interactions with Val 
196 (helix 3) was different (pi-sigma interaction or alkyl interaction) according to the protein 
involved (homology model or crystal structure respectively) (see Figures 45, 46, 51 and 52). 
As regards to Autodock 4.0 outcomes, the binding pose of JWH-018 and the type of 
interactions with the protein (crystal structure) were slightly different compared to those 
obtained with Vina docking programme. In detail, alkyl interactions were observed with Met 
103, Phe 189, Pro 269 and Val 196; van der Waals interactions with Ile 105, Ser 383 and Trp 
356; pi-sulphur interactions with Met 384; and pi-pi T-shaped interactions with Phe 170 (see 
Figures 53 and 55).   
Overall, the binding modes of JWH-018 were supported by mutation studies on the helix 6 
(Trp 356) and 3 (Phe 189) and structure–activity relationship (SAR) studies of N-alkyl chain 
length (Mc Allister et al., 2003; Aung et al., 2000).  
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According to Vina docking outcomes, when complexed with either receptor (homology model 
or crystal structure) the agonist WIN-55,212-2, formed pi-sulphur and van der Waals 
interactions with residues placed on the N-terminal group (Cys 107, Ile/Met 105, Met 103) and 
helix 2 (Phe 170, Phe 174). Other shared interactions were observed with Ala 380, Ser 383, 
Met 384, although the nature of interactions was different according to the protein involved 
(alkyl, hydrogen bond and van der Waals interactions referring to the homology model; and 
alkyl, van der Waals interactions referring to the crystal structure) (see Figures 45, 46, 51 and 
52).  
On the other hand, according to Autodock 4.0 outcomes, WIN-55,212-2 showed van der Waals 
and hydrogen bond interactions with residues placed on the N-terminal group (Ile 105, Met 
103) and hydrophobic and van der Waals interactions with amino acids placed on the helix 2 
(Ile 169, Phe 170) of the crystal structure. Additionally, other interactions were observed with 
residues placed on the helix 6 (Trp 356, pi-pi staked) and helix 7 (Phe 379, van der Waals 
interactions), which were considered crucial for WIN-55,212-2 binding, and were not detected 
with Vina docking programme (see Figures 53 and 54).  
The binding modes of WIN-55,212-2 were supported by relationship (SAR) studies of N-alkyl 
chain length (Mc Allister et al., 2003) and computational studies where Phe 170 and Phe 174 
(helix 2) and Trp 356 (helix 6) were described as interacting residues for WIN-55,212-2 
binding (Hua et al., 2016).  
According to Vina outcomes, the endocannabinoids anandamide and 2-AG, when complexed 
with either, the homology model or the crystal structure, shared interactions with the N-
terminal loop (Phe 102, met 103) and the ECL2 (Phe 268); while their long aliphatic tails 
mostly interacted through van der Waals or hydrogen bond interactions with helix 2 (Gly 166, 
Phe 170) and helix 3 (Thr 197, Val 196). The type of interaction with Tyr 275 (helix 5) was 
different based on the receptor involved. In detail, anandamide formed van der Waals or alkyl 
interactions when complexed with either the homology model or crystal structure; while 2-AG 
formed alkyl, or van der Waals interactions when complexed with either protein. Other van der 
Waals interactions were observed with residues placed on the helix 6 (Leu 359) and helix 7 
(Ser 383, Phe 379) on both ligand-protein complexes (see Figures 45, 46, 51 and 52). 
According to Autodock 4.0 results, the compounds anandamide and 2-AG, complexed with the 
crystal structure, mainly formed hydrophobic interactions with residues placed on the N-
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terminal loop (Phe 102, Met 103), the ECL2 (Phe 268) and the 3, 5, 6 and 7 helices, consistent 
with those obtained with the docking programme Vina. By contrast, no interactions were 
observed with the helix 2 and an additional relevant alkyl interaction was observed between 
Phe 189 and anandamide which was not detected with Vina docking programme (see Figures 
53 and 54). Overall, these results were in line with those described by Hua et al. (2016) and 
were in accordance with mutation studies by which Tyr 275 (consistent with Vina and 
Autodock 4.0 outcomes) and Phe 189 (consistent with Autodock 4.0 outcome) were key 
residues for anandamide binding (Mc Allister et al., 2003). 
According to Vina docking outcomes, Δ9‐THC and CP-55,940 complexed with either, the 
homology model or the crystal structure, had their rings placed between the N-terminal loop 
and the second extracellular loop (ECL2), and they shared hydrophobic interactions with Met 
103, Phe 102, Met/Ile 105 and Phe 268. Other van der Waals interactions were observed 
between CP-55,940 and the 3 and 7 helices (Phe 189; Ser 383), while hydrophobic interactions 
were detected with the helix 2 (Phe 170) and helix 5 (Tyr 275). Referring to the crystal 
structure-Δ9-THC complex, van der Waals and alkyl interactions were observed with some 
residues considered crucial for ligand binding (Ser 383 and Phe 174), while no interaction with 
Phe 174 was detected on the complex with the homology model (Vina outcomes) (see Figures 
45, 46, 51, 52).  
On the other hand, according to Autodock 4.0 results, CP-55,940 complexed with the crystal 
structure, showed relevant alkyl interactions with Phe 189 and Phe 268 and hydrogen bond 
interactions with Ser 383; while Δ9‐THC formed crucial alkyl interactions with Leu 193 as 
well (see Figures 53 and 54). 
These results were supported by those described by Hua et al. (2016) and were in accordance 
with mutation studies by which Phe 189, Ser 383, Phe 268, Ile 271, Tyr 275 were described as 
key residues for CP-55,940 binding; while Ser 383, Phe 174 and Leu 193 were reported to be 
crucial residues for Δ9‐THC binding recognition (Shim et al., 2006; Shao et al., 2016). 
Binding modes of representative CB1 receptor antagonists 
Referring to the CB1 antagonists, the docking outcomes slightly changed according to the 
docking programme used (Vina or Autodock 4.0) and the receptor involved (CB1R homology 
model or crystal structure).  
According to Vina outcomes, AM-251 complexed with either, the homology model or the 
crystal structure, showed alkyl interactions with residues placed on the N-terminal loop (Phe 
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102, Met 103) and pi-sulphur or van der Waals interactions with |Met/Ile 105 according to the 
protein involved (CB1R homology model or crystal structure). In detail, the dichlorophenyl 
group of AM-251 complexed with either protein, interacted through hydrophobic and van der 
Waals interactions with the helix 2 (Phe 170, Phe 174); and through alkyl interactions with Leu 
359 (helix 6), Leu 387 (helix 7) and the N-terminal loop (Phe 102). Additionally, the 
iodophenyl group of the ligand formed alkyl and hydrophobic interactions, or van der Waals 
and alkyl interactions with Leu 193 and Val 196, when the ligand was complexed with either 
the homology model or the crystal structure; while alkyl interactions with Leu 359 and Phe 268 
and pi-sulphur interactions with Cys 386 (helix 7) were observed on both ligand-protein 
complexes. The type of interaction with Trp 356 (helix 6) was different based on the receptor 
involved. In detail, the iodophenyl group of AM-251 formed van der Waals or alkyl 
interactions when the ligand was complexed with either the homology model or the crystal 
structure. Additionally, the pyrazole ring of AM-251 interacted through hydrogen bond 
interactions and alkyl interactions with Ser 383 and Phe 379 (helix 7) of both proteins; and 
formed pi-sulphur and alkyl interactions or van der Waals and hydrogen bond interactions with 
the N-terminal group (Met/Ile 105, Met 103) according to the type of protein complexed with 
the ligand (homology model or crystal structure) (see Figures 47, 48, 55 and 56).  
On the other hand, Autodock 4.0 outcomes obtained with the crystal structure, were slightly 
different compared to those obtained with Vina docking programme. In detail, the 
dichlorophenyl group of AM-251 did not interact with the helix 2 and showed alkyl and van 
der Waals interactions with the helix 3 (Leu 193, Thr 197), while forming alkyl interactions 
with the helix 5 (Trp 279). Additionally, some interacting residues were the same detected with 
Vina docking programme and included Leu 359 (alkyl interaction), Cys 386 (sulphur 
interaction), Phe 102 (van der Waals interaction). On the other hand, the interactions with the 
iodophenyl group of AM-251 were different compared to those detected with Vina docking 
programme and involved hydrophobic and van der Waals interactions with the helix 2 (Phe 
170, Gly 166), alkyl interaction with the 3, 7 helices (Val 196, Leu 387), and hydrophobic 
interactions with the helix 6 (Trp 356); while the pyrazole ring, consistently with Vina 
outcomes, mainly interacted with the N-terminal loop through alkyl interactions (Met 103) and 
with the helix 7 (Phe 379) through van der Waals interactions (see Figures 57 and 58). 
According to the high structural similarity of AM-251 with Rimonabant, several interactions 
considered crucial for rimonabant binding recognition (Mc Allister et al., 2003; Shim et al., 
2012) were detected and involved the following residues:  Leu 193, Phe 379, Phe 170, Trp 356, 
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Cys 386 (Vina and Autodock 4.0 outcomes); Phe 189, Trp 279, Thr 197 (Autodock 4.0 
outcomes); Phe 174 (Vina outcomes). 
According to Vina outcomes obtained with either protein (CB1 receptor homology model or 
crystal structure), the antagonist rimonabant shared several identical interacting residues with 
AM-251 and principally interacted through hydrophobic interactions, with amino acids placed 
in the N-terminal loop, the ECL2, and the 3, 6, 7 helices. In detail, when the ligand was 
complexed with the homology model, the chlorophenyl group formed pi-sigma and alkyl 
interactions with the helix 3 (Leu 193, Val 196), van der Waals interactions with the helix 6 
(Trp 356), hydrogen bond interactions with the helix 7 (Ser 383), and alkyl interactions with 
the ECL2 (Phe 268). Slightly different type of interactions involving the same residues, were 
observed when the ligand was complexed with the crystal structure. In detail, alkyl interactions 
were detected with the helix 3 (Leu 193, Val 196), van der Waals interactions with the 6 and 7 
helices (Trp 356, Ser 383) and alkyl interactions with the ECL2 (Phe 268). Additionally, the 
pyrazole ring mainly interacted with the N-terminal loop (Met 103) through alkyl interactions 
on both complexes, while sulphur or van der Waals interactions were detected with Met/Ile 
105, based on the protein involved (homology model or crystal structure). Moreover, the 
dichlorophenyl group of rimonabant, primarily interacted through pi-pi interactions with the 
helix 2 (Phe 170) and alkyl interactions with the helix 7 (Leu 387), on either complex 
(rimonabant-homology model or rimonabant-crystal structure) (see Figures 47, 48, 55 and 56). 
Autodock 4.0 results were slightly different from Vina outcomes. In detail, the chlorophenyl 
group of rimonabant formed van der Waals interactions with Phe 170 and Ser 383, and alkyl 
interactions with Val 196 and Leu 387; its dichlorophenyl group formed van der Waals 
interactions with Leu 193, alkyl interactions with Trp 279, Trp 356, Leu 359 and halogen 
interaction with Cys 386; while its pyrazole ring mainly interacted with the N-terminal loop 
(Phe 102, pi-pi hydrophobic interaction) and the ECL2 (Phe 268, van der Waals interactions). 
(see Figures 57 and 58). 
Overall, consistent with mutation studies (Shim, 2010; Mc Allister et al., 2003), rimonabant 
showed interactions with residues considered crucial for rimonabant binding recognition, 
including Leu 193, Phe 379, Phe 170, Cys 386 (Vina and Autodock 4.0 outcomes) and Phe 
189, Trp 279 (Autodock 4.0 outcomes). Additionally, these results were in line with those 
described by Hua et al. (2016) by which Phe 268, Leu 359, Cys 386, Trp 356, Val 196, Ser 
383, Phe 170, directly interacted with rimonabant. 
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According to Vina outcomes, the antagonists otenabant and taranabant complexed with either, 
the homology model or the crystal structure, shared relevant interactions with some residues 
considered crucial for rimonabant binding recognition (Shim, 2010; Mc Allister et al., 2003) 
and in line with those described by Hua et al. (2016). In detail, otenabant complexed with either 
protein, the homology model or the crystal structure, shared alkyl interactions with Phe 268, 
Leu 359, Trp 356; hydrophobic interactions with Val 196, Phe 170 and van der Waals 
interactions with Phe 174. By contrast, the type of interactions with Ser 383 and His 178 were 
different (hydrogen bonds or van der Waals interactions) depending on the protein involved 
(homology model or crystal structure). On the other hand, taranabant when complexed with 
the homology model, formed van der Waals interactions with Cys 386, Val 196, Phe 170, Phe 
174 and a hydrogen bond interaction with Ser 383; while, when complexed with the crystal 
structure, it formed van der Waals interactions with Cys 386; pi-alkyl interactions with Val 196 
and Phe 174; pi-pi hydrophobic interactions with Phe 170; and van der Waals interactions with 
Ser 383 (see Figures 47, 48, 55 and 56). Autodock 4.0 outcomes related to otenabant and 
taranabant, were quite different from Vina outcomes. However, Phe 170, Phe 174, His 178 
seemed to be interacting residues for both compounds, consistently with Vina outcomes and 
previous computational studies (Hua et al., 2016). In detail, otenabant formed hydrophobic 
interactions with Phe 170 and van der Waals interactions with Phe 174; while taranabant 
interacted through alkyl interactions with His 178 and Phe 174, and through van der Waals 
interactions with Phe 170 (see Figures 57 and 58). 
Referring to Vina outcomes, the compound AM-6358 formed alkyl and pi-sulphur interactions 
with the N-terminal group (Met 103, Met/Ile 105) when complexed with the homology model, 
and van der Waals and hydrogen bond interactions with the same residues when complexed 
with the crystal structure. Additionally, AM-6358 complexed with either protein, the homology 
model or the crystal structure, shared hydrophobic and van der Waals interactions with the 
helix 2 (Phe 170, Phe 174, Gly 166, Ile 271), hydrogen bond and van der Waals interactions 
with the helix 3 (Thr 197, Leu 193); van der Waals interactions with helix 5 (Tyr 275, Trp 279), 
alkyl interactions and van der Waals interactions with the helix 6 (Leu 359, Trp 356); sulphur 
interactions with the helix 7 (Cys 386); van der Waals interactions with the ECL2 (Phe 268, 
Ile 271) (see Figures 47, 48, 55 and 56). On the other hand, Autodock 4.0 results (ligand 
interactions and binding pose) were slightly different from Vina outcomes. In detail, AM-6358 
formed alkyl, hydrogen bond and van der Waals  interactions with the N-terminal loop ( Met 
103, Ile 105); hydrophobic and alkyl interactions with the helix 2 (Phe 170, Phe 174), alkyl and 
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van der Waals interactions with the helix 3 (Val 196, Leu 193); hydrogen bond interactions 
with the  helix 5 (Trp 279); pi-alkyl and van der Waals interactions with the helix 6 (Leu 359, 
Trp 356); sulphur interactions with the helix 7 (Cys 386) and hydrophobic interactions with the 
ECL2 (Phe 268) (see Figures 57 and 58). 
Overall, most of the interacting residues obtained with Vina and Autodock 4.0 programs, were 
in line with those described by Hua et al. (2016) and these docking results were supported by 
previous studies by which mutagenesis of Phe 170 and Phe 174 caused a dramatic decrease of 
functional affinity for AM-6538 (Mc Allister et al., 2003; Hua et al., 2016).  
Binding modes of novel synthetic cannabinoids 
Referring to Vina outcomes, when complexed with the CB1R homology model, the indole 
group of BB-22 formed hydrogen bond and hydrophobic interactions with residues placed on 
the N-terminal loop (Met 103, Phe 102, respectively); its cyclohexyl methyl group interacted  
through alkyl interactions with the helix 2 (Phe 170), helix 3 (Val 196), helix 7 (Leu 387); 
while its quinolinyl group formed alkyl and hydrophobic interactions with the ECL2 (Pro 269, 
Phe 268); and alkyl and van der Waals interactions with the N-terminal loop (Met 105, Glu 
106, Asp 104, Asn 101) (see Figures 49 and 50). On the other hand, when complexed with the 
CB1R crystal structure, BB-22 showed several interactions with the same residues as those 
observed on the complex with the homology model; although the types of interactions were 
slightly different. In detail, the indole group of BB-22 interacted through alkyl and van der 
Waals interactions with residues placed on the N-terminal loop of the receptor (Met 103, Phe 
102, respectively); its cyclohexyl methyl group formed alkyl and van der Waals interactions 
with the ECL2 (Phe 268, Pro 269, respectively) and the N-terminal loop (Asp 104); its 
quinolinyl group formed alkyl interactions with the helix 3 (Val 196) and helix 7 (Leu 387); 
van der Waals interactions with the helix 6 (Trp 356, Leu 359, respectively) and helix 2 (Phe 
170, Ile 169), and pi-sulphur interactions with the helix 7 (Cys 386) of the crystal structure (see 
Figures 59 and 60). 
On the other hand, Autodock 4.0 results (ligand interactions and binding pose) were slightly 
different from Vina outcomes. In detail, the indole group of BB-22 interacted through 
hydrophobic and pi-sulphur interactions with the  helix 7 (Phe 379, Cys 386, respectively) and 
alkyl interactions with the helix 3 (Leu 359); its cyclohexyl methyl group interacted through 
alkyl interactions with the helix 3 (Val 196), helix 2 (Phe 170) and helix 7 (Leu 387); while its 
quinolinyl group formed mainly  interactions with the helix 2 (Phe 268, Pro 269) and van der 
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Waals interactions with the N-terminal loop (Asn 101, Asp 104, Glu 106) (see Figures 61 and 
62). 
According to Vina outcomes obtained with either protein (CB1 receptor homology model or 
crystal structure), the indole group of 5F-PB-22 interacted with the N-terminal loop through 
hydrogen bond and hydrophobic interactions (Met 103, Phe 102), its fluorinated pentyl tail 
interacted with the helix 3 (Val 196; halogen interaction), and helices 5 and 6 (Trp 279, Trp 
356; alkyl interactions); while its quinolinyl group formed hydrophobic interactions with the 
helix 2 (Pro 269) and the N-terminal loop (Met/ile 105; alkyl interactions) (See figures 49, 50, 
59 and 60). On the other hand, Autodock 4.0 results (ligand interactions and binding pose) 
were slightly different from Vina outcomes. Specifically, the indole group and the pentyl tail 
of the ligand mainly interacted with the ECL2 (Ile 267, Pro 269) and the N-terminal loop (Asp 
104, Ile 105, Glu 106); while the quinolinyl group formed alkyl interactions with the helix 3 
(Val 196), and van der Waals interactions with the helices 2 (Phe 170) and 7 (Phe 379, Ser 383) 
(see Figures 61 and 62).  
Referring to Vina outcomes, 5F-AKB-48 and STS-135, when complexed with the homology 
model, presented almost identical binding poses. In detail, their indazole and indole groups 
formed mainly hydrophobic interactions with the N-terminal group of the receptor (Phe 102, 
Met 103) and the helix 3 (Val 196); their fluorinated pentyl tail interacted mainly through alkyl 
interactions with the helix 6 (Trp 356) and through van der Waals interactions with the helix 7 
(Cys 386, Leu 387); while their adamantyl groups mostly formed alkyl interactions with the 
helix 6 (Leu 359, Met 363) and helix 5 (leu 276, Trp 279) and van der Waals interactions with 
the helix 3 (Thr 197) (see Figures 49 and 50).  
When complexed with the crystal structure, 5F-AKB-48 and STS-135 binding poses were 
slightly different between each other, and showed similar interactions as those observed with 
the homology model. In detail, their indazole and indole groups mainly interacted with the N-
terminal loop through hydrophobic interactions (Met 103, Phe 102, Ile 105); their fluorinated 
pentyl tails interacted primarily through alkyl interactions with the helix 2 (Phe 170) and helix 
7 (Leu 387, Cys 386); while their adamantyl groups formed alkyl interactions with the helix 2 
(Phe 174, His 178) (see Figures 59 and 60).  
On the other hand, Autodock 4.0 results were slightly different from Vina outcomes. In detail, 
the indazole group of 5F-AKB-48 interacted with the N-terminal loop (met 103: pi-sulphur 
interaction) and the helix 3 (Val 196: alkyl interaction); its fluorinated pentyl tail formed 
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interactions with the helix 3 (Leu 193, Val 196, Thr 197) and helix 6 (Trp 356); while the 
adamantyl group formed mostly alkyl interaction with the helix 2 (Phe 268, Pro 269) and van 
der Waals interactions with the helix 7 (Phe 379, Ser 383). Referring to STS-135, the indole 
group interacted with the N-terminal loop (Phe 102: hydrophobic interaction), while its 
fluorinated pentyl tail showed alkyl interactions with the helix 3 (Val 196), helix 6 (Trp 356) 
and helix 7 (Cys 386). Furthermore, the adamantyl group of the ligand formed mostly alkyl 
interactions with the helix 2 (Phe 268, Pro 269) (See Figures 61 and 62).  
Notably, the novel aminoalkylindole derivatives under study, interacted with some residues 
belonging to the same binding pocket observed for other aminoalkylindoles such as WIN-
55,212-2, and described for the antagonist/inverse agonist Rimonabant (Mc Allister et al., 
2003, Shim et al., 2006; Shim et al., 2012).  
6.25) Vina and Autodock binding energies against experimental Ki values: comparison 
between outcomes obtained with the CB1R homology model and the crystal structure 
According to our findings, the binding energies obtained with Vina and Autodock 4.0 
programs, did not correlate with the experimental Ki values, regardless which protein was 
employed in our docking studies (homology model or crystal structure). The results of this 
studies highlighted some limitations and shortcomings that can be ascribed to a combination 
of factors. In detail, both Vina and Autodock 4.0, do not include receptor motion during 
docking process and docking accuracy could be affected by the fact that upon ligand binding, 
the binding site may undergo a conformational change that these docking programs are not able 
to predict. Additionally, they employ simplified scoring functions and the number of degrees 
of freedom applied to the ligands is necessarily limited with errors on estimated binding 
energies around 2–3 Kcal/mol (Forli et al., 2016).  
Referring to Vina only, some other limitations include the use of implicit hydrogens and 
spherically symmetric hydrogen bond potentials, while no electrostatic contribution or atomic 
charges are considered. On the other hand, Autodock 4.0, unlike Vina, includes explicit polar 
hydrogens and electrostatics; and uses a directional hydrogen-bonding term (Forli et al., 2016), 
however several limitations are encountered when ligands contain more than about eight 
torsion angles. More advanced tools and scoring function optimization could be necessary to 
predict binding energies more accurately (Forli et al., 2016). 
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6.26) SCs and CB1 receptor docking studies: Conclusions 
In the past decades, the high-speed synthesis of NPS has revolutionized the drug scenario, 
raising the urge to identify potential drug targets and investigate drug-target protein chemical 
interactions aiming to provide a rationale for different biological effects that specific NPS 
exert. Not surprisingly, molecular docking has been successfully used in recent years to predict 
the 3D structure of a range of drug-target complexes in order to find a biological/chemical 
explanation behind the pharmacological effects of specific drugs. In our initial studies, the 
index novel SCs were docked against a homology model, and the highest-ranking poses were 
analysed for ligand interactions. Subsequently, the CB1 receptor crystal structure was released 
and the docking screen and ligand interaction analysis were repeated. The opportunity to 
investigate how homology model interacted with these compounds compared to crystal 
structure, and how different docking programme packages (Vina and Autodock 4.0) modify 
the results, allowed us to predict drug-target complex 3D structures and related intermolecular 
interactions, with appreciable accuracy. Notably, in view of some limitations inherent to our 
docking approaches, all results must be regarded as preliminary findings requiring further 
optimization with more sophisticated tools.  
Initially, our docking approach was validated by the evidence that the binding properties of 
representative CB1 receptor agonists and antagonists were consistent with those described in 
previous mutation and molecular modelling studies. However, the lack of correlation between 
binding energies (obtained with both docking programmes and both receptors) and 
experimental Ki values highlighted some limitations inherent to our docking approach, leading 
us to regard our outcomes as preliminary evidences that must to be approached with caution, 
and from which other insights may be conceived.  
According to our findings, the docking programme Vina generated similar binding poses 
against the homology model and the crystal structure, suggesting that both models were useful 
for scoring and pose selection for virtual screening. On the other hand, slightly different 
interactions were observed with the docking programme Autodock 4.0, highlighting some 
differences in binding pose calculations.  
Despite the binding poses of each compound slightly changed according to the docking 
programme used and the protein involved (homology model, crystal structure), they were 
characterised by common interactions with amino acid residues that participate as interacting 
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residues, suggesting with some approximation, the putative potential binding mode and 
properties of these compounds. 
Based on the docking results, the novel aminoalkylindole derivatives under study (BB-22, 5F-
PB-22, 5F-AKB-48, STS-135), all share the same binding pocket and formed mainly 
hydrophobic interactions with residues placed on the helices 2, 3, 6, 7, the ECL2 and the N-
terminal loop. Common interacting residues detected with both docking programmes and both 
proteins, included Met 103, Phe 102, Phe 170, Phe 379, Ser 383; while all novel SCs, except 
for 5F-PB-22 formed interactions with Cys 386. 
On the other hand, the agonists analysed, showed different interactions according to their 
chemical properties. Notably, the agonists belonging to the aminoalkylindole class, such as 
JWH-018 and WIN-55,212-2, shared some interacting residues (e.g. Met 103, Phe 170, Ser 
383) with the index SCs in our study; while agonists belonging to the endocannabinoid class 
like anandamide, showed additional crucial interactions with the helix 5 (Tyr 275) that were 
not observed with the aminoalkylindole class compounds. On the same path, the agonist CP-
55,940 (non-classical SC) showed interactions with Ile 271, which, according to mutation 
studies, is a crucial residue for CP-55,940 (Shao et al., 2016), but not for AAI recognition. 
Notably, this key interaction was detected only by the docking programme Vina, suggesting 
that it seemed to perform better compared to Autodock 4.0. 
Referring to the antagonists, some interacting residues detected for rimonabant, AM-251, AM-
6358, were the same as those observed for the novel SCs under study (e.g. Met 103, Phe 170, 
Ser 383), with the evidence of additional interactions with residues such as Leu 193, Phe 379, 
Trp 356, considered key residues for rimonabant binding and analogues (Mc Allister et al., 
2003; Shim et al., 2012). 
Overall, our docking outcomes provided new insights into the binding properties of the index 
SCs in our study, and suggested the evidence of a shared CB1R binding pocket, composed by 
residues considered crucial for AAI recognition, and which overlaps to some extent, with that 
observed for other CB1 agonists and antagonists. Additionally, it was found that using different 
proteins (homology model and crystal structure) produced consistent Vina outcomes; while 
Autodock 4.0 findings were slightly different compared to Vina results. Further advanced 
studies are needed to better predict the correct binding pose and ligand interactions for all 
compounds detected. 
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Chapter 7: Web‐based study on 4,4′‐Dimethylaminorex misuse  
Role played by the internet on NPS marketing and use 
The internet and social media play a key role in the distribution and marketing of NPS drugs. 
The anarchic nature of online markets is gradually changing the illegal drug scenario due to 
the availability of several communicative and interactive tools (e.g. blogs and fora) which allow 
the easy distribution of drugs with convincing and attractive marketing approaches, and provide 
novel opportunities for individuals all over the world to share information and experiences 
related to NPS. The fast-growing popularity of online drug market-places has been fuelled by 
a convergence of factors, including: relative anonymity, wide variety of available drugs, 
interactivity, online large-scale distribution, facilitation of multi-media news. Internet purchase 
has been reported as a crucial factor that drives users to consume NPS and represents a 
challenge for control policies and enforcements as the huge size and ever-changing content of 
the Internet interferes with the constant monitoring of drug-related websites (Dargan and 
Wood, 2013).  
Among the social media users, the ‘psychonauts’ possess large levels of technical and/or 
pharmacological knowledge regarding NPS and share information on their patterns of use, 
reasons for using them, desirable effects, dosages, routes of administrations, drug sourcing 
mechanisms etc. (Orsolini et al., 2015). However, many of these sites include claims from 
enthusiasts that give poor advice and misjudge risks (Khey et al., 2013). Although social 
communities are virtual they can influence many aspects of the members’ behaviour including 
initiation of use, altered perceptions, modification of favourite drugs (Kozinets, 2002; Loi et 
al., 2017). The virtual communities in general are conceived as a new aspect of social existence, 
characterised by its own distinctive style of interaction, and mode of personal communication. 
The interest in online communities has given rise to a new qualitative method called 
‘netnography’, devised specifically to investigate the cultures and behaviours present on the 
Internet (Kozinets, 2016). The netnography approach may be really useful to gain some insights 
into some clinical and psychopharmacological aspects pertaining to the NPS drugs.   
7.1) Web‐based study on 4,4′‐Dimethylaminorex misuse: aim 
Our study aimed at describing, through an assessment of related anecdotal online reports, a 
range of clinical and pharmacological issues related to 4,4’-DMAR misuse, additionally 
reviewing the available evidence‐based literature on this topic (Loi et al., 2017).  
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7.2) Web‐based study on 4,4′‐Dimethylaminorex misuse: methods 
Peer‐reviewed papers and online reports focused on 4,4′‐DMAR misuse issues, were identified 
by performing a wide-range search on the Embase, Google Scholar, Scopus; and 
Pubmed/Medline databases typing the following key words: (4,4′‐DMAR) AND (abuse OR 
misuse OR poisoning OR dependence OR addiction). The search focused on both preclinical 
and clinical data and covered the period up to November 15, 2016 (Loi et al., 2017). An 
additional web-based qualitative/observational approach was undertaken to identify 
information on 4,4′‐DMAR misusers' first‐hand experiences. To this end, between March and 
October 2016, multiple qualitative Google searches were carried out, using key words such as 
‘4,4′‐DMAR and abuse’, ‘4,4′‐DMAR and misuse’; ‘4,4′‐DMAR and experience’; ‘Serotoni 
and forum’; ‘Speckled Cherry forum’; ‘Speckled Cross forum’; ‘Para‐Methyl‐4‐
Methylaminorex forum’; ‘4‐methyl‐euphoria forum’; ‘4‐methyl‐U4Eu forum’; ‘4,4‐
dimethylaminorex forum’. The first two pages/20 hits per keyword were considered and a 
range of websites was later excluded, because not pertinent; being duplicates; or requiring a 
registration or payment procedure (Loi et al., 2017). Overall, six websites hosting forum 
activity on 4,4′‐DMAR use were identified: https://www.chemsrus.com; 
https://www.reddit.com; https://www.ukchemicalresearch.org; http://www.bluelight.org; 
http://www.psychonaut.com/forum.php;  and https://drugs‐forum.com. In total, 20 detailed 
posts focusing on 4,4′‐DMAR use were found and individually analysed by identifying the 
common topics of discussion including: routes of administration (ROAs) and doses; desired 
effects; adverse effects; comparisons with other substances; concurrent intake with other drugs; 
medication use to counteract 4,4′‐DMAR action; overall impression; and availability of harm‐
reduction messages (Loi et al., 2017).  
7.3) Web‐based study on 4,4′‐Dimethylaminorex misuse: results 
Literature identification analysis 
The critical analysis was undertaken on 13 peer‐reviewed papers and 3 reports (ACMD, 2014c; 
EMCDDA and Europol, 2014) identified with the comprehensive literature search above 
described. According to the evidence-based literature, the most widely used routes of 
administration (ROAs) were nasal insufflation and ingestion, followed by inhalation and 
injection; while commonly reported desired effects included: euphoria, disinhibition, increased 
energy and confidence (ACMD, 2014c; EMCDDA and Europol, 2014; Loi et al., 2017). Oral 
dosages were reported ranging from 10 to 200 mg, while the insufflated ones varied from 10 
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to 65 mg (ACMD, 2014; Coppola and Mondola, 2015). Reported untoward effects included: 
hyperthermia, sweating, tachycardia, nausea, dysphoria, psychosis (Coppola and Mondola, 
2015; Cosbey et al., 2014; Glanville et al., 2015); while desired and undesired effects were 
often compared to those produced by stimulant drugs such as ecstasy or amphetamine 
(Schifano et al., 2015 and 2016). 4,4′‐DMAR long‐lasting stimulants' effects (12–16 hours) 
were commonly reversed using sedative and anxiolytics (Glanville et al., 2015; Schifano et al., 
2016), while combination with other drugs was described causing several intoxication events 
and fatalities (EMCDDA and Europol, 2014; Glanville et al., 2015; Hentig, 2016). Social 
cohesion, and harm‐reduction advice have been widely described among NPS users (Soussan 
& Kjellgren, 2016). 
Self‐reported ROAs and dosages 
According to our analysis, dosages and routes of administration were widely debated, with 
users describing dosages; eventual redosing; and suggesting the optimal combination of 
ROAs to achieve the pursuit ‘high level’. Specifically, dosages and ROAs were reported by 
85% of users, with 76% of them describing oral use and dosages ranging from 10 to 120 mg; 
12% reporting the intranasal ROA or vaping with dosages in the 10-to 60‐mg range; and 12% 
describing an oral ingestion followed by the intranasal route, or by snorting and vaping 
(multiple redosing practice). Powder and pellets were the mostly described formulations (Loi 
et al., 2017). 
Self‐reported desired and untoward effects 
Overall, 70% of users described a range of positive effects including stimulation, energy 
increase, euphoria, relaxation, increased sociability, empathy, disinhibition, and arousal. By 
contrast, a range of adverse effects was described by 55% of users and included hallucinations, 
altered perceptions, insomnia, queasiness, jaw clenching or tension or bruxism, blurry vision, 
nystagmus, psychosis, confusion, nausea, sweatiness, increased heart rate, and hyperthermia. 
The effects of 4,4′‐DMAR were compared with those associated with other stimulant 
consumptions (e.g., 4FA, MDMA, 6‐APB, APB, 3‐MMC, 4‐MMC, MDPV a‐PVP, 4‐MMA, 
and MDMA) by 50% of the users (Loi et al., 2017). 
Association with other recreational drugs 
Understanding the effects of 4,4’-DMAR is complicated by the phenomenon of polydrug use. 
According to our analysis, some 30% (6/20) of users associated 4,4’-DMAR with other drugs, 
including alcohol (66%), 6-APB (17%) and phenylpiracetam (17%). The most reported reason 
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for using alcohol or 6-APB along with 4,4’-DMAR, was the necessity to cope with social 
anxiety issues (Loi et al., 2017).  
Medication(s) self-administered to revert 4,4’-DMAR action 
Some users described having trouble falling asleep after using 4,4’-DMAR, and some 20% of 
users reported the necessity to reverse the long-lasting stimulant effects of 4,4’-DMAR by 
using sedatives or anxiolytics (e.g., diazepam, zolpidem, trazodone, baclofen, flubromazepam, 
and etizolam) (Loi et al., 2017).  
Overall impression 
Some 50% of fora users provided their peers with a positive or a negative overall evaluation of 
their 4,4’‐DMAR personal experiences, aiming at promoting or denigrating the use of this drug. 
Indeed, most of them described their personal experience as ‘awesome’, ‘clear’, ‘enjoyable’, 
‘comfortable’, ‘nice’; while others considered it ‘disappointing’ compared to their 
expectations. Other users described their experience using a technical language that involved a 
reference to the molecule's pharmacodynamics; pharmacokinetics; or addictive liability levels 
(Loi et al., 2017).  
Harm reduction advice 
Some 30% of users posted discussions and a range of advices characterised by a general 
concern for safety and social support aimed at minimizing/preventing drug-related harms, 
including avoiding polydrug use; being careful about the dosages and the tendency of re-
dosing; and being aware of the intensity of the psychoactive effects of 4,4’-DMAR (Loi et al., 
2017). 
Limitations of the study 
This study is characterised by a range of methodological limitations. In detail, only public 
websites of the surface web were analysed here and further analysis of the deep Web and ‘dark 
net’ materials would have provided a wider range of information on this topic (Orsolini et al., 
2015); a multilingual analysis approach of a wider sample would have allowed the 
identification of further data of interest;  there is no certainty that multiple discussions were 
posted by different individuals  and an independent verification of the information provided by 
the fora communities is needed as it cannot completely trusted (Loi et al., 2017). 
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Ethical considerations 
Our research involved the analysis of already existing reports published on public Internet fora. 
A discrete approach was undertaken, and no interactions with fora members and purchase 
attempts were made. Users' pseudonyms were not mentioned, and the quotes were slightly 
changed and not integrally reported to preserve the anonymity of fora members. 
Ethics’ approval for the observational web-based study on 4,4’-DMAR was granted by the 
University of Hertfordshire School of Pharmacy Ethics Committee, on December 15th, 2010 
(reference code PHAEC/10-42), with a further 5-year extension of the approval having been 
granted in November 2013. 
7.4) Web‐based study on 4,4′‐Dimethylaminorex misuse: discussion 
4,4′‐DMAR diffusion in several countries may be associated with its wide web-based 
distribution and its sought-after stimulant psychoactive effects (EMCDDA and Europol, 2014). 
Several factors may contribute to the public health threat posed by 4,4′‐DMAR use, including 
drug quality, purity, and concomitant use with other recreational drugs (alcohol, entactogens, 
stimulants) (EMCDDA and Europol, 2014). A discrete amount of knowledge on 4,4’-DMAR 
originates from discussions posted by recreational users in widely available online fora, who 
used these platforms to share information and experiences related to drugs. According to 
previous published reports (ACMD, 2014; EMCDDA and Europol, 2014), oral ingestion and 
nasal insufflation were the most widely described way of administrations with dosages in the 
10 to 200 mg-range and 10 to 65 mg-range, respectively, and injection practice having been 
rarely described. In the present study, fora users widely shared their personal 4,4’-DMAR 
related experiences, with most of the discussions dating back to 2013, before control 
legislation, and in parallel with the first seizures in the Europe. From 2015 and after control 
legislation, the online discussion sharply disappeared from the surface Web suggesting the 
potential move of 4,4′‐DMAR‐related illicit activities into the “deep Web,” as already observed 
with other controlled substances (Orsolini et al., 2015). Overall, fora users described oral 
ingestion of powder and pellets at dosages (10-120 mg) consistent with those described in the 
evidence-based literature; while vaping and snorting ROAs were described in a context of 
multiple redosing practice, which is considered a quite popular approach according to the 
literature (Coppola & Mondola, 2015; Cosbey et al., 2014; Glanville et al., 2015). Most of the 
users in this study had a previous history of drug misuse, while possessing high levels of 
technical knowledge on drugs (psychonaut profile). The present investigation confirmed that 
4,4’-DMAR is a recreational drug with stimulant properties (feelings of stimulation, euphoria, 
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energy, alertness, and increasing confidence) and pro-social effects (e.g. increased empathy, 
feelings of friendliness, interpersonal closeness, and openness), closely resembling those of 
other stimulants (EMCDDA and Europol, 2014). Consistent with previous published reports, 
the onset of the action seemed to be quite slow (peaking in 2–5 hr) and the stimulant effects 
quite long-lasting (e.g. 12–16 hr) (Glanville et al., 2015). Adverse effects being described 
(nausea, dysphoria, agitation, confusion, aggression, sweating, increased heart rate, 
hyperthermia, dilated pupils, psychosis, hallucinations, insomnia, jaw clench or jaw, tension or 
bruxism, blurry vision, and nystagmus) were consistent with those reported in previous studies 
(Glanville et al., 2015) and with 4,4′‐DMAR being a MDMA-like compound. Poly-drug use 
was described by 30% of users, arising a reason for particular concern, resulting from the 
ingestion of 4,4’-DMAR with other serotonergic or dopaminergic compounds (Coppola & 
Mondola, 2015) and potentially responsible for disturbingly high rate of 4,4′‐DMAR fatalities 
(EMCDDA and Europol, 2014). Notably, to counteract the long‐lasting stimulant effects, 20% 
of users here, used a range of sedatives, potentially adding further health risks to the already 
risky practice of consuming 4,4′‐DMAR (Loi et al., 2017). 
Overall this study suggested that fora users cooperate in sharing an extensive range of 
information on 4,4’-DMAR, having sometimes detrimental consequences on people who may 
not be fully aware of the potential medical consequences of the compound being ingested. 
Additionally, the polydrug intake practice may potentially add further health risks, as the 
pharmacokinetic interactions of 4,4′‐DMAR with other substances are not known. Further 
pharmacological analyses should be performed to better draft a risk profile for this drug and 
prevention strategies should be developed and promoted (Loi et al., 2017).  
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Chapter 8: Overall discussion of the PhD project 
Over the last decades, the phenomenon of NPS has been constantly evolving and expanding, 
posing a healthcare challenge over the world. While some legislative interventions have 
attempted to curb the availability/marketing/abuse of these substances; scientists have tried to 
gather as much information as possible to gain some understanding into the complex multi-
faceted phenomenon of NPS. The integration of knowledge resources coming from different 
areas of expertise has been providing valuable support against the NPS challenge; however, 
keeping pace with this highly-dynamic phenomenon turned out to be quite challenging despite 
the valuable efforts made by competent and experienced professionals.  
The present project adopted a multi-disciplinary approach, involving a range of methodologies 
from different areas of expertise (neurobiology, pharmacology, chemistry, netnography) all 
engaged to gain some understanding into the complex phenomenon of NPS abuse.  
The overall aim of this project was to gain insights into pharmacological, neurochemical and 
molecular properties of selected NPS in order to provide a reliable background needed for 
detection, assessment, management of NPS-related harms.  
Different substances have been selected as targets for the present project according to their 
worldwide pattern of diffusion; the numerous toxicity events associated to their use and the 
lacking scientific knowledge available about them. In detail, the substances under study 
included the synthetic cannabinoids BB-22, 5F-PB-22, 5F-AKB-48 and STS-135; the synthetic 
stimulants 2-DPMP, D2PM, 5-IT, 4,4’-DMAR; and the dieting aid compound 2,4’-DNP.  
The methods employed were in vitro quantitative autoradiography, in vitro fast scan cyclic 
voltammetry; in vivo microdialysis; in silico molecular docking, and the web-based analysis 
approach (netnography). The overall studies conducted by our group, branched into different 
analyses, each one characterised by specific goals and approaches. 
Synthetic cannabinoids and CB1R autoradiography studies: In the present study, the potential 
binding properties of BB-22, 5F-BP-22, 5F-AKB-48 and STS-135 at the level of CB1 receptors 
were investigated. The binding properties of these drugs have been recently fully investigated 
on tissue homogenates (rat cortical membranes) using the radiolabelled competition binding 
assay (De Luca et al., 2016). However, the originality of our study lied in the methodological 
approach used in the binding analysis of the novel SCs. In detail, we employed the ARG 
procedure which is a refined method used to establish the anatomical distribution of drug-target 
interactions in specific areas of coronal brain sections (cortex and CPu) with the advantage of 
215 
 
preserving tissue architecture. Consistent with the experiments performed on cortical tissue 
homogenates, competition binding assay studies have been performed. As expected, our results 
were consistent with previous homogenate study findings, by which all index SCs in our study 
were described as high-affinity agonists at CB1 receptors, with BB-22 and 5F-PB-22 showing 
higher affinities compared to 5F-AKB-48 and STS-135. 
The quantitative image-based data of the binding of these drugs at the level of CB1 receptors 
from intact brain tissue (brain slices), provided a support and a further contribution to the 
existing knowledge-base with additional information on the anatomical distribution of the 
radioligand displacement mediated by these SCs, and allowed a comparative analysis of the 
displacement in different cerebral regions of the brain sections (Cortex and CPu).  
Synthetic cannabinoids and NMDAR autoradiography studies: In this study, the potential 
binding properties of the same SCs at the level of glutamate NMDA receptors were investigated 
in cortical and striatal brain slices. The rationale behind this study was related to the necessity 
to discover the underlying pharmacological mechanism responsible for several hallucinogenic 
events experienced by SC users. Hallucinations may indeed result from NMDAR dysfunction, 
which has been previously described as a potential and specific hallucinatory mechanism 
(Rolland et al., 2014). The originality of our study lays in the fact that no published information 
was available, at the time of our study, on the activity of these novel SCs at the level of the 
NMDAR. According to our findings, all synthetic cannabinoids tested were not able to compete 
with the high affinity and selectivity NMDAR radioligand, rejecting the hypothesis of potential 
binding of these SCs to the NMDA receptors at all concentrations investigated. These findings 
provide a valuable contribution to the existing knowledge-base, leading us to consider 
alternative mechanisms responsible for hallucinogenic events (serotoninergic, dopaminergic, 
or pure CB1 mediated dis-inhibitory or inhibitory mechanisms of other pathways). Further 
investigations are needed to determine which one of these hypotheses would be the most valid 
one.  
Synthetic stimulants and DAT autoradiography studies: This study aimed to investigate the 
potential binding properties of 5-IT and 2-DPMP at the level of the DAT, in rat brain slices 
using the autoradiography procedure. Previous in vitro studies confirmed that 5-IT can cause a 
reversible inhibition of MAOA enzymes (Herraiz and Brandt, 2014) and it behaves as a full 
efficacy releasing agent at the level of DAT and NET (Marusich et al., 2016). Additionally, 2-
DPMP was found to be a potent dopamine and norepinephrine reuptake inhibitor without 
releasing properties (Simmler et al., 2014) able to stimulate evoked dopamine efflux in NAc 
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brain slices to a greater extent compared to cocaine (Davidson and Ramsey, 2012). Notably, 
the monoamine uptake transport inhibition and releasing properties of 5-IT were monitored 
using in vitro release assays in brain synaptosomes (Marusich et al., 2016), while 2-DPMP 
studies have been conducted in embryonic kidney 293 cells (HEK 293) (Simmler et al., 2014) 
and in brain slices using the FSCV procedure (Davidson and Ramsey, 2012). The originality 
of our study lays in the methodological approach used. The binding properties of these drugs 
were indeed investigated for the first time in brain slices using the autoradiography procedure 
rather than the brain synaptosome-based approach (Marusich et al., 2016) or the embryonic 
kidney 293 cells-based analysis (Simmler et al., 2014). To this aim, we decided to perform the 
ARG procedure in specific areas of coronal brain sections and we employed the competition 
binding assay approach. The target regions examined were the striatum and NAc shell which 
exhibit a high expression of dopamine transporters. 
Consistent with previous in vitro studies, 5-IT and 2-DPMP behaved as highly potent DAT 
ligands able to compete with the radioligand of [125I]RTI-121 in a concentration-dependent 
way in CPu and NAc brain slices. Notably, 2-DPMP could displace the radioligand in both 
cerebral regions, starting from lower concentrations (0.3 µM) compared to 5-IT (1 µM in the 
NAc shell and 3.0 µM in the CPu). On the other hand, higher concentration of 5-IT (10 and 30 
µM) in both areas caused a comparable displacement as 2-DPMP. The quantitative image-
based analysis of the binding of these drugs at the level of DAT from intact brain tissue (brain 
slices), provided a support and a further contribution to the existing knowledge-base with 
additional information on the anatomical distribution of the radioligand displacement mediated 
by these synthetic stimulants, and allowing a comparative analysis of the displacement in 
different cerebral regions of the brain sections (CPu and NAc shell). 
BB-22 fast scan cyclic voltammetry studies: This study aimed to investigate the effects of BB-
22 on evoked DA efflux and DA re-uptake half-life in brain slices containing the NAc. Using 
brain slices limited the investigation of dopamine dynamics in the NAc shell, avoiding the 
potential influence of other regions of the reward system. The originality of this study lays in 
the rationale of our purpose of research based on the hypothesis that part of the rewarding 
actions of BB-22 could be mediated via direct interactions on synaptic processes within the 
NAc shell not necessarily mediated by CB1 receptors. According to our findings, local 
application of the synthetic cannabinoid BB-22 in brain slices was not able to change evoked 
DA efflux and dopamine reuptake time-constant in the NAc shell at any doses tested. This 
finding would suggest the relative contributions of complex neuronal circuits, either within or 
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outside the NAc, that may represent critical pathways accounting for some of the rewarding 
properties of BB-22 exposure. Notably, this mechanism would potentially rely on the integrity 
of DAergic projections from the VTA to the NAc which is affected in NAc brain slices. These 
findings contributed to the existing body of knowledge, allowing us to support the idea that 
neuronal circuits outside the NAc are indispensable to mediate in vivo DA increase in the NAc 
shell induced by BB-22; and to discard the hypothesis of any direct action of BB-22 at the level 
of dopamine transporter in the NAc shell at the doses tested.  
SC microdialysis studies: These studies aimed to monitor DA release in three different areas 
of the reward system (NAc shell, core, and medial PFCx) after acute intravenous administration 
of BB-22 and only in the NAc shell after acute intravenous administration of 5F-PB-22, 5F-
AKB-48 and STS-135, in freely moving adult rats. These specific brain regions were selected 
as target areas in accordance with their role played in addiction. The originality of this study 
lays in the type of compounds analysed (third generation SCs) along with the technical 
procedure employed (in vivo microdialysis) and the target cerebral regions assessed. At the 
time of our studies, no analyses had been performed before, using the same combinations of 
variables; indeed, our study was the first one to analyse specific aspects of the rewarding 
properties of these compounds, providing more conceptual thinking and practical proposals in 
the pharmacological and clinical fields. According to our findings, all SCs tested were able to 
increase dopamine release in the NAc shell. These results were in line with previous research 
according to which almost all drugs of abuse are able to increase DA release in the NAc shell 
(Pontieri et al., 1995; Tanda et al., 1997; Cadoni et al., 2000). Notably, BB-22 and 5F-PB-22, 
elicited a 50% increase of DA release over basal at the dose of 0.01, mg/kg, i.v., while a dose 
of 5F-AKB-48 and STS-135 ten and fifteen times higher respectively, was necessary to obtain 
the same extent of increase on DA release in the NAc shell. Importantly, the same magnitude 
of increase was previously observed after administration of a dose 100 times higher of Δ9‐THC 
(1 mg/kg, i.v.) (Pistis et al., 2002). Overall, these findings provided the first circumstantial pre-
clinical evidence for a greater putative abuse liability of the third generation SCs compared to 
the natural compound found in Cannabis (Δ9‐THC) and this evidence could make a significant 
contribution to the existing body of knowledge. Researchers and clinicians could indeed use 
this new data as valid background to develop further experimental analyses (e.g. on behavioural 
and reinforcing aspects of SC use) and valid strategies (e.g. more suitable therapeutic 
approaches) against use/abuse of these substances.  
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2,4-DNP microdialysis studies: These studies aimed to monitor DA release in two different 
areas of the reward system (CPu and NAC shell) after acute intraperitoneal administration of 
the dieting aid compound 2,4-DNP. The underlying mechanism causing the abuse of this drug 
has been widely debated over the years. Despite the widespread use of 2,4’-DNP, no published 
neurochemical studies up to now have described a central mediation of 2,4-DNP effects (Perry 
et al., 2013). In view of the above, we hypothesised that some alterations could occur in the 
reward system following 2,4-DNP exposure. To this end, we used a unique dose of 2,4-DNP 
(e.g. 20 mg/kg, i.p.) able to cause a moderate increase of temperature without fatal 
complications (Gatz and Jones, 1970). According to our findings, the acute treatment with 2,4-
DNP (20 mg/kg i.p.) did not cause any change in DA release in the NAc shell and CPu, 
rejecting the hypothesis of psychoactivity of this substance at this specific dose. Although 
being characterised by some methodological limitations, this study suggested that the abuse of 
this drug could be simply driven by its dieting aid properties rather than being centrally 
mediated. The originality of this study lays in the fact that it represented the first attempt to 
explain the abuse of this drug assuming its potential central activity at the level of the reward 
system. Although our hypothesis was rejected, our findings represent a valuable contribution 
to the body of knowledge, because a preliminary evidence of non-psychoactivity has been 
provided for this drug. However, further neurochemical and pharmacological analyses are 
needed to confirm this evidence.  
D2PM and 2-DPMP microdialysis studies: In our study the pipradrol derivatives 2-DPMP and 
D2PM, were selected among other stimulants to monitor DA release in two different areas of 
the reward system: NAc shell, and CPu after their intravenous administration in freely moving 
rats. Previous in vitro pharmacological studies focusing on the effect of these drugs have been 
performed in brain slices (Davidson and Ramsey, 2012) and in embryonic kidney 293 cells 
(HEK 293) (Simmler et al., 2014). However, the originality of our study lays in the fact that no 
in vivo studies had been conducted before ours, on the effect of these two drugs on DA release 
in target areas of the reward system, in freely moving animals. According to our findings, the 
acute treatment with 2-DPMP (0.5 and 1 mg/kg) elicited a comparable increase of DA release 
in the NAc shell and CPu, while a dopamine release increase was observed selectively in the 
NAc shell after injection of the highest dose (3.0 mg/kg, i.v.) of D2PM. These findings 
provided circumstantial preclinical evidence for a putative effect of these drugs in specific areas 
of the reward system and may provide a further contribute to the body of knowledge that can 
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be used to plan new tailored strategies for a more successful abuse management and treatment 
against the use/abuse of these drugs. 
In silico molecular docking studies: These studies aimed to evaluate the intermolecular 
interactions of the synthetic cannabinoids BB-22, 5F-PB-22, 5F-AKB-48 and STS-135, and 
other referent compounds (CB1 agonist and antagonists) within a homology model of the rodent 
CB1 receptor and the crystal structure of the human CB1 receptor. The originality of these 
studies lays in the fact that no published docking studies were available at the time of our 
studies on these target drugs (BB-22, 5F-PB-22, 5F-AKB-48 and STS-135) using the same 
docking approach. These studies contributed to the existing body of knowledge, because they 
demonstrated that the SCs BB-22, 5F-PB-22, 5F-AKB-48 and STS-135 interact with rodent 
and human CB1 receptor residues that, according to previous mutation and computational 
studies, are considered crucial for aminoalkylindole derivative binding recognition. 
The web-based analysis approach: This study aimed at analysing the information provided by 
the fora communities on 4,4’-DMAR use, additionally critically reviewing the available 
evidence-based literature on this topic. The originality of this study lays in the fact that no 
published studies were available at the time of our studies on this topic, using the same 
methodological approach. According to our findings, fora members co-operate in exchanging 
an extensive body of knowledge about this drug, and the recurring topics of discussion include: 
routes of administration and dosages, desired and undesired effects, comparison and 
association with other drugs and medications, overall impression, provision of harm reduction 
advice. This approach has contributed to the existing body of knowledge, providing further 
insights into the clinical and psychopharmacological issues pertaining to 4,4’-DMAR, on 
which little is known in terms of use/abuse, pharmacology, pharmacodynamics, 
pharmacokinetics.  
To sum up: 
• our analytical studies allowed the characterisation of the NPS binding sites providing a 
detailed and reliable anatomical distribution of the radioligand displacement mediated 
by the index drugs;  
• our neurochemical studies provided some new knowledge into the biological 
mechanisms of NPS addiction and contributed to our understanding of how these drugs 
alter functional dopaminergic transmission in the neural systems;  
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• our docking studies provided new insights into the binding properties of the index SCs 
in our study, and suggested the evidence of a shared CB1R binding pocket composed 
by residues considered crucial for AAI recognition, and which overlaps to some extent, 
with that observed for other CB1 agonists and antagonists; 
• our web-based studies provided further insights into the clinical and 
psychopharmacological issues pertaining to the NPS object of our study. 
 
8.1) Conclusions 
Overall, drugs of abuse may alter the brain’s normal level of biochemical activity through a 
variety of different mechanisms, complicating the understanding of the role of biology and 
neurochemistry in drug use and abuse. Specifically, they may affect the synthesis, degradation, 
release, or reuptake of a neurotransmitter, and mimic or block the action of a neurotransmitter 
at a receptor in the brain. Since NPS use/abuse is a complex phenomenon involving a complex 
interaction of biological, neurochemical, environmental factors, the individual analysis of these 
aspects was crucial to gain a better and wider comprehension on this topic.  
Globally, the findings of our study provided some preliminary understandings on: 
• how the index drugs work in specific brain regions;  
• how they interact with their targets; 
• why certain drugs have the potential for abuse; 
• what are their psychopharmacological and untoward effects. 
All these aspects, provided some insights into neurobiological and pharmacological aspects 
of the index NPS and helped us to better understand the mechanisms of drug action in the 
brain. Overall, this knowledge represents a valuable background useful to develop valid 
strategies against NPS use/abuse. 
8.2) Summary of the methodologies employed and analysis of the findings obtained for 
each drug assessed 
BB-22, 5F-PB-22, 5F-AKB-48, STS-135: The biological activity of these synthetic 
cannabinoids was assessed using autoradiography, in silico docking and microdialysis 
procedures. While the autoradiography studies confirmed the super agonism of the index 
compounds at the CB1 receptors and their inactivity at the NMDA receptors, the in silico 
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docking studies provided detailed information on the intermolecular interactions between 
the novel SCs and the CB1 receptor, highlighting that crucial residues involved in ligand 
binding and the active binding pocket at which these drugs display their agonist activity are 
comparable to those observed for other aminoalkylindole derivatives (e.g. JWH-018). On 
the other hand, microdialysis studies demonstrated the ability of these drugs to increase DA 
release in the NAc shell, suggesting the underlying biological mechanism responsible for 
their putative and addictive properties. In vitro FSCV studies have been employed only in 
the neurochemical analysis of the highest potency, affinity and intrinsic activity CB1R 
agonist BB-22. These studies confirmed that the rewarding effects of this drug are highly 
related to the complex interplay among neural pathways originating from different cerebral 
areas of the reward system, and no effect can be observed in brain slices where most of 
these projections have been lesioned. Overall, these outcomes can provide a biological 
background needed for developing efficient therapeutic approaches finalised to cope with 
the untoward effects caused by their activity at the level of specific pathways.  
2-DPMP and D2PM: The biological activity of the pipradrol derivative 2-DPMP has been 
assessed using autoradiography and microdialysis procedures. The competition binding 
data demonstrated that this compound acts at the level of DAT in the NAc, starting from 
lower concentrations (0.3 µM) compared to D2PM (1 µM) and cocaine (3 µM). This 
outcome highlights the extreme dangerousness of this drug according to its high abuse 
potential and monoaminergic activity. Considering these data, clinical interventions can be 
planned to address sympathomimetic toxidromes and to cope with the persistent duration 
of the extent of DA signal in the brain caused by this drug. On the other hand, the 
neurochemical activity of D2PM was assed only using the microdialysis procedure and a 
DA release was observed selectively in the NAc shell with a delayed onset of effects 
probably resulting from the presence in its structure of a polar functional group likely 
responsible for its slow passage through the BBB. Additionally, the involvement of 
psychoactive metabolites in its central activity cannot be excluded. Although additional 
studies are needed to better draft a pharmacological profile of these drugs, these preliminary 
studies can direct prevention strategies towards specific tailored interventions in order to 
limit the untoward effects caused by the interaction of this drug at the level of DAT. 
5-IT:  The neurobiological activity of the tryptamine derivative 5-IT has been assessed only 
using the ARG procedure. According to these studies, a binding of this drug at DAT has 
been demonstrated, and its effect was notable especially considering that lower 
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concentrations of 5-IT (1 µm) compared to cocaine (3 µm) were able to displace the 
radioligand in the NAc. These outcomes highlighted the potential clinical effects caused by 
this drug which are furthermore exacerbated by its additional activity as inhibitor of MAO 
activity. Serious sympathomimetic toxidromes may result from its use/abuse and the urge 
to cope therapeutically with these non-fatal and fatal toxicity events is needed.  
2,4-DNP: the neurochemical effect of this dieting aid compound was hypothesised and 
monitored only using the microdialysis procedure. The absence of psychoactive effects 
found for this compound suggests that the clinical effects produced by this drug are mainly 
related to its ability to cause oxidative phosphorylation disruption rather than being 
centrally mediated. The fatal hyperthermia which can arise after its use, represents a 
challenging clinical issue and clinicians are currently trying to address this threat by 
planning tailored therapeutic interventions.  
4,4’-DMAR: The psychopharmacological effects of this aminoindane derivative were 
analysed through a careful observational approach of web fora reports published by 4,4’-
DMAR first-hand users. Several topics of discussion (e.g. dosages, ROAs, 
desired/undesired effects, concomitant use with other drugs/medications, overall 
impression, harm reduction advice) were identified associated to the use of this substance, 
and a comparative critical approach was undertaken in view of the existing literature on 
this topic. Pharmacological effects being described were consistent with 4,4’-DMAR being 
a monoaminergic releasing agent, and a poly-drug intake practice was described and 
advised by several users. Detailed recipes with dosages, ROAs and effects over time have 
been posted. However, some users showed some concerns about the potential harmful 
effects of this drug and harm reduction advice was observed in several reports along with 
an overall impression about the effect of this drug. Overall, this study suggested that social 
communities can have some detrimental effects on members’ behaviour and prevention 
strategies towards the diffusion of misleading information over the Internet should be 
developed and promoted. 
8.3) Future studies 
NPS use/abuse/addiction is a phenomenon that cannot be reproduced in a laboratory setting 
without limitations. However, some of the behavioural characteristics of this drug abuse and 
addiction can be satisfactorily modelled in laboratory animals and may contribute to the 
understanding of the neurobiological basis of drug taking behaviour. To this aim, future studies 
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may employ a drug self-administration model to test whether animals will work (in general, 
this means to lever press) to obtain the substance and to evaluate the reinforcing properties of 
the index NPS; a drug discrimination procedure which is a behavioural paradigm based on 
specific perceptions experienced by animals after drug administration and which helps to 
predict drug abuse properties and  subjective feeling in humans; a conditioned place-preference 
paradigm that provides information on reward/aversion effects associated to tested drugs in 
animals. Additional locomotor activity studies may be conducted to provide some information 
on the level of behavioural stimulation/inhibition caused by the index NPS.  
Overall, these studies may help to explain the neurobiological and molecular mechanisms 
underlying the addictive and reinforcing properties of NPS and are also excellent tools for the 
investigation of therapeutic agents against NPS use/abuse/addiction. 
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